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Nutritional zinc deficiency
Nutritional deficiencies are estimated to be responsible for 21% of worldwide 
deaths in children aged below 5 years (2.1 million in 2004) and 21% of their 
total disease burden. This disease burden is mostly due to deficiencies in 
zinc and vitamin A, and is highest in Asia and sub-Saharan Africa (Black et 
al. 2008).
Zinc plays a critical role in maintaining epithelial barrier function (Keen and 
Gershwin 1990, Alam et al. 1994, Truong-Tran et al. 2001, Zalewski et al. 2005, 
Finamore et al. 2008), which is the body’s first-line defence against intestinal 
and airway pathogens. In vitro studies using Caco-2 cells (human epithelial 
cells derived from a colon adenocarcinoma that, when appropriately 
cultured, become differentiated and polarised so that they morphologically 
and functionally resemble enterocytes lining the small intestine; Hidalgo et 
al. 1989) suggest that tight junctions between intestinal epithelial cells have 
impaired function in zinc deficiency (Finamore et al. 2008). Morphological 
studies and findings from a zinc supplementation trial in Bangladeshi 
children with diarrhoea suggest that zinc deficiency adversely affects 
intestinal permeability (Moran and Lewis 1985, Roy et al. 1992).
Zinc is central in the formation of ‘zinc fingers’, i.e. loops in proteins that 
typically bind with DNA and RNA and that are essential for gene expression 
and many other processes, including DNA replication and transcription. 
Thus zinc deficiency particularly affects short-lived enterocytes and cells of 
the immune system such as macrophages that must divide and differentiate 
rapidly in response to antigenic stimulation (Shankar and Prasad 1998, 
Klug 1999). Zinc deficiency is associated with decreased numbers and 
impaired functioning of neutrophils and natural killer cells, both  important 
components of the innate immune system.
Zinc is also important for adaptive immune responses (Cuevas et al. 2002, 
Fraker et al. 1987, Prasad 2000, Rink and Kirchner 2000, Rink and Gabriel 2000, 
Salgueiro et al. 2000, Ibs and Rink 2003, Fraker and King 2004). Deficiency 
results in a reduction in thymic size and cellularity, mostly in the thymic cortex 
where thymocytes mature into T cells (Shankar and Prasad 1998), and in 
decreased activity of thymulin (Prasad et al. 1988, Keen and Gershwin 1990), 
a zinc-dependent thymic hormone in serum that stimulates proliferation, 
differentiation and function of T cells. This may account for the decrease in 
concentrations of cytokines such as IFN-γ and IL-2 that are produced by Th1 
cells, whereas Th2 cell responses seem unaffected (Beck et al. 1997). Thus 
by regulating secretion patterns of these cytokine, zinc may be needed to 
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maintain balance in cell-mediated and humoral immunity pathways that 
are driven by Th1 and Th2 cell responses to infection, respectively (Prasad 
2000, Kidd 2003). In addition, the decreased production of IL-2 may lead to 
decreased recruitment of naive T cells, a decreased percentage of T cytolytic 
cells, and decreased NK cell lytic activity (Prasad 2000).
The supply of zinc from exclusive breastfeeding is probably sufficient to 
meet the dietary needs of infants for at least the first 3 months after birth and 
possibly for as long as the first 6 months (IZiNCG 2004, Brown et al. 2009a). 
The risk of deficiency increases with the introduction of complementary 
foods, which generally have lower nutrient densities than breast milk. 
Because these foods are usually based on cereals, they also contain high 
concentrations of phytates and polyphenols that inhibit the intestinal 
absorption of dietary zinc. Consequently, two-thirds of sub-Saharan Africans 
are at risk of inadequately low zinc intake (Brown and Wuehler 2000).
Zinc status is usually measured using biochemical indicators such as serum or 
hair concentrations of zinc. These markers are useful at a population level but 
poorly predict zinc status or functional impairment in individuals (IZiNCG 
2004). Thus randomised placebo-controlled trials remain the best available 
method to establish zinc deficiency in populations, and to determine the 
health gains that can be obtained by increasing the population’s zinc intake. 
The outcomes in such trials usually concern morbidity or growth indices, 
because zinc deficiency is known to cause children becoming stunted and 
underweight (Brown et al. 2002, 2009b).
A recent meta-analysis showed that preventive supplementation with zinc 
can reduce the incidence of acute diarrhoea and lower respiratory tract 
infections by 20% and 14%, and overall child mortality by 6% (Brown et 
al. 2009b). The same meta-analysis, however, also found inconsistencies in 
trial results. Thus research priorities must shift from studies to measure 
efficacy to identifying factors that determine the magnitude of the effect of 
zinc supplementation. Most trials have so far been conducted in Asia and 
Latin America. The response to supplementation may be different in Africa, 
where different dietary and other environmental factors may influence the 
efficacy of zinc, and where children’s health may be challenged by different 
pathogens (Galanis et al. 2006, Chimalizeni et al. 2010), malaria being the 
prime example. Table 1 provides an overview of the trials have so far been 
carried out with zinc supplements in Africa.
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1. Zinc and malaria 
More than 90% of global malaria deaths occur in African children, and up to 
90% of African toddlers in many areas are symptom-free but infected with 
Plasmodium parasites (asymptomatic infection).
Unless restrained by immunity and anti-malarial drugs, populations of 
Plasmodium parasites expand logarithmically at around 10-fold every 48 
h (Simpson et al. 2002), thus rapidly reaching potentially lethal densities. 
Both innate and adaptive immune responses are crucial for the control of 
P. falciparum infection and host survival (Stevenson and Riley 2004, Walther 
et al. 2006, Newman et al. 2008) but are also associated with the severity of 
the disease (Figure 1). Thus severe malaria is probably at least in part an 
immune-mediated disease (Stevenson and Riley 2004).
Zinc deficiency results in decreased percentage of precursors to cytotoxic T 
lymphocytes (Prasad 2000), thus possibly resulting in impaired control of 
liver stages of Plasmodium parasites. Because of its role in innate immunity 
and in maintaining balance of Th1 and Th2 responses to infection, however, 
one may expect zinc to have a particularly important role in the control 
of blood stages of Plasmodium spp. Zinc deficiency affects NK cells and 
neutrophils (see above), both of which play major roles in controlling 
Plasmodium infection (Nnalue and Friedman 1988, Good and Doolan 1990, 
Stevenson and Riley 2000). Through its effects on NK cells, zinc deficiency can 
interfere with the production of interferon (IFN)-γ (Figure 1), whilst a strong 
IFN-γ response is associated with reduced susceptibility to infection (Korbel 
et al. 2005). Neutrophils are important because they readily phagocytose 
Plasmodium-parasitised erythrocytes coated with opsonin (Perlmann and 
Troye-Blomberg 2000). Although the exact role of Th1 and Th2 immune 
responses in controlling P. falciparum infection is not entirely clear, the 
balance between Th1 and Th2 cytokines seems important (Perlmann and 
Troye-Blomberg 2000).
If, as suggested in the paragraph above, zinc is essential for the functioning 
of cells from the adaptive immune system, one may expect zinc deficiency to 
result in a reduced ability to control blood stage proliferation of Plasmodium 
spp. (Figure 1). If on the other hand, protection by zinc against infectious 
diseases were conferred exclusively through its effect on epithelial barriers, 
then little effect may be expected against uncomplicated malaria, because 
malaria parasites are injected by infectious Anopheles mosquitoes and do not 
pass through such barriers to enter the body. 
Introduction 15
Figure 1. Putative innate and adaptive immune responses to Plasmodium-parasitized 
erythrocytes (Stevenson and Riley 2000)
One of the earliest events in the innate response to a new Plasmodium infection might be the 
activation of dendritic cells and possibly macrophages. Following recognition of parasitized 
erythrocytes through toll-like receptors (TLRs) or CD36 protein, dendritic cells eliminate 
these erythrocytes by phagocytosis and present Plasmodium antigens at their cell surface. 
Simultaneously, they upregulate CCR7, a chemotactic receptor protein that leads the 
dendritic cell to migrate through the blood stream to the spleen, the primary site of immune 
responses against blood-stage malaria parasites. Plasma concentrations of cytokines such as 
interleukin-12 (IL-12) derived from dendritic cells and macrophages increase within hours 
of the emergence of parasitized erythrocytes in the circulation. IL-12 results in activation 
of natural killer (NK) cells that are mainly found in peripheral blood, the spleen and bone 
marrow, and that can respond rapidly to P. falciparum-parasitized erythrocytes by producing 
interferon-γ (IFN-γ) and lysing parasitized erythrocytes. IFN-γ further stimulates the 
maturation of dendritic cells but also results in increased antigen presentation by macrophages, 
enhanced nitric oxide (NO) production and enhanced killing activity of macrophages of 
parasitized erythrocytes and free merozoites. The fast response by NK cells and macrophages 
following the release of Plasmodium parasites in the blood stream results in suppression of 
parasitaemia while allowing the body several days to develop an effective T cell response. 
In the spleen, by presenting antigens and co-stimulation with cell-surface receptors (CD80, 
CD86 and CD 40), dendritic cells activate antigen-naive T cells (Th0) and induce them to 
proliferate and differentiate under the influence of IL-12 into antigen-specific T helper 1 (Th1) 
cells. IFN-γ, initially produced by NK cells and later also by Th1 cells, assists in this process 
by promoting Th1 differentiation and suppression of Th2 cell activity. IL-2 produced by 
Th1 cells further activates NK cells and further amplifies the adaptive immune response. A 
Th1 response typically involves the proinflammatory cytokines INF-γ and tumour-necrosis 
factor-α (TNF-α), and is directed at maximising the killing efficacy of macrophages, the 
proliferation of cytotoxic T cells and the production of opsonizing antibodies. Cytotoxic 
T cells can affect liver stages but not affect blood stages of Plasmodium parasites, however, 
because erythrocytes, being anucleate cells, do not express major histocompatibility complex 
(MHC) class I molecules that are needed for recognition by cytotoxic T cell receptors. An 
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When we planned the studies described in this thesis, the effect of preventive 
zinc supplementation on malaria had been investigated in four trials, with 
discordant and inconclusive results. In The Gambia, zinc led to a statistically 
non-significant reduction by 33% in the mean number of clinic visits for 
malaria (Bates et al. 1993). This trial was designed to measure effects on child 
growth; illness episodes were recorded through routine clinic procedures 
and, accordingly, they were inappropriate to adequately measure effects on 
malaria rates. In Papua New Guinean children, zinc led to a reduction of the 
number of fevers attributable to malaria due to P. falciparum by 38% (Shankar 
et al. 2000). By contrast, in a recent trial in Burkina Faso, zinc provided no 
or only little protection against malaria (Müller et al. 2001), despite evidence 
that the children studied were zinc deficient.
The findings from these trials may have been discordant because the response 
to zinc supplementation is suppressed in children who are also deficient 
in other nutrients known to be essential for immunity, or in nutrients that 
impair zinc absorption or utilisation (Ronaghy et al. 1969, 1974). If so, then 
zinc and other micronutrients would act synergistically, and simultaneous 
supplementation with other nutrients might be required to overcome the 
lack of effect that may occur when zinc is given alone. To our knowledge, 
the effect of supplementation with multiple micronutrients combined on 
malaria morbidity has not yet been investigated.
The reports of several related trials became available after we started our 
studies. In Peru, there was no strong support that zinc reduced malaria 
risk (Richard et al. 2006). Among children aged 6–72 months in Burkina 
Faso, combined supplementation with zinc and vitamin A reduced malaria 
incidence by 30% (Zeba et al. 2008), but the design of this study does 
not allow attribution of the effect to either zinc alone or vitamin A alone. 
Lastly, a recent trial in Ghana reported that addition of zinc to the routine 
intervention package of malaria chemoprophylaxis, iron and folic acid for 
pregnant women in Ghana was associated with reduced densities of malaria 
parasites (Saaka et al. 2009). In children initially aged 1–35 months living in 
appropriate acquired immune response to malaria is characterised by the ability to control 
circulating proinflammatory cytokines at levels that facilitate parasite clearance but do not 
trigger pathology. Th1 responses are classically suppressed by subsequent Th2 responses, 
which also serve to stimulate B-cell proliferation, to induce B-cell antibody class switching, 
and to increase neutralizing antibody production. The mechanism by which this switch is 
achieved is unknown but key immunoregulatory cytokines involved seem to be IL-10 and 
transforming-growth factor-β (TGF-β) that are produced by macrophages and regulatory T 
cells, and either of which might contribute to the regulation of innate responses.
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a highly malaria-endemic area (Sazawal et al. 2007), supplementation with 
zinc resulted in a modest reduction of overall mortality (7%; 95% CI: –6% 
to 19%) but sub-group analysis suggested that it reduced overall mortality 
in children aged ≥ 12 months by 18% (0% to 32%), perhaps mostly due to 
a reduced fatality in children admitted to hospital of with severe malaria 
(Black et al. 2007).
In a multi-country study, zinc supplementation did not appear to provide 
benefit as an adjunct therapy in preschool children with uncomplicated 
malaria due to P. falciparum (Zinc Against Plasmodium Study Group 2002).
2. Safety of supplementation with other micronutrients
Despite the potential benefits of nutrient supplementation, its safety is 
controversial, particularly in malaria-endemic areas. Micronutrients, in 
addition to having a role in host immunity, may also serve as a nutritional 
source for pathogens, thus resulting in increased morbidity. A review of 
the associations between single micronutrients and malaria (Shankar et al. 
2000), based on evidence from human and animal studies, shows how little 
is known about this subject; the evidence available should raise concern, 
however, about the safety of at least several of these micronutrients.
A randomised trial among children aged 1–35 months in Pemba, Tanzania 
showed that daily supplementation with iron (12.5 mg as ferrous sulphate) 
and folic acid increased rates of hospital admission and all-cause mortality 
(combined endpoint) by 12% (2% to 23%) (Sazawal et al. 2006). This report 
reinforced earlier concerns that iron interventions can increase the incidence 
of malaria and infectious disease, even in individuals without iron overload 
(Oppenheimer 2001, 2002). 
The Pemba study is unique in scale and objectives, and important in view 
of some of the findings to be presented later in this thesis, so its design and 
findings are described here in some detail. The main trial (n=32,155) was 
conceived as a 2×2 factorial trial, with either iron, folic acid and zinc; zinc 
alone; iron and folic acid; or placebo. Because of excess adverse events, 
supplementation in the two arms receiving iron and folic acid (n=16,070) 
was stopped ahead of schedule, converting the trial into one with two arms, 
namely zinc versus placebo.
The study also included a smaller sub-study (n=3,171, with analyses based 
on 162 adverse events in 2,262 child-years of follow-up) with the same 
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interventions and surveillance for adverse events as the main trial; however, 
the sub-study differed from the main trial in that a blood sample was collected 
at baseline for haematological analysis and for assessment in whole blood of 
zinc protoporphyrin: haem ratio (used by the authors to indicate iron status) 
and Plasmodium parasite density (number of parasites per unit volume of 
blood); in addition, children were medically examined at 6 months and 12 
months after randomisation, and the diagnostic work-up and therapeutic 
practices were more extensive. As per local guidelines at the time, the first-
line anti-malarial therapy consisted of a combination of antifolate medicines 
(sulfadoxine-pyrimethamine). Paradoxically, in the sub-study it seemed that 
iron and folic acid reduced the rate of hospitalisation and death by 24% (–9% to 
48%). The authors concluded that this discrepancy from the main study was 
caused by more intensive diagnosis and management of children with malaria 
and other infections in the sub-study. Lastly, as reported by the authors, 
subgroup analysis suggested that the supplementation effect depended on 
baseline iron status: in children with elevated zinc protoporphyrin:haem 
ratio, or with moderate anaemia at baseline, supplementation protected 
against adverse events (hazard ratios: 0.62, 0.41–0.93 and 0.59, 0.37–0.92, 
respectively), whereas in children with normal zinc protoporphyrin:haem 
ratio or without anaemia, there was no statistical evidence of effect: 1.63, 
0.72–3.66 and 1.08, 0.58–1.98).
An expert group convened following the Pemba trial by the World 
Health Organization (WHO) recommended that iron supplementation in 
young children (6-24 months) should be restricted in areas where malaria 
transmission is intense and infectious disease highly prevalent (WHO 2006, 
2007). Based on the results of the sub-study, the group recommended that 
iron supplementation should not be implemented without the screening of 
individuals for iron deficiency, because this mode of iron administration 
may cause severe adverse events in iron-sufficient children.
3. Strategies to control deficiencies of zinc and other micronutrients
Based on an analysis of possible interventions, an authoritative group, 
comprising some of the world’s top economists, recently considered 
supplementation of undernourished children with vitamin A and zinc to be 
the best investment for advancing global health (www.copenhagenconsensus.
com/Home.aspx). Much research is needed, however, to determine cost-
effective methods of supplying zinc to deficient populations. Supplements 
can possibly be delivered to children using existing delivery platforms that 
provide reasonably frequent and reliable contacts with target groups and 
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high levels of coverage. Thus zinc supplementation may be integrated with 
twice-yearly vitamin A supplementation, growth monitoring activities, 
programmes to distribute anti-parasitic medicines, and delivered through 
private-sector distribution channels (Brown et al. 2009c). 
A global consortium (www.harvestplus.org) led by some of the world’s 
leading agricultural research institutes has embarked on a programme to 
breed and disseminate new staple crop varieties with high concentrations of 
micronutrients (‘biofortification’). This initiative has generated the potential 
to create a safe, low-cost and self-sustaining approach to deliver zinc to 
poor farmer families (Hotz 2009). Development and dissemination of such 
‘biofortified’ crops requires large initial research investments and sustained 
support by national and international policy makers; by contrast to other 
interventions, however, the long-term recurrent costs are low. Because of 
technical constraints, and contrary to other methods of delivery such as 
supplementation or fortification, the biofortification approach must focus on 
single nutrients or at most a few nutrients. This imposes a need to identify 
micronutrients that are critical to health, and reinforces the need to determine 
to what extent zinc is efficacious when given alone, or in combination with 
other micronutrients. Efforts to develop typically ‘African’ crops rich in zinc 
have so far been limited, and require increased support that is probably 
best obtained when showing compelling evidence of the health benefits of 
increasing zinc intake.
Fortification of staple cereal flours is a cost-effective, sustainable way to 
improve nutritional status in developing countries. Zinc fortification is 
technically feasible even if questions remain on the appropriate formulation 
of fortificant zinc and the target dosage that are required for efficacious 
fortification (Brown et al. 2010). International efforts to advocate flour 
fortification have nonetheless produced a small but rapidly increasing 
number of African countries planning to include zinc in national flour 
fortification programmes. The beneficiaries will be mainly urban and peri-
urban populations who buy industrially processed flour; the prospects are 
more limited for small-scale fortification of flour for rural families relying 
in subsistence farming. In addition, it remains to be investigated to what 
extent fortification levels can be adjusted to meet the dietary needs of young 
children but without exceeding the tolerable upper intake levels for other 
population groups.
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4. Aims and outline of the thesis
The long-term objective of this study was to develop efficacious and safe 
nutritional interventions to control common infectious diseases in African 
preschool children.
The specific aims were as follows:
1. To assess the effect of supplementation with zinc, alone or in 
combination with other nutrients, on the rates of malaria (primary 
objective);
2. To assess intervention effects on rates of other common diseases 
(diarrhoea, respiratory infections, non-malarial febrile illness);
3. To identify factors that determine the magnitude of the effect of the 
interventions;
4. To assess the effect of α+-thalassaemia on rates of malaria and on the 
degree of anaemia associated with Plasmodium infection.
The field work was conducted in Tanzania and comprised two studies. 
First, we conducted a pilot survey (May–July 2006) with the primary aim 
to identify communities with a high prevalence of malaria that would be 
suitable for inclusion in a subsequent randomised controlled trial (February 
2008–March 2009). Objectives 1–3 were pursued in the trial, the results of 
which are described in Chapters 2–5. This was primarily conceived as an 
explanatory trial (i.e. it aimed at measuring effects that can be achieved 
when supplements are administered under optimal, controlled conditions; 
Schwarz and Lellouch 2009) although some aspects were rather pragmatic 
(i.e. to guide practice by measuring effects under real-life conditions). 
The trial also provided an opportunity to assess an issue not directly related 
to the primary objective: in Chapters 6 and 7, we assessed to what extent 
α+-thalassaemia is associated with protection against malaria (objective 4). 
This haemoglobin disorder is highly prevalent in eastern Africa, and has 
recently been reported to protect against severe malaria. Another spin-off 
about the safety of iron fortification is provided in Annex 1.
The study site in Tanzania: Our studies were carried out in a lowland area 
(~250–350 m altitude) in Segera and Kwedizinga wards, Handeni District, 
northern Tanzania, close to the junction of the tarmac roads Tanga–Dar es 
Salaam and Moshi–Tanga (Figure 2). Virtually all villagers in the area live 
in self-constructed clay houses with thatch roofs, and there is no access 
to electricity or running water. The vast majority of people depend on 
subsistence farming, while some produce oranges as cash crops.
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To our knowledge, no studies had been conducted previously in this 
area. We expected transmission patterns to be similar, however, to those 
in adjacent area towards the East, where previous entomological studies 
and parasitological surveys found transmission to be mostly by Anopheles 
gambiae s.s. and An. funestus, and to a small degree by An. arabiensis (Dr. 
Caroline Maxwell, personal communication, 2008) with people being bitten 
on average by Plasmodium-infected Anopheles mosquitoes 35–400 per person 
per year (Ellman et al. 1998).
Figure 2. Location of the study site in north-eastern Tanzania
The study site is marked by a dashed red circle. Zanzibar, a semi-autonomous part of Tanzania, 
consists of two main islands: Pemba and Unguja.
The pilot survey was conducted in a predefined area that included several 
villages (Chan’gombe, Segera, Michungwani) along the tarmac roads, as 
well as an inland area to the east of Michungwani village (05°20.089 S, 38 
°32.937 E). We used a lot quality sampling technique (Lanata and Black 1991, 
Lemeshow and Taber 1991) that is statistically efficient in distinguishing 
between ‘lots’ (communities) with high and low malaria prevalence. Thus, 
we conducted a census in the study area, and derived a list of all resident 
children aged 6–72 months (total: 2,472 children). Based on the existing 
Tanga
Muheza
Segera
Bondo
Pemba
Unguja
Dar es Salaam
Moshi
TANZANIA
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administrative boundaries, the overall population was divided into 19 lots. 
By means of this list, 16 children were randomly selected from each of the 19 
lots, resulting in a total of 304 sampled children. Communities were eligible 
for the trial when ≥ 9 of 16 children tested were infected with P. falciparum as 
assessed by an antigen test for P. falciparum-specific lactase dehydrogenase 
(pLDH). With communities of 100 children, the procedure provided 90% 
probability of including a community with a prevalence of infection of > 
63%, and 90% probability of excluding a community with a prevalence of 
infection of < 37%. In smaller communities, this strategy would lead to even 
better performance to distinguish between communities with high and low 
prevalence, whereas this performance would be only marginally worse in 
larger communities (not shown).
This process resulted in the selection of a contiguous area that we used 
for the intervention study, with an overall prevalence of P. falciparum 
infection of 71%. It was located along a dead-end, unpaved road to the 
east of Michungwani village, and contained four villages (Ngojoro, Bondo, 
Kwangwe and Kwadoya). There is no public transport to the main road, 
except on Saturday (market day), when there is limited service by local 
minibuses between the furthest village (Kwadoya) and the main road. The 
road becomes difficult to travel in the rainy season. Access to healthcare was 
limited before the trial, with the nearest health care facility in Segera village, 
which is located at a range of 8–25 km from the homesteads of the children 
studied. In collaboration with local villagers and authorities, we constructed 
and staffed a research clinic at a central location in the study area (Bondo 
village, 5°22’60’’ S, 38°34’60’’ E).
Several findings from the pilot survey are not described in subsequent 
chapters of this thesis but provide a context for our studies. We found the 
following prevalence estimates (methods described in subsequent Chapters): 
anaemia (haemoglobin concentration < 110 g/L): 50%; inflammation (whole 
blood C-reactive protein concentration > 8 mg/L): 34%; P. falciparum infection 
(positive test result for pLDH-based dipstick test): 46%; Helicobacter pylori 
antigenaemia (Amplified IDEIA Hp StAR enzyme immunoassay test, 
DakoCytomation, Ely, UK): 31%; Giardia intestinalis infection (by microscopical 
examination of a single stool sample per child): 30%; α+-thalassaemia (by 
PCR test): 38%; being stunted, wasted and underweight (z-scores height-for-
age, weight-for height and weight-for-age < –2 SD, respectively): 39%, 2% 
and 22%, respectively. Microscopic examination of a single stool sample per 
child revealed a single case of hookworm; no cases were reported of Trichuris 
trichiura, Ascaris lumbricoides or Schistosoma infestation. In a multivariate 
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regression model, we identified deficiencies of iron, vitamin B12, and possibly 
vitamin A as independent risk factors for anaemia (Table 2). It was estimated 
that the prevalence of these disorders was 13%, 4% and 13%, respectively.
Table 2. Factors associated with haemoglobin concentration, pilot survey (n=304)
Association with haemoglobin concentration, g/L
Crude (95% CI) Independent (95% CI)
Nutritional factors 1
Iron deficiency –7.8 (–13.6 to –2.0) –12.7 (–18.5 to –6.8)
Vitamin A deficiency –9.9 (–15.7 to –4.0) –3.0 (–8.8 to 2.8)
Vitamin B12 deficiency –15.8 (–25.9 to –5.8) –12.4 (–21.5 to–3.4)
Infection-related factors
Plasmodium spp. –8.9 (–12.8 to –5.0) –8.5 (–13.4 to –3.6)
Helicobacter pylori –1.0 (–5.3 to 3.3) –1.0 (–5.0 to 3.0)
Inflammation –13.2 (–17.4 to –9.0) –9.7 (–14.0 to –5.3)
α+-thalassaemia
Without Plasmodium infection
Heterozygous 0.7 (–4.6 to 6.0) –0.5 (–5.7 to 4.8)
Homozygous –17.8 (–30.8 to –4.7) –14.3 (–27.2 to –1.3)
With Plasmodium infection
Heterozygous 0.3 (–6.5 to 7.1) 0.7 (–7.2 to 8.6)
Homozygous –5.2 (–20.1 to 9.7) –7.0 (–25.2 to 11.3)
Source: Veenemans et al. 2009
1 Deficiencies of iron, vitamin A and vitamin B12 were defined by plasma concentrations of ferritin, 
retinol and cobalamin < 12 µg/L, < 0.70 mmol/L and < 150 pmol/L, respectively.
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The primary objective of the trial described in this thesis was to assess the 
effect of supplementation with zinc, alone or in combination with other 
nutrients, on the rates of malaria (see Chapter 1). The aim of this chapter 
is to describe several features of the design and analysis of the trial that are 
important for the interpretation of its findings. The results of the trial will be 
presented in subsequent chapters.
1. Factorial design
If adding vitamins and other minerals does not enhance the efficacy of 
zinc supplementation, then there is no use in combining zinc and other 
micronutrients. We employed a full factorial design, whereby each 
participating child was randomised to one of four groups receiving either 
placebo, zinc alone, vitamins and other minerals (‘multi-nutrients alone’), 
or multi-nutrients including zinc. Such a design is unique in allowing 
the investigation of interaction between interventions. Thus, a key issue 
in our study was to what extent the rate ratio achieved by combined 
supplementation with multi-nutrients including zinc diverged from the 
product of the rate ratios achieved by supplementation with either zinc 
alone or multi-nutrients alone. A limitation of such a design, however, is 
that precision achieved is often insufficient to provide conclusive statistical 
evidence for such interaction if extant in the study population, unless the 
interaction effect is relatively large. Thus we conservatively determined the 
sample size of our trial on expected rate reductions by single interventions 
(zinc alone or multi-nutrients alone) relative to placebo, and a further rates 
reduction by combined intervention (multi-nutrients including zinc) relative 
to single interventions. We were guided in our exploration of interaction 
mostly by the magnitude of the estimated interaction effect and not only by 
the corresponding confidence interval or p-value (McAllister et al. 2003).
When assuming absence of interaction, i.e. the interventions act 
independently, data can be analysed ‘at the margins’ (McAllister et al. 2003), 
in our case, by comparing the pooled two groups receiving zinc (with or 
without multi-nutrients) versus the pooled two groups not receiving zinc 
(placebo or multi-nutrients); conversely, the effect of multinutrients can be 
analysed by comparing groups receiving multi-nutrients (with or without 
zinc) versus those without multi-nutrients (placebo or zinc). Under this 
assumption, the factorial design has the advantage that the number of 
participants required to evaluate the effects of two interventions is identical 
to the sample size required to assess single interventions. In this sense, a 
factorial design can ‘achieve two trials for the price of one’: every participant 
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contributes information to each of the randomized factors simultaneously 
(Lubsen and Pocock 1994).
Analysis of first episodes versus analysis of repeated events: Most trials have 
assessed intervention efficacy against malaria as group differences in time to 
first episode or incidence of first episodes. In highly endemic areas, however, 
children often experience multiple episodes of malaria over time, and the 
exclusion of second and subsequent episodes is controversial and may lead 
to biased estimates of intervention efficacy (Cheung et al. 2010).
Because of differences between individuals in exposure to infectious 
mosquito bites, immunity and therapy-seeking behaviour, some children 
experience malaria more frequently than others (Figure 1). In addition, when 
children are studied longitudinally, between-individual variation may occur 
in the frequency of malaria because of differences in the time of recruitment 
and follow-up in relation to the transmission season.
In the presence of such heterogeneity in susceptibility to malaria, ‘high risk’ 
individuals tend to become sick more rapidly than ‘low risk’ individuals, 
and once they have experienced an episode they are no longer considered 
in a time-to-first-event analysis. Thus, with the passing of follow-up time, 
only the ‘low risk’ individuals remain in the risk set and, accordingly, the 
event rate observed will decrease. In randomised trials with efficacious 
interventions, this decrease is generally more pronounced in groups with 
high overall event rates (placebo group), which have ‘high-risk’ individuals 
dropping out more efficiently. Thus in time-to-first-event analysis, group 
contrasts can become underestimated and efficacy may appear decrease 
with time.
Due to genetic, nutritional and immunological factors, some children 
may also benefit more from an intervention than others. Because of this 
heterogeneity in response to intervention, a protective effect introduces an 
additional selection process in time-to-first-event analysis: ‘low-responders’ 
tend to develop malaria and leave the risk set earlier than ‘high-responders’. 
Because this process does not occur in the control group, it may result in an 
overestimate of intervention efficacy (Halloran et al. 1996, (Valim et al. 2008, 
White et al. 2010).
To better reflect the impact on the total burden of disease and to eliminate 
sources of bias that are described in the preceding paragraphs, we based our 
estimates of intervention efficacy on the total number of episodes and rather 
than time-to-first event analysis (Annex 2). We used a robust estimate of 
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the standard error to account for dependence among multiple events within 
persons, because confidence intervals will be underestimated when this is 
not done.
2. Case definition and detection
The validity of efficacy estimates greatly depends on a sensitive and 
specific detection of cases. In settings that are highly endemic for malaria, 
the performance of any diagnostic test is limited by the fact that, at any 
point in time, a considerable proportion of the paediatric population under 
study is asymptomatically infected. In such children, incident episodes of 
non-malarial febrile illness would be misclassified as being malaria. The 
resulting lack of specificity normally results in intervention efficacy being 
underestimated (O’Meara and Lang 2009).
To redress this problem, we tested all children at baseline with a highly 
sensitive malaria dipstick test, and gave all those with infection a 3-day 
course of anti-malarial drug combination (artemether-lumefantrine) that is 
highly efficacious in clearing asexual parasites (Annex 2). Thus we assumed 
that children subsequently presenting with fever or inflammation and with 
confirmed infection would have malaria due to a newly acquired infection. 
Our primary endpoint was defined accordingly as: a) reported febrile illness 
with axillary temperature ≥ 37.5 °C and a positive result for a Plasmodium-
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Figure 1. Number of malaria episodes per child, per year
Based on data collected during the trial described in this thesis (methods: see Chapter 3)
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specific pLDH-based dipstick test; or b) reported (but unconfirmed) febrile 
illness with inflammation (whole blood C-reactive protein concentration ≥ 8 
mg/L) and a positive result for a pLDH dipstick test.
Another, widely used approach to increase the specificity of the malaria case 
definition is to attribute a febrile episode to malaria only when the density of 
asexual parasites exceeds a pre-specified threshold value (Schellenberg et al. 
1994, Smith et al. 2004). This method has been advocated by WHO for the use 
in malaria vaccine trials (Moorthy et al. 2007) and is based on the observation 
that high parasite densities are found less frequently among asymptomatic 
children in cross-sectional surveys, and the idea that the probability of fever 
is associated with parasite density. Based on a logistic regression model 
of this association, the probability can be calculated that a fever case is 
attributable to malaria given the parasite density observed at time of illness 
presentation. The pyrogenic threshold for uncomplicated malaria depends 
on age, transmission intensity and season (as proxy indicators for immunity) 
but is usually within the range of 0–6,000 asexual parasites/µL for infants, 
and 2,500–7,500 asexual parasites/µL for children aged 12–60 months (e.g. 
McGuinness et al. 1998, Bloland et al. 1999, Mwangi et al. 2005).
When designing our studies, we did not apply such threshold approach, for 
the following reasons:
a. Microscopy, the conventional standard for the detection and counting of 
malaria parasites in peripheral blood, is in many aspects deficient for 
this purpose. The method suffers from high inter- and intra-observer 
variability, particularly when the true parasite density is low (Figure 2) 
(O’Meara et al. 2007, Hänscheid 1999). A low precision can be inevitable 
even under ideal circumstances. For example, if the leukocyte count 
is 8,000/µL, and one counts an area of the slide in which a total of 200 
leukocytes are found, as is typical in many studies, the volume of blood 
examined is only 0.0625 µL. At a true parasite density of 150/µL, one 
would expect this to result in only four parasitized cells being counted. 
However, repeated examination would result in 95% of times to 1–8 
parasites being counted (calculations based on Poisson distribution), 
corresponding to a range of estimated densities of 40–320 parasites/µL. 
Particularly for infants, this range is disturbingly large in view of low 
thresholds reported in some studies (e.g. 100/µL and 150/µL in the dry 
and wet seasons in an area with an entomological inoculation rate of 8.5 
infective mosquito bites per person per year, McGuinness et al. 1998). 
More studies seem warranted to assess the influence of this random error 
on the threshold value.
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Figure 2. Discrepancy in density between two microscopists reading a single slide as a 
function of parasite density (O’Meara et al. 2007)
In addition, within individuals, great variations in parasite density 
have been observed within short periods of time: in a single untreated 
individual, the parasite density may vary by more than 100-fold within 
6 h (Delley et al. 2000, Koram and Molyneux 2007). Asexual stages of 
P. falciparum have a 48-h life cycle, of which only the first half is visible 
to the microscopist. At 16–24 h after parasite invasion, erythrocytes 
start expressing adhesins on their surface, aggregate with uninfected 
erythrocytes (rosetting) and also begin to adhere to vascular endothelium, 
particularly in the venules (cytoadherence). Thus, depending on stage and 
synchronicity, a predominance in parasite biomass in the body may be 
either circulating and detectable, or sequestered in the deep vasculature 
and not detectable (White 1997). Pathophysiological processes in P. 
falciparum malaria are probably due to the mature forms of the parasite 
and subsequent release of pyrogens during erythrocyte lysis, and not to 
the younger circulating asexual stages. Thus patients tend to be more ill 
when the majority of their parasites are sequestered or just after schizont 
rupture (White 1997), which further complicates the loose relationship 
between parasitaemia and disease severity.
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A practical problem, which also complicated the use of parasite density 
in our trial, is that it is not always logistically feasible to obtain leukocyte 
counts for blood samples collected from sick children. We would thus be 
restricted to using an assumed, fixed leukocyte count. Because malaria is 
known to suppress immunity and to produce leukopaenia (McKenzie et 
al. 2005), this could lead to substantially overestimated parasite counts. 
On the other hand, many children may have had concurrent bacterial 
infections, with an accompanying increase in leukocyte count, which 
could lead to substantial underestimates of parasite density. In addition, 
if the intervention would affect leukocyte counts during illness, as may 
theoretically occur with nutrient interventions, this would introduce 
additional bias.
b) Many assumptions must be made when establishing such threshold 
and its application does not guarantee an unbiased assessment of 
intervention efficacy (Smith 2007). First, because these thresholds are 
usually established based on a single survey, this approach does not 
account for seasonal and other external variations in the relation between 
density and fever risk, which may occur during the follow-up of trial 
participants.
Second, applying a threshold that uniformly applies to groups of children 
does not reflect heterogeneity in individual fever thresholds. Because 
malaria susceptibility will depend on immunity, age and several other 
factors, such a threshold will vary between individuals and – assuming 
that the threshold depends on previous malaria episodes – even within 
individuals. Thus misclassification of cases cannot be avoided. When 
affecting a similar proportion of cases in intervention groups being 
compared, such misclassification would increase the similarity between 
groups so that any true intervention effect would be underestimated 
(Hennekens and Buring 1987).
Third, the threshold approach assumes that the intervention under 
evaluation reduces malaria risk solely by reducing parasite densities and 
thus the proportion of infected children who exceed the fever threshold, 
but it fails when it also influences the fever threshold itself. In our trial, 
we expected this to be an important limitation because zinc and other 
micronutrients may achieve their protective effects at least in part by 
improving immunity, which is likely to modulate the relationship 
between parasite density and fever risk, and to influence the fever 
threshold. Thus the use of a single threshold would result in a differential 
specificity of the case definition between intervention arms, which causes 
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bias in the efficacy estimates that is difficult to control for, and of which 
magnitude and direction are difficult to predict. It can be argued that the 
use of different density cut-offs per intervention arm may partly solve 
this problem, but this is less easy to interpret, and such cut-offs cannot be 
specified in advance.
3. Subgroup analysis
Subgroup analyses are conducted to assess to what extent individuals with 
certain characteristics respond differently to the intervention than those 
without. In quantitative interaction, the intervention is either superior or 
inferior for all subgroups but its effect is more marked in one subgroup. 
In qualitative interaction, the treatment effect is in opposite directions in 
different subgroups. Although indications for interaction may be obtained by 
stratified analysis, it should be formally investigated by assessing interaction 
between the subgroup variable and the intervention in a multiple regression 
model (Yusuf 1991, Parker et al. 2000).
Subgroup analyses feature prominently in this thesis. Even though their 
results can be informative, the extent to which they should influence the 
interpretation and conclusions in a trial report is open to dispute (Yusuf et al. 
1991, Assmann et al. 2000, Fletcher 2007, Wang et al. 2007, Sun et al. 2010). On 
one hand, the sample size is often insufficient to provide adequate statistical 
support for interaction. On the other hand, the abundance of baseline 
factors that are usually measured creates the risk of assessing intervention 
effects in multiple subgroups in the hope that something will ‘come up’ 
that is ‘statistically significant’. Selective reporting of such factors leads to 
publication bias.
Criteria to evaluate the credibility of subgroup analyses are provided by 
several authors (e.g. Oxman and Guyatt 1992, Wang et al. 2007, Sun et al. 
2010). The evaluation of subgroup effects should not be framed in terms of 
absolute rejection or acceptance but one should rather assess the likelihood 
that a subgroup effect is real. To enhance their plausibility, anticipated 
subgroup effects (and their direction) should be predefined based on 
expected mechanisms and preferably in the context of similar findings from 
other studies. Statistical examination of the interaction effect should confirm 
that the observed differences are indeed unlikely to have occurred by chance. 
Consistency of subgroup effects across closely related outcomes enhances 
its credibility. Ideally, it should be shown that differences in effect between 
subgroups are independent of factors that may be associated with the criteria 
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that define the subgroups, although this assessment is usually compromised 
by limitations in the number of events that occurred. Exaggerated subgroup 
claims that are not sufficiently supported by the evidence or even coincidental 
findings may mislead decisions about intervention policies and should be 
avoided (Pocock et al. 2002).
On the basis of previous evidence and presumed mechanisms, we anticipated 
several interactions and, accordingly, predefined a limited number of 
subgroup analyses in a pre-established analysis plan for the primary outcome 
variable. In accordance with established guidelines (ICH 1998), we reviewed 
and updated this plan before breaking the blind (Annex 2).
4. Ethical aspects
Justification to include placebo: The use of a placebo is essential to reach 
conclusions about efficacy. We felt that the use of zinc placebo was justified 
because there are no national policies for micronutrient supplementation 
in Tanzania, and there was substantial uncertainty about the benefits of 
zinc and multi-nutrients in our study population (Verhoef 2007). We also 
anticipated that the implementation of the trial would provide benefits to 
all participating children, including those who received placebo. Because of 
the research dispensary that we constructed for this trial, all children in the 
area had 24h/day access to primary care and received medical free of charge 
for common childhood illnesses. Those receiving placebo were probably 
better off than non-participating children because they were seen daily by 
community health workers and, when they were sick, we administered 
diagnostic tests that were not available to non-participating children.
Based on evidence for age interaction and significant mortality reduction 
in children older than 12 months found in the Pemba trial (Sazawal et al. 
2007), Black and colleagues (2007) questioned the ethical acceptability of 
using placebo for zinc in children older than 12 months. To some extent, this 
claim seems supported because the authors reported to have pre-specified 
such subgroup analysis in their study protocol. It is inappropriate, however, 
to assess effect modification by statistical significance within subgroups, 
because it uses a within-subgroup comparison to draw inferences about 
between-subgroup differences (Parker et al. 2000), whilst the p-value 
reported (0.07) (Sazawal et al. 2007) does not provide conclusive evidence 
for such effect modification by age, particularly in the context of a trial with 
multiple subgroup analyses (Lagakos 2006, Sun et al. 2010).
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Although the uncertainty principle is widely used to ethically justify a 
randomised trial, ‘substantial uncertainty’ is a subjective judgment, and it is 
difficult to see who should make this judgment, how it should be practically 
interpreted and how consensus can be reached (Senn 2003). There may be 
sceptics who disagree with the ‘substantial uncertainty’ about the benefits 
of zinc, and argue that it is not ethical to include a placebo, on the grounds 
that poverty prevents the study population from having access to zinc 
and prevents the implementation of policies to increase zinc intake. In this 
view, the use of placebo would be unacceptable, and our trial would lack a 
rationale for assessing the efficacy of zinc. However, an alternative defence 
is possible: because zinc is not generally available to the study population, 
our trial represents the only chance for eligible children of getting zinc. Thus 
a prohibition of the trial on ethical grounds would be against the interest of 
the eligible child (or his/her guardian).
Justification to include iron and folic acid in the supplement: Critics may also 
argue that universal supplementation with iron and folic acid is unethical in 
view of the findings of the Pemba study that was reviewed in the preceding 
sections of this chapter. In the main trial of the Pemba study, however, 
children were not offered malaria prevention, diagnosis or treatment services 
other than those available through routine care by the primary health system 
in Zanzibar. By contrast, we treated all Plasmodium-infected children at 
baseline; excluded those with haemoglobin concentration < 70 g/L; provided 
iron and folic acid in a supplement that also contained other micronutrients, 
at least one of which (vitamin A) has been reported to protect against malaria 
(Shankar et al. 1999); improved access to care through construction of the 
research dispensary and provision of free transport for children referred to 
hospital; conducted a medical examination at a survey during the follow-
up period; provided medical examinations, diagnostics and treatment for 
common childhood diseases free of charge; and we were warned of severe 
disease in study children through daily reports from community workers. 
These measures were probably more extensive than those used in the Pemba 
sub-study, where iron and folic acid protected against severe adverse events. 
A recent systematic review, which included data from the Pemba study, 
also concluded that iron does not increase malaria incidence or death when 
regular malaria surveillance and treatment services are provided (Ojukwu 
et al. 2009).
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Summary
Background: Protection by zinc supplementation against malaria may 
depend on concomitant supplementation with other nutrients. We measured 
the effect of supplementation with zinc and other nutrients on the rates of 
malaria and other febrile illnesses.
Methods: In a highly malaria-endemic area in Tanzania, we selected children 
aged 6-60 months with height-for-age z-score ≤ –1.5 SD. Plasmodium-infected 
children were treated with artemether-lumefantrine at baseline. Children 
(n=612) were randomly assigned to daily oral supplementation with zinc 
alone (10 mg), multi-nutrients without zinc, multi-nutrients with zinc, or 
placebo. The primary outcome, episodes of malaria, was assessed in children 
reported sick at a primary care research clinic. In the primary, intention-
to-treat analysis, we adjusted for pre-specified baseline factors that were 
prognostic for outcome (age class, Plasmodium infection status, distance 
between homestead and clinic, height-for-age z-score and mosquito net use). 
Findings: The primary analysis included 1,572 episodes of malaria during 
526 child-years of observation. Supplementation with zinc, multi-nutrients 
without zinc and multi-nutrients with zinc resulted in adjusted hazard ratios 
of 0.99 (95% CI: 0.82-1.18), 1.04 (0.87-1.23) and 1.14 (0.96-1.35), respectively. 
Corresponding values for non-malarial febrile illnesses were 0.79 (0.63-0.99), 
0.83 (0.65-1.06) and 0.85 (0.68-1.07). In the first 100 days of intervention, and 
in the analysis of first events, supplementation with multi-nutrients, with or 
without zinc, increased the hazard of malaria by one-third.
Interpretation: In this zinc-deficient population, we found no evidence that 
zinc supplementation protected against malaria. However, it reduced the 
rate of non-malarial fevers. Supplementation with multi-nutrients including 
iron may be unsafe in malaria-endemic areas, even when recipients have 
excellent access to health care. (ClinicalTrials.gov number, NCT00623857).
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Introduction
Preventive zinc supplementation can reduce the burden of diarrhoea and 
respiratory tract infections (IZiNCG 2009). If effective against malaria, it 
would be a tremendous advance in public health, particularly in Africa, where 
90% of malarial deaths occur. Anti-malarial efficacy has been investigated in 
four trials, with discordant results. In Gambian toddlers, twice-weekly zinc 
seemed to reduce the mean number of clinic visits for malaria by 32% (Bates 
et al. 1993). In Papua New Guinea, daily zinc reduced rates of malaria due to 
Plasmodium falciparum by 38% (Shankar et al. 2000). By contrast, in Burkina 
Faso and Peru (Müller et al. 2001, Richard et al. 2006), there was no evidence 
of protection, despite zinc deficiency being highly prevalent at baseline and 
reversed by supplementation.
Malaria was detected among children self-reporting at clinics in Papua New 
Guinea and The Gambia, whereas cases were detected through regular home 
visits in Burkina Faso and Peru, possibly indicating that zinc supplementation 
is more efficacious in preventing severe malaria than mild episodes. 
Alternatively, the response to zinc may be suppressed when children are 
also deficient in other nutrients (Ronaghy et al. 1969, 1974). Simultaneous 
supplementation with other nutrients may be required to overcome a lack of 
effect of zinc supplements when given alone.
Our study aimed to assess the effect of supplementation with zinc, alone or 
in combination with other nutrients, on the rates of malaria and other febrile 
illnesses among Tanzanian children.
Methods
Study population: We conducted the study between February 2008 and 
March 2009, in a rural area in Handeni District, Tanzania (Veenemans et 
al. 2008) where malaria transmission is intense (Ellman et al. 1998). As per 
national guidelines, we treated uncomplicated malaria with artemether-
lumefantrine (Novartis Pharma, Basel, Switzerland). This drug combination 
is highly efficacious (Ogbonna et al. 2008, White 2008), and was available 
for free at government health-facilities but not in local shops. Participating 
children received free medical care for common illnesses. Because of the 
strategic location of the research clinic, and based on interviews with local 
informants, we believe that very few sick participants were brought to other 
health facilities, or were treated at home.
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The study (ClinicalTrials.gov: NCT00623857) received ethical clearance in 
The Netherlands and Tanzania; parents/guardians gave written consent. 
There were no important changes to methods after trial commencement.
Study design: In this explanatory efficacy trial with a 2×2 factorial parallel 
design, children randomly received daily supplements with: a) both zinc 
and multi-nutrients (Annex 3); b) zinc; c) multi-nutrients without zinc; or d) 
placebo.
Recruitment: In four villages, we listed all resident children aged 6-60 
months and screened them in daily batches until attaining the target number 
(n=600) in August 2008 (Figure 1). We computed anthropometric indices 
as the average of two recordings, taken on consecutive days. Following a 
physical examination, we collected venous blood in EDTA-tubes suitable 
for trace element analyses (Becton-Dickinson, Franklin Lakes, NJ). We 
centrifuged one aliquot immediately after collection and stored plasma in 
liquid nitrogen; we examined a second aliquot by haematology analyzer 
(Sysmex KX21, Kobe, Japan).
Figure 1. Participant flow over time. The black line indicates the cumulative number of 
children in the trial; the blue line indicates the cumulative children who had been included in 
the second survey; the dashed line indicates the date that the trial was stopped.
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We used malaria dipstick tests (CareStart, G0121, Access Bio, Monmouth 
Jct, NJ, USA) to detect lactate dehydrogenase produced by live P. falciparum 
or other human Plasmodium species. This test has a sensitivity of 96% for 
samples with > 50 P. falciparum parasites/mL (Piper et al. 1999). Blood films 
were prepared for all children. Children with Plasmodium infection were 
treated with artemether-lumefantrine.
We excluded children with height-for-age z-scores > –1.5 SD (who are at 
lower risk of zinc deficiency) (Brown et al. 2002), weight-for-age z-score < 
–3 SD, haemoglobin concentration < 70 g/L, those unlikely to comply with 
interventions, whose parents/guardians refused consent, or with signs of 
severe or chronic disease.
Randomisation and blinding: A colleague not otherwise involved in the 
trial used tables with random numbers to generate randomly permuted 
blocks with random size 4 or 8 within each of 6 strata defined by Plasmodium 
infection (yes/no infected) and age class (6-17 months, 18-35 months and 
36-60 months). Interventions were indicated by colour code on paper 
slips in opaque, consecutively numbered envelopes that were prepared in 
advance, in excess of the expected number required. A simple colour code 
was employed to minimize the possibility of children receiving the wrong 
supplements.
Supplements, as powder in colour-coded capsules, were contained in blister 
packs, and administered orally after suspending capsule contents in clean 
water or breastmilk. All types of powder had similar appearance, smell 
and taste. At the end of each screening day, when eligibility had been fully 
established, children were individually allocated in order of their screening 
number to intervention groups by drawing successive envelopes from a box 
corresponding to the infection- and age-specific stratum for that child. The 
number of the envelope was then recorded on a list before the envelope was 
opened. The randomisation code was not revealed to the researchers until 
data collection and the database had been completed.
Follow-up and case detection: Community volunteers administered 
supplements 7 days per week close to the homes of participating children 
and reported daily to field staff, who followed up the same day in case of 
non-compliance. Field staff made regular, unannounced spot checks to 
ensure adherence to procedures. Supplementation and follow-up continued 
for all children until 12 March 2009, when the trial was stopped. 
At recruitment, we asked parents to bring study children to the clinic if their 
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child would develop fever or became unwell. A clinical officer was on 24h-duty 
and collected medical information on standardised forms. According to 
standard procedures, axillary temperature was measured and dipstick tests 
administered for any child with current or recent guardian-reported fever; 
for those with positive dipstick test results, we prepared blood films and 
measured whole-blood C-reactive protein concentrations and haemoglobin 
concentrations using point-of-care tests (QuikRead, Orion Diagnostica, 
Espoo, Finland and HemoCue, Ängelholm, Sweden, respectively).
A second survey, at 251 days (median; 95% reference range: 191-296 days) 
after enrolment, followed similar procedures. 
Laboratory analyses: Plasma concentrations of C-reactive protein and ferritin 
were measured (Meander Medical Centre, Amersfoort, The Netherlands) on 
a Beckman Coulter Unicel DxC880i system according to the manufacturer’s 
instructions. Plasma zinc concentrations were determined by inductively-
coupled plasma-mass spectrometry (Varian 820-MS; CV: 9% at 26.8 µM; 13% 
at 21.25 µM and 13% at 15 µM; n=32, V=10 µL).
Statistical analysis: Data were analysed following a pre-specified plan, by 
intention-to-treat, using SPSS (v15·0 for Windows, SPSS, Chicago, IL, USA), 
CIA (v2.1.2) (Altman et al. 2000) and STATA (v11; College Station, Tx, USA). 
Compliance was measured as the proportion of children who consumed 
> 95% of scheduled supplements. Nutritional status was defined by the 
presence of iron deficiency (plasma ferritin concentration < 12 µg/L; UNICEF/
UNU/WHO 2001), zinc deficiency (plasma zinc concentration < 9.9 µmol/
mL; IZiNCG 2004) or being stunted (height-for-age z-score < –2 SD). Because 
inflammation can influence these plasma concentrations independently 
of iron and zinc status, we also conducted analyses that were restricted to 
individuals without inflammation.
The primary outcome, an episode of malaria, was pre-defined as a positive 
result for the malaria dipstick test in children with guardian-reported fever 
and any of the following: a) confirmed fever (axillary temperature ≥ 37.5°C), 
or b) unconfirmed fever with inflammation (whole blood C-reactive protein 
concentrations ≥ 8 mg/L), separated by at least 14 days from a previous 
malaria episode. We considered episodes with pre-defined parasitaemia 
thresholds as secondary outcomes.
Because we considered a priori a reduction in overall disease burden of 
primary public-health importance, and because analysis of first episodes 
may give biased estimates of intervention effects (O’Meara and Lang 2009, 
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Cheung et al. 2010), our primary analysis included all events. We used Cox 
models with robust methods to account for correlation between episodes 
within children. Following the analysis plan, we adjusted for prognostic 
factors at baseline (age class [6-18 months, 18-35 months and 36-59 months], 
Plasmodium infection, mosquito net use, distance between homestead and 
clinic, height-for-age z-score). We also conducted a pre-specified secondary 
analysis to assess the influence on effect estimates of excluding observations 
in a 14-day post-treatment prophylactic period.
To assess changes in intervention effect over time, we estimated effects on all 
events within the first 100 days versus the subsequent period. We arbitrarily 
defined a cut-point of 100 days because this period covered almost half of all 
episodes, and adjusted for baseline factors as described above. We similarly 
explored effects within the first 50 days.
In a secondary analysis we assessed intervention effects on time-to-first 
malaria episode using Kaplan-Meier analysis. 
We conducted pre-specified subgroup analyses (all events; unadjusted) to 
explore to what extent the magnitude of treatment effects depended on age 
class, presence of parasitaemia, and nutritional status at baseline. To further 
explore whether interactions between iron deficiency and multi-nutrient 
interventions could be explained by age, we assessed effect differences 
between iron deficient and replete children in each age class separately.
Role of the funding source: The funder had no other role in the trial 
whatsoever, except for supplying finance and peer reviewing the original 
grant application. HV had full access to all the data in the study; takes 
responsibility for the integrity of the data and the accuracy of the data 
analysis; and had the final responsibility to submit this report for publication.
Results
Of 1029 screened children, 662 had height-for-age z scores ≤ –1.5 SD; of these, 
612 were eligible and randomised. 20 children (3%) did not complete the trial: 
3 died; 2 were withdrawn by parents; 15 emigrated from the area (Figure 
2). Another 2 children discontinued the intervention but were available for 
follow-up. Compliance was high (96%) and similar in all four groups.
Groups were similar in baseline characteristics except that there were 
slightly more boys and zinc-deficient children in the multi-nutrient group 
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Table 1.  Baseline characteristics of study participants, by intervention group
Zinc Multi-nutrients 
without zinc
Multi-nutrients 
with zinc
Placebo
n  153 155  151  153
Sex M/F [n/n] 46%/54% [70/83] 56%/44% [87/68] 44%/56% [66/85] 50%/50% [76/77]
Age class
6-17 months 24% [36]  23% [36] 24% [36] 24% [36]
18-35 months 36% [55] 36% [55] 34% [51] 35% [54]
36-59 months 41% [62] 41% [64] 42% [64] 41% [63]
Plasmodium infection 1 43% [66] 41% [64] 44% [67] 44% [68]
Height-for-age, z-score -2·36 ± 0·69 -2·50 ± 0·69 -2·39 ± 0·71 2·45 ± 0·69
Inflammation 2 34% [52] 33% [51] 34% [51] 31% [47]
Zinc deficiency 3
All children 63% [97] 71% [110] 70% [105] 65% [100]
Without 
inflammation 4
58% [59] 65% [68] 59% [59] 60% [64]
Haemoglobin 
concentration, g/L
101·8 ± 12·6 102·7 ± 12·8 103·8 ± 12·7 102.8 ± 12·7
Anaemia 5 75% [114] 65% [100] 68% [103] 65% [100]
Iron deficiency 6
All children 16% [25] 18% [28] 20% [30] 19% [28]
Without 
inflammation 4
23% [23] 24% [25] 24% [24] 24% [25]
Iron deficiency 
anaemia 
All children 12% [18] 12% [19] 15% [23] 14% [21]
Without 
inflammation 4
16% [16] 16% [17] 18% [18] 18% [19]
Distance from 
homestead to 
dispensary, km 7
3·66 ± 2·31 3·52 ± 2·06 3·54 ± 2·07 3·60 ± 3·38
Mosquito net use 8 32% [48] 36% [55] 30% [45] 31% [46]
Mean ± SD, % [n] or median (25- and 75-percentiles) unless indicated otherwise.
1 As indicated by a positive result for pLDH-based dipstick test (see text); 2 Plasma C-reactive protein 
concentration ≥ 8 mg/L; 3 Plasma zinc concentration < 9.9 µmol/L; 4 n=101, 104, 100 and 106, respectively (5 
missing values for plasma ferritin concentration); 5 Haemoglobin concentration < 110 g/L; 6 Plasma ferritin 
concentration < 12µg/L (6 missing values); 7 Measured as the crow flies, based on global positioning data; 
8 Data missing for 11 children.
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(Table 1). The prevalence of zinc deficiency was 67% overall, and 60% in 
those without inflammation; this prevalence was dramatically reduced by 
zinc supplementation, whether given alone or with other micronutrients 
(Table 2).
Of 2,462 episodes of reported fever, 1,618 were accompanied by Plasmodium 
infection and were treated with anti-malarial drugs; 1,572 episodes classified 
as malaria: 1,499 (95%) due to P. falciparum and 73 (5%) due to other Plasmodium 
species. The incidence of malaria was 2.93 events/ child-year. There were 
1,314, 1,119 and 263 episodes with densities exceeding 3,000, 10,000 and 
100,000 parasites/µL, respectively. Thirty cases, occurring in 27 children, 
were referred to hospital: 5 for life-threatening disease; 25 lived far from the 
dispensary, and the clinician referred them as a precaution (haemoglobin 
concentrations < 60g/L without respiratory distress or dehydration: 18; other 
reasons: 7). There were no episodes of cerebral malaria.
When analyzing all episodes of malaria, we found no effect of zinc or multi-
nutrients without zinc, whereas multi-nutrients with zinc seemed to increase 
the malaria rate (hazard ratio 1.14, 95% CI: 0.96-1.35; Figure 3). Similar results 
were obtained when excluding observations for 14 days post-treatment or 
when restricting analysis to P. falciparum cases (not shown). We found no 
evidence that zinc alone protected against episodes with parasite densities 
exceeding 3,000, 10,000 and 100,000 parasites/µL (hazard ratios: 0.96 [0.78-
1.19], 0.93 (0.75-1.16) and 1.13 [0.75-1.68], respectively), or influenced the 
incidence or time-to-first episode of malaria (Table 3, Figure 4).
Supplementation with multi-nutrients, both with and without zinc, increased 
the incidence of malaria by one-third (Table 3), and reduced the time-to-first 
event (median: 54 days for both groups, as compared to 78 days for placebo; 
p=0.01 and 0.02, respectively; Tarone-Ware test); adjustment for baseline 
factors gave similar ratios (Table 3).
 
In the first 100 days of supplementation, we recorded 695 malaria episodes 
in 408 children. In this period, malaria rates in the groups receiving multi-
nutrients without and with zinc exceeded those in the placebo group by 15% 
and 30%, respectively (Table 3). Corresponding estimates for the first 50 days 
were 28% (-3% to 70%) and 42% (6% to 91%).
Of 890 febrile episodes that did not classify as malaria cases, 827 (93%) were 
without Plasmodium infection. Zinc reduced the rate of non-malarial fever 
episodes by 21% (1%-37%), whilst multi-nutrients, with or without zinc, 
resulted in slightly lower reductions (Figure 3).
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Figure 2.  Study profile. Compliance was measured as the proportion of children who 
consumed > 95% of scheduled supplements.
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Figure 3.  Intervention eff ects on hazard of malaria (1st episodes and all episodes; top and 
centre) and non-malarial fevers (all episodes; bott om), adjusted for age class (18-35 months 
and 36-59 months), Plasmodium infection status, distance between homestead and clinic 
(continuous variable), height-for-age z-score (continuous variable) and mosquito net use at 
baseline.
Figure 4.  Intervention eff ects on time to fi rst episode of malaria, as assessed by Kaplan-
Meier analysis. Values indicate the number of children, by intervention group, who had 
remained free of malaria at 0, 100, 200 and 300 days. Pairwise group comparison with placebo 
yielded p-values of 0.32, 0.02 and 0.01 for zinc, multi-nutrients without zinc and multi-
nutrients with zinc, respectively (Tarone-Ware test).
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We found no evidence that baseline factors influenced the magnitude of the 
zinc effect. In contrast, the increased malaria rates due to multi-nutrients, 
whether with or without zinc, seemed more pronounced in younger children, 
and seemed mostly restricted to those who were zinc or iron deficient at 
baseline (Figure 5). Even when assessed in separate age classes, the increased 
effects of multi-nutrients on rates of malaria remained mostly and consistently 
restricted to children with iron deficiency at baseline (not shown). Among 
children who received multi-nutrients with zinc, the increased rate of malaria 
also seemed to be limited to the least stunted children.
Discussion
Despite a high prevalence of zinc deficiency, excellent compliance and few 
drop-outs, we found no evidence that preventive zinc supplementation, 
alone or with multi-nutrients, reduced rates of febrile attacks of malaria; there 
was strong evidence, however, that it protected against non-malarial febrile 
episodes. Multi-nutrient supplementation was associated with increased 
numbers of malaria episodes within the first 100 days but also seemed to 
reduce rates of non-malarial febrile episodes.
To increase specificity of malaria case definitions, a threshold parasitaemia 
is often used that is pre-determined by modelling fever risk as a function 
of density of asexual parasites (Schellenberg et al. 1994, Smith et al. 1994). 
Because densities can vary greatly within short time spans, ideally require 
leukocyte counts to be determined simultaneously (Delley et al. 2000, Koram 
and Molyneux 2007, O’Meara et al. 2007), and parasitaemia thresholds can 
vary with intervention group (O’Meara et al. 2007, Smith 2007), we favoured 
our approach of treating Plasmodium-infected participants at baseline. 
Even so, 32% of children had become infected but were symptom-free at 
the second survey. In such children, episodes of non-malarial fevers would 
have been misclassified as being malaria. Such misclassification may have 
increased with time as more children became asymptomatically infected, so 
that intervention effects on malarial fevers would have become increasingly 
mixed with protective effects that we measured against non-malarial fevers. 
This is consistent with hazard ratios on malaria measured after 100 days 
of follow-up being lower in all three micronutrient intervention groups 
than values observed within the first 100 days (Table 3), and the more 
pronounced effects measured in the analysis of first events. Thus estimates 
for the initial period may better reflect overall effect on malarial morbidity 
than estimates for the entire intervention period. Alternatively, intervention 
effects, particularly those of multi-nutrients, may have changed over time, 
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whereby a short-lived increase in risk would not be adequately reflected in 
the analysis of the overall time period.
                                                                                                                    
Two previous trials indicated that zinc can protect against malaria. The 
Gambian trial (Bates et al. 1993) was not designed to assess this association, 
and episodes were recorded through routine clinic procedures. In Papua New 
Guinea, zinc reduced the incidence of febrile episodes with parasitaemia ≥ 
9,200/µL and ≥ 100,000/µL by 38% (3%-60%) and 69% (36%-87%), respectively 
(Shankar et al. 2000). Both studies were smaller than our study (91 cases of P. 
falciparum malaria in Papua New Guinea, as compared to 1,499 in our study).
It seems unlikely that discrepancies with our findings are explained by 
differences in access to health care and a differential effect on rates of severe 
malaria: even with episodes with parasitaemia ≥ 100,000/µL, our confidence 
intervals (Table 3) are incompatible with the magnitude of the protective 
effect reported from Papua New Guinea. In addition, the overall and malaria-
specific mortality reduction found in Pemba (7% and 10%, respectively) 
(Sazawal et al. 2007), seems inconsistent with the 69% reduction in episodes 
with parasitaemia ≥ 100,000/µL that was reported from Papua New Guinea. 
The intensity of malaria transmission in Papua New Guinea was much lower 
than in Burkina Faso, Pemba or our study, raising the question whether zinc 
only affords protection in populations with low acquired immunity. The 
absence of an age-dependent decrease in efficacy of zinc supplementation 
in our study (Figure 4) makes this unlikely. Thus the divergent results from 
Papua New Guinea are most likely due to unknown differences in host, 
parasite or environmental factors that predict the response to zinc.
When results from all trials are considered together, there is no evidence that 
zinc interventions can reduce the burden of malaria in Africa. In most African 
settings, however, any fever is treated with anti-malarial drugs, whether due 
to malaria or other causes (WHO 2010). Through its protective effect on non-
malarial fevers, preventive zinc supplementation may reduce unnecessary 
anti-malarial therapy, particularly in settings with low malaria transmission. 
This is important in view of emerging P. falciparum resistance to artemisinin 
(Dondorp et al. 2009). Our results, and findings of protection afforded by 
zinc against diarrhoea and respiratory infections (IZiNCG 2009), should 
encourage efforts to increase the intake of zinc in deficient populations.
Our findings strongly suggest that multi-nutrient supplementation and home 
fortification can be unsafe in malaria-endemic areas even in conditions with 
excellent access to health care and appropriate treatment. The adverse effect 
of multi-nutrients was probably due at least in part to iron (Oppenheimer 
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2001, Sazawal et al. 2006, WHO 2007). Safety may be improved by modifying 
the formulation of supplements, in particular by reducing the iron dose, but 
multi-nutrients cannot be recommended until this has been demonstrated. 
Based on a subgroup analysis of the Pemba sub-study with 162 adverse events 
(hospitals admissions or deaths), WHO now advocates a policy to restrict 
universal iron supplementation to individuals with iron deficiency (WHO 
2007). Our subgroup analyses, based on 807 episodes of malaria (Figure 4), 
do not support this strategy, but rather suggest that effects of iron and other 
nutrients on malaria are more pronounced in iron-deficient children. Sub-
group analyses are often over-interpreted, however, and should generally be 
considered exploratory (Assmann et al. 2000). 
We found no evidence that zinc supplementation reduced the burden of 
malaria. However, it reduced the incidence of non-malarial febrile episodes. 
In malaria-endemic countries, caution should be taken when implementing 
multi-nutrient supplementation or home fortification as a public health 
measure.
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Summary
Background: There are concerns about the safety of supplementation with 
iron and other micronutrients in malaria-endemic areas. We assessed its 
effect on rates of malaria, using various case definitions.
Methods: Rural Tanzanian children aged 6–60 months and with height-for-
age z-score < –1.5 SD (n=612) were randomly allocated to multi-nutrient 
supplements (with or without zinc) or placebo. Case definitions for malaria 
included episodes with asexual parasite densities > 10,000/µL or > 100,000/
µL, or with haemoglobin concentration < 80 g/L. We compared rates using 
Cox regression, also to assess the influence on effects of age and iron status 
at baseline.
Findings: We found no effect of multi-nutrients on the overall rate of malaria 
episodes, regardless the case definition used. Subgroup analysis indicated, 
however, that this effect strongly depended on age and iron status at 
baseline; multi-nutrients increased malaria rates in the youngest children 
(HR 1.26; 95% CI: 0.97–1.64) and in those with iron deficiency (HR 1.53; 1.11–
2.11), while supplementation had no evident effect among older and iron 
replete children (p-value for interaction with age and iron status: 0.02 and 
0.007 respectively, for episodes with > 10,000 parasites/µL). For the effect 
on haemoglobin concentrations during malaria, an opposite age-dependent 
pattern was observed. Children aged 6-17 months were better able to 
maintain haemoglobin concentrations during malaria episodes (p-value for 
interaction with age: 0.008) when having received multi-nutrients.
Conclusions: Supplying multi-nutrients at levels normally provided through 
supplementation or home fortification cannot be universally recommended 
in malaria-endemic areas until its safety has been demonstrated. Our findings 
call into question the recommendation by the World Health Organization 
that iron supplements should be administered routinely to iron-deficient 
infants in settings with adequate access to anti-malarial treatment.
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Introduction
Randomised trials in malaria-endemic areas have consistently shown that 
supplementation with iron, alone or in combination with other micronutrients, 
increases haemoglobin concentrations and reduces the prevalence of anaemia 
(Ekvall et al. 2000, Ouédraogo et al. 2008, Friis et al. 2003, Ojukwu et al. 2009). 
On the other hand, these nutrients can increase the incidence and severity 
of malaria episodes. In a large trial among children aged 1–35 months in 
Pemba, supplementation with iron and folic acid increased the incidence of 
serious adverse events by 12%, presumably due to malaria (Sazawal et al. 
2006). Recently, we found that multi-nutrient supplementation in Tanzanian 
children aged 6–60 months increased malaria rates (Veenemans et al., 
submitted) but we did not assess effects on the severity of malaria.
During episodes of malaria, maintenance of haemoglobin concentration is 
critical for child survival. By increasing parasite propagation, supplementation 
may exacerbate haemolysis. Thus, gains in haemoglobin concentrations due 
to supplementation before febrile malaria attacks may be counteracted or 
outdone by more pronounced haemoglobin losses during such episodes. 
In a randomised trial in Papua New Guinean infants aged 6–12 months, 
the decrease in haemoglobin concentration associated with asymptomatic 
Plasmodium infection at two follow-up surveys seemed more pronounced 
among those receiving iron (Oppenheimer et al., 1986). By contrast, while 
supplementation with iron and folic acid increased rates of cerebral malaria 
in Pemba (Sazawal et al. 2006), it seemed to reduce the risk of hospitalisation 
with severe anemia, although the statistical evidence for this reduction was 
not strong. We have not found reports of randomised trials on the effect of 
preventive supplementation with iron or multi-nutrients on haemoglobin 
concentration during febrile episodes of uncomplicated malaria.
Subgroup analysis of data from a sub-study within the Pemba trial suggested 
that the increase in adverse events due to iron and folic acid is restricted to 
those who were iron-replete at baseline, and more pronounced in children 
aged 12–23 months than in their peers from other age groups. Such effect 
modification by iron status was not supported, however, by a recent meta-
analysis of iron supplementation studies in malaria-endemic countries 
(Ojukwu et al. 2009). In our recent trial, subgroup analysis suggested that 
the effect of multi-nutrients on rates of malaria was larger in children aged 
6–18 months than in older pre-school children (Veenemans et al., submitted). 
The absence of adequate protection in the youngest children and the gradual 
acquisition of protective immunity make an age-dependent effect plausible.
In the present study, we assessed the effect of supplementation with multi-
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nutrients on rates of malaria episodes with high parasite densities or with 
low haemoglobin concentrations, and on indicators of disease severity 
(including haemoglobin concentrations) during these episodes. We also 
explored to what extent the magnitude of intervention effects depended on 
age and iron status at baseline.
Methods
Study design: This study was part of a randomised efficacy trial with the 
primary aim to assess the effect of supplementation with zinc and other 
nutrients on malaria rates. Children received daily oral supplements with: 
a) zinc; b) multi-nutrients without zinc; c) both multi-nutrients and zinc ; or 
d) placebo. The multi-nutrient supplement included iron (18 mg as ferrous 
fumarate), folic acid (93.75 µg), vitamin A (450 µg, as retinyl palmitate), 
vitamin B12 (1.17 µg), vitamin B1 (0.625 mg as thiamin nitrate), vitamin 
B2 (0.55 mg riboflavin), copper (340 µg) and vitamin E (6.6 mg as RRR-α-
tocopherol), all of which may have haematinic effects. Further details about 
the composition of the supplement, study design and intervention effects on 
malaria rates, will be reported elsewhere (Veenemans et al., submitted).
Study population and recruitment: The trial was conducted between 
February 2008 and March 2009 in a rural area in north-eastern Tanzania, 
with intense year-round transmission. All resident children listed in a pre-
conducted census were invited for an information meeting and screening. 
They were eligible for randomisation when aged 6–59 months and with a 
height-for-age z-score below –1.5 SD. We excluded children with severe 
wasting (weight-for-age z-score < –3 SD), haemoglobin concentration < 
70 g/L, signs of chronic illness, and those unlikely to remain permanently 
resident or comply with the supplementation for the duration of the trial, or 
whose parents or guardians refused consent.
At baseline, we recorded anthropometric measurements, collected venous 
blood in EDTA tubes, and conducted a rapid dipstick test to detect 
Plasmodium infection. Children with a positive test result were treated 
immediately with artemether-lumefantrine. We performed an automated 
blood examination (Sysmex KX21, Kobe, Japan) the same day, and stored 
plasma for subsequent analyses of biochemical indicators of iron status 
and inflammation in The Netherlands. An aliquot of fresh blood was used 
to detect Plasmodium infection by microscopy. The location of the child’s 
homestead was determined using a global positioning system.
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Randomisation and intervention: We used permuted blocks with random 
size (4 or 8) within 6 strata defined by the presence of Plasmodium infection 
and age class (6–17 months, 18–35 months and 36–60 months). The allocation 
sequence was generated a priori by a person not involved in the field work, 
using a table of random numbers, and the intervention (indicated by colour 
code) was enclosed in consecutively numbered opaque envelopes, separated 
in 6 batches for the strata mentioned above. At the end of each screening 
day, the names of eligible children were listed by screening number and 
each name was randomly allocated to an intervention by drawing the next 
envelope from a box that corresponded to the age- and malaria- specific 
stratum for that child.
Supplements, in the form of powder in colour-coded capsules, were 
contained in blister packs, and administered orally after suspending capsule 
contents in clean water or breastmilk. Supplementation was performed by 
local community volunteers, who daily reported about compliance to field 
staff at the research dispensary.
Follow-up and case detection: A clinical officer was on duty at the research 
clinic 24 hours, 7 days per week. At recruitment, parents or guardians were 
requested to bring participating children to the dispensary immediately 
when detecting fever or any other illness. 
For all children with reported fever, we collected blood by finger puncture to 
detect the presence of lactate dehydrogenase produced by live P. falciparum 
or other human Plasmodium species (CareStart™, G0121, Access Bio, 
Monmouth Jct, NJ). For those with a positive dipstick test result, we prepared 
two blood slides, and measured whole blood concentrations of haemoglobin 
and C-reactive protein using a portable photometer (HemoCue, Ängelholm, 
Sweden) and an immunoturbidimetric test (QuikRead, Orion Diagnostica, 
Espoo, Finland; detection limit: 8 mg/L), respectively. C-reactive protein is 
an acute phase protein; its plasma concentration increases within 6 hours 
after inflammatory stimulus, decreases rapidly with recovery, and reflects 
the severity of inflammation (Jaye and Waites 1997).
In children with confirmed malaria (case definition defined a priori; see 
below), we collected and stored an aliquot of plasma (EDTA Microtainer, 
Becton Dickinson, Franklin Lakes, NJ) in liquid nitrogen for subsequent 
measurement of histidine-rich protein-2 (HRP2) concentration. This protein 
is released into the plasma at schizont rupture, and its plasma concentration 
may more accurately represent total body parasite biomass, because it also 
reflects the presence of parasites that are sequestered by cytoadherence 
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to endothelial cells in the microvasculature of organs, so that they remain 
undetected with conventional microscopy. In patients with severe malaria 
admitted to hospital, plasma HRP2 concentrations better predict disease 
severity and death than parasite count determined by microscopy (Dondorp 
et al. 2005). Because the protein has a mean plasma elimination half-life 
exceeding 3.5 days, however, concentrations not only reflect current parasite 
load, but are also determined by the duration of the infection and preceding 
densities at the time of sample collection.
We conducted a second survey, following similar procedures as the baseline 
survey, at a median of 251 days (95% reference range: 191–296 days) after 
enrollment.
Artemether-lumefantrine (Novartis Pharma, Basel, Switzerland) was 
administered to any child with current Plasmodium infection upon enrolment, 
or with reported fever and a positive dipstick test result during the follow-
up period.
Laboratory analyses: Peripheral blood parasite density was determined by 
microscopy; slides with results that were inconsistent with those from the 
dipstick test were read twice. Asexual Plasmodium parasites were counted 
against at least 200 leukocytes, and density, expressed per µL blood, was 
estimated using an assumed leukocyte density of 8,000/µL. For children with 
very high densities, parasites were counted per 2,000 erythrocytes, in which 
case we used the estimated erythrocyte count at the time of the episode to 
determine the number of parasites per µL. The erythrocyte concentration 
was estimated based on haemoglobin concentration measured by HemoCue 
meter, using a linear model describing the relationship between haemoglobin 
concentrations and erythrocyte counts as assessed during surveys.
Plasma concentrations of HRP2 were determined by enzyme-linked 
immunosorbent assay using a commercial kit (Cellabs, Sydney, New South 
Wales, Australia). Due to financial limitations, we assessed this indicator only 
in samples collected from children with a first episode of malaria. Samples 
were aliquoted by 2-, 10-, 25- and 50-fold dilution into microwells precoated 
with anti-HRP2 capture antibodies. Each plate included a positive and a 
negative control provided with the kit, and assay steps were performed 
according to the manufacturer’s instructions. As a modification to the kit, we 
included serially diluted reference plasma on each plate, relative to which 
the concentration of HRP2 was determined for each plasma sample. The 
reference plasma consisted of a pooled sample collected from 50 children 
from the same study area with malaria, and was added by 10-, 20- ,40- ,80- 
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and 160-fold dilution to each plate. For samples that did not yield optical 
densities within the linear range of the reference curve, we repeated the 
assay at lower or higher dilutions as appropriate. HRP2 concentration in the 
reference plasma was estimated by comparison to a standard (also provided 
by the manufacturer of the kit) that was serially diluted in HRP2-negative 
human plasma, at decreasing concentrations (eight two-fold dilutions 
starting at 27.5 µg/L).
In plasma samples collected at baseline and the second survey, we measured 
concentrations of C-reactive protein and ferritin on a Beckman Coulter Unicel 
DxC880i system according to the manufacturer’s instructions. Genotype for 
α+-thalassaemia was determined as described earlier (Veenemans et al. 2008).
Definitions and statistical analysis: An episode of malaria was pre-
defined as a positive result for the malaria dipstick test with any of the 
following: a) confirmed fever (axillary temperature ≥ 37.5 °C as measured 
by electronic thermometer), or b) reported but unconfirmed fever, in the 
presence of inflammation (whole blood C-reactive protein concentrations > 
8 mg/L), separated by at least 14 days from a previous malaria episode. Iron 
deficiency was defined as plasma ferritin concentration < 12 µg/L; because 
inflammation can influence plasma ferritin concentrations independently of 
iron status, we also conducted analyses that were restricted to individuals 
without inflammation (C-reactive protein concentration < 8 mg/L). Anaemia 
was defined by haemoglobin concentration < 110 g/L (WHO, 2001).
All data were double-entered, cleaned and analyzed in SPSS (v15·0 for 
Windows, SPSS, Chicago, IL) and STATA (v11; College Station, Tx). For 
continuous outcome variables, we visually inspected distribution plots, and 
log transformed variables that were not normally distributed. We report 
arithmetic or geometric means (and 95% CIs) as appropriate. We expected 
no effect of zinc on haemoglobin concentrations, and in previous analysis 
we found no evidence of effects on malaria rates of zinc, either alone or with 
multi-nutrients. Thus, in the present analysis, we present marginal effects, 
whereby the pooled placebo and zinc groups are compared with the pooled 
groups receiving multi-nutrients.
We used Kaplan-Meier analysis and Cox regression models to assess 
intervention effects on rates of malaria with varying definitions to indicate 
disease severity (as defined above, episodes with parasite densities > 10,000/
µL or > 100,000/µL, and episodes with haemoglobin concentrations < 80 
g/L). In the Cox models, we used robust methods to account for correlation 
between episodes within children, and also assessed the influence of 
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adjustment for baseline factors that were prognostic for malaria (haemoglobin 
concentrations, Plasmodium infection, α+-thalassaemia genotype, distance 
between homestead and research clinic, mosquito net use, and height-for-
age z-scores) on effect estimates. 
As indicators of severity, we assessed parasite density, P. falciparum-specific 
HRP2 concentration and C-reactive protein concentration and haemoglobin 
concentration. We used multivariate linear regression to assess crude 
effects of multi-nutrient supplementation on these indicators, with log 
transformation as appropriate. As with HRP2 concentration, we restricted 
our analysis of intervention effects on C-reactive protein concentration and 
parasite density to first episodes of malaria. For haemoglobin concentrations, 
we also explored intervention effects at the second episode to assess whether 
associations found were consistent with those found in the analysis of 
haemoglobin concentration at the first episode. In the analysis of the effect 
on haemoglobin concentration, we adjusted for standardised baseline 
haemoglobin concentration and time between randomisation and outcome 
measurement.
For all outcomes, we assessed the influence of adjustment for prognostic 
factors at baseline (see preceding paragraph), and assessed intervention 
effects with stratification by age class and iron status at baseline, and used 
multivariate regression models to test differences in effect between these 
subgroups.
Results
Of 612 randomised children, 592 (97%) completed the study: 3 died; 2 were 
withdrawn by parents; 15 emigrated from the study area (Webfigure 1). 
Another 2 children discontinued the intervention but were available for 
follow-up. Overall, 96% of all children took more than 95% of the scheduled 
supplements. Groups had similar baseline characteristics (Table 1). 
Of 612 study participants, 507 (83 %) experienced at least one episode of 
malaria. The overall incidence of malaria episodes (1,572 malaria episodes in 
526 child-years of observation, or 2.93 per child-year) declined with age (3.73, 
3.49 and 2.19 among children aged 6–17 months, 18–35 months and 36–60 
months, respectively). There were 1,119, 263 and 178 episodes with densities 
above 10,000, 100,000 parasites/µL or with haemoglobin concentrations 
below 80 g/L. Episodes with densities > 100,000/µL occurred most frequently 
among the youngest children (0.88, 0.52 and 0.16 episodes/child-year for the 
3 age classes, respectively). 
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Table 1.  Baseline characteristics of study participants, by intervention group
Characteristic Without multi-nutrients With multi-nutrients
n 306 306
Sex M/F [n/n] 48%/52% [146/160] 50%/50% [153/153]
Age 32·6 ± 15·7 32·4 ± 15·6
Plasmodium infection * 44% [134] 43% [131]
Haemoglobin concentration, g/L
All children 102·3 ± 12·7 103·2 ± 12·7
6–17 months 97·2 ± 13·4 [72] 99·4 ± 13·2 [72]
18–35 months 101·0 ± 12·9 [109] 102·5 ± 13·0 [106]
36–59 months 106·4 ± 10·7 [125] 106·0 ± 11·7 [128]
Anaemia † 70% [214] 66% [203]
Inflammation ‡ 32% [99] 33% [102]
Plasma ferritin concentration, µg/L §
All children 37·5 (17.1 to 66.4) [304] 37·3 (15.4 to 73.6) [302]
No inflammation ¶ 27·6 (12.6 to 53.9) [205] 24·9 (12.0 to 49.8) [201]
Iron deficiency ║
All children 17% [53] 19% [58]
No inflammation ¶ 24% [49] 25% [50]
Distance from homestead to 
dispensary, km **
3·6 ± 2·3 3·5 ± 2·1
Mosquito net use †† 31% [94] 33% [100]
Anthropometric indices
Height-for-age, z-score –2·41 ± 0·69 –2·45 ± 0·70
Weight-for-height, z-score –0·13 ± 0·83 –0·12 ± 0·84
Weight-for-age, z-score –1·58 ± 0·74 –1·60 ± 0·76
Mean ± SD, % [n] or median (25- and 75-percentiles) unless indicated otherwise.
* As indicated by a positive result for pLDH-based dipstick test that detects the presence of lac-
tate dehydrogenase of P.falciparum or other human Plasmodium species.
† Haemoglobin concentration < 110 g/L.
‡ With 6 missing values for plasma ferritin concentration.
§ Plasma C-reactive protein concentration ≥ 8 mg/L.
¶ Analysis restricted to children without inflammation (n=101, 106, 103 and 104, respectively), 
with 5 missing values for ferritin.
║ Iron deficiency: plasma ferritin concentration < 12µg/L.
** Measured as the crow flies, based on global positioning data.
†† Data missing for 11 children.
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Webfi gure 1.  Flow chart
The identical number of participants in the groups with and without multi-nutrients is 
coincidental.
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Assessment of the burden of iron deficiency: The prevalence of iron 
deficiency strongly declined with age (38%, 20% and 5% in children aged 
6–17 months, 18–35 months and 36–60 months, respectively; p<0.001; 
corresponding values in those without inflammation: 45%, 28% and 7%; 
p<0.001). Analysis of haemoglobin concentrations at the second survey 
confirmed that children in the youngest age class responded most to multi-
nutrient supplementation, with effects of 8.7 g/L (5.3 to 12.2 g/L), 2.5 g/L (–0.4 
to 5.3 g/L) in children aged 6–17 months and 18–35 months, and no evident 
effect in children aged 36–60 months (Figure 1, Webtable). In children aged 
6–17 months and 18–35 months, multi-nutrient supplementation reduced 
the prevalence of anaemia by 40% and 14%, respectively, whilst there was 
no evidence for such an effect in the oldest age class (Webtable).
Effect of multi-nutrients on malaria rates: Multi-nutrient supplementation 
led to decreased time to first episodes of malaria (Webfigure 2). We found no 
effect of multi-nutrient supplementation on the overall rate of episodes with 
densities > 100,000 parasites/µL, whether analysed for first events (HR, 95% 
CI: 0.93; 0.69–1.26), or for repeated events (1.07; 0.80–1.45). Stratification by 
age, however, showed that this effect strongly depended on age: among the 
youngest children, multi-nutrients increased rates by 55%, as compared to a 
decrease by 58% in the eldest children (p-value for interaction: 0.005; Figure 
2). For episodes with parasite density > 10,000/µL, our data showed a similar 
age-dependent trend (p=0.02), although the contrast in effects between age 
classes was less pronounced (Figure 2). Adjustment for prognostic factors at 
baseline led to similar effect estimates (not shown).
When analyzing the effect of multi-nutrient on malaria with haemoglobin 
concentrations < 80 g/L, this trend seemed reversed (Figure 2).
Stratification by iron status at baseline indicated that the increase in malaria 
rates due to multi-nutrient supplementation was restricted to children with 
iron deficiency; there was no evidence that multi-nutrients increased malaria 
rates in their iron-replete peers (Figure 3). We found no evidence that iron 
deficiency was associated with protection against malaria among those 
receiving zinc or placebo (not shown).
Effect of multi-nutrients on indicators of malarial severity: There was no 
evidence that multi-nutrient supplementation affected parasite density, 
C-reactive protein concentration or HRP2 concentration at the time of first 
malaria episode (Table 2). When stratified by age, however, multi-nutrients 
resulted in increased parasite densities in the youngest age class (p=0.02) 
whereas they seemed to slightly reduce densities in the eldest children 
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Figure 1. Eff ect of multi-nutrient supplementation on haemoglobin concentration at 
the second survey, by age class
Top panel: haemoglobin concentrations, by supplementation group and age class (n=598); 
bott om panel: eff ect of multi-nutrients on haemoglobin concentrations, by age class. Line bars 
indicate 95% CIs (only upper half of the interval indicated in top panel). The p-value for 
the diff erence in eff ect between age classes is indicated in the lower panel. All estimates are 
adjusted for standardized haemoglobin concentrations at baseline.
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Webfi gure 2.  Eff ect of multi-nutrient supplementation on time to fi rst malaria episode
Episodes of malaria were as pre-specifi ed (see text). Median time to event: 54 days and 72 
days for groups with or without multi-nutrients, respectively; p-value for diff erence between 
groups obtained by Tarone-Ware test.
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Figure 2.  Eff ect of multi-nutrient supplementation on the rates of malaria, with case 
defi nitions of varying severity, by age class
Case defi nitions were either as predefi ned (see text), as predefi ned with densities > 10,000/µL 
or > 100,000 asexual parasites/µL, or with haemoglobin concentration below 80 g/L. Values 
on the right indicate crude hazard ratios (95% CIs); p-values for diff erences in eff ect between 
age classes (entered on an ordinal scale). Slide results were not available for 32 malaria cases; 
these were imputed as having densities below 10,000 parasites/µL. Adjustment for distance 
between homestead and dispensary, height-for-age z scores, mosquito net use and Plasmodium 
infection at baseline led to similar estimates (not shown).
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Figure 3.  Eff ect of multi-nutrient supplementation on the rates of malaria, with case 
defi nitions of varying severity, by iron status at baseline
Iron status was defi ned as iron defi cient (closed circles; plasma ferritin concentration < 12 µg/L) 
or iron replete (open circles; plasma ferritin concentration ≥ 12 µg/L, without infl ammation). 
In the analysis, we excluded children in whom iron status was uncertain (plasma ferritin 
concentration ≥ 12 µg/L, with infl ammation). P-values indicate diff erences in eff ect between 
iron-defi cient and iron-replete children. For further explanation, see text and fi gure 2.
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Figure 4.  Intervention eff ects on indicators of severity of illness at the time of the fi rst 
malaria episode, by age class
Estimates represent geometric means and 95% CIs, with p-values for the interaction between 
intervention and age. Analysis is based on 507 episodes, with 26, 11 and 1 missing values for 
parasite density, HRP2 concentration and C-reactive protein concentration, respectively.
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Figure 5.  Eff ect of multi-nutrient supplementation on haemoglobin concentrations in 
children with malaria, by age class
Panels A, C: haemoglobin concentrations, by supplementation group and age class, at the 
time of fi rst and second malaria episodes (505 and 381 cases, respectively); panels B, D: 
eff ect of multi-nutrients on haemoglobin concentrations, by age class, at the time of fi rst and 
second episodes. Line bars indicate 95% CIs (only upper interval indicated in panels A and 
C). P-values for diff erences in eff ect between age classes are indicated in panel B and D. All 
estimates are adjusted for standardized haemoglobin concentrations at baseline and time 
between randomisation and outcome measurement; further adjustment for prognostic factors 
at baseline led to similar estimates (not shown).
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(p=0.07; p-value for interaction: 0.01, Figure 4). Adjustment for prognostic 
factors at baseline resulted in virtually identical point estimates with slightly 
higher precision (not shown).
For the other indicators of severity (concentrations of C-reactive protein and 
HRP2) we also found a decrease with age (p<0.001 and 0.001 respectively), 
but no marked effect of multi-nutrients, whether analyzed with (Figure 4) or 
without stratification by age class (table 2). 
We found no evidence that iron deficiency at baseline was associated with 
any of these indicators of malarial severity, or that it influenced the effect of 
multi-nutrient supplementation on these indicators (not shown).
Effect of multi-nutrients on haemoglobin concentration during malaria 
episodes: We found no evidence that multi-nutrient supplementation affected 
haemoglobin concentrations or the proportion of children with anaemia at 
the first malaria episode (Table 2). Analysis by age class, however, showed 
that multi-nutrient supplementation increased haemoglobin concentrations 
by 5.3 g/L (0.8 to 9.8 g/L) in children aged 6–18 months, as compared to –0.7 
g/L (–4.5 to 3.0 g/L) and –3.9 g/L (–7.5 to –0.2 g/L) in children aged 18–35 
months and 36–59 months, respectively (difference in effect relative to that 
in the youngest class: –5.9 g/L [–11.7 to –0.1 g/L] and –9.2 g/L [–15.0 to –3.4 
g/L]; p-value for differences in effect between age classes: 0.008). Adjustment 
for time between start of intervention and episode led to virtually identical 
estimates (Figure 5). Similar patterns were observed for the intervention 
effects on haemoglobin concentrations during the second malaria episode; 
the effect of multi-nutrients depended on age (p-value for interaction: 0.01), 
with children in the youngest age class gaining 9.1 g/L (5.3 to 14.4 g/L; Figure 
4), compared to no evident effect in children ≥ 18 months. 
When stratifying by iron status at baseline, we found that multi-nutrients 
increased hemoglobin concentrations at the time of the first malaria episode 
by 6.5 g/L ( 1.2 to 11.9 g/L) among children with iron deficiency at baseline, 
whereas no effect was apparent in their peers who were iron replete (–2.1 
g/L, –4.7 to 0.5 g/L; difference in effects: 8.6 g/L, 2.7 to 14.6 g/L; p-value for 
interaction=0.004). 
Discussion
Although multi-nutrient supplementation reduced the time to the first 
malaria episode, we found no evidence that it influenced overall rates of 
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malaria, regardless of the case definition used, or that it increased the severity 
of malaria as assessed by concentrations HRP2 or C-reactive protein. The 
effect of supplementation on overall malaria rates varied, however, with age 
class and iron status at baseline. Among children aged 6-17 months, multi-
nutrients increased rates of malaria episodes, particularly of episodes with 
hyperparasitemia (> 100,000/ uL), while in older children (>35 months) they 
led to reduced rates of episodes with hyperparasitemia.
Nonetheless, the youngest children, who had a much higher prevalence 
of iron deficiency than their older peers, were better able to maintain their 
haemoglobin concentration when having received multi-nutrients, both at 
the time of the first and the second malaria episodes. 
Contrasts between age-specific effects on malaria rates increased when 
defining episodes with higher parasite density cut-off values (Figure 2). 
To some extent, this may be because multi-nutrients led to increased 
parasite densities during malaria episodes (Figure 4), but an improved 
specificity of episodes with higher density cut-offs may also have played 
a role; while episodes with > 100,000 asexual parasites/µL are highly likely 
to be attributable to malaria (e.g. Bejon et al. 2007), the analysis based on 
episodes defined by lower density cut-off values will have included cases 
of non-malarial fever that were misclassified as being malaria because 32% 
of children had asymptomatically infected at the time of the 2nd survey. 
The resulting reduction in specificity of the case definition is likely to have 
biased measured intervention effects towards naught (O’Meara and Lang 
2009). Either way, because our findings indicate that, among the youngest 
children, multi-nutrients increase rates of malaria with hyperparasitaemia, 
and probably also increase the rates of malaria episodes with lower densities, 
these findings strengthen earlier concerns about the safety of multi-nutrient 
supplementation in malaria-endemic areas (Sazawal et al. 2006, Veenemans 
et al. submitted), even in settings with excellent access to primary care.
In children aged 6–17 months, who had the highest prevalence of iron 
deficiency (45%), supplementation with multinutrients resulted in increased 
haemoglobin concentrations, as shown at the second survey (Figure 1). As 
a consequence, their initial haemoglobin concentrations just before malaria 
episodes were probably higher than in those without multi-nutrients, 
preventing anaemia from becoming as severe during malaria as in children 
who did not receive multi-nutrients (Figure 5). In older children, who had 
a lower prevalence of iron deficiency (7%), there was no obvious benefit 
of multi-nutrient supplementation during the second survey or during 
malaria episodes (Figures 1 and 5). An improvement of haemoglobin 
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concentrations by multi-nutrients in children with iron deficiency, resulting 
in the prevention of low haemoglobin concentrations during malaria 
episodes, may likewise explain the opposite trend in age-specific effects 
on episodes with haemoglobin concentrations < 80 g/L as compared to 
episodes with hyperparasitaemia (Figure 2). Thus our data suggest that iron 
supplementation can prevent episodes of malaria with severe anaemia. The 
critical issue remains, however, whether the benefits of higher hemoglobin 
concentrations during acute malaria and the expected reduced risk of severe 
malarial anemia on one hand outweigh the risk of potentially lethal disease 
manifestations associated with an increased frequency of malaria on the 
other hand. 
We speculate that the iron in the multi-nutrients may have enhanced parasite 
proliferation specifically in the youngest children, because iron deficiency 
in this group leads to more efficient iron absorption and thus may lead to 
transient production of non-transferrin bound iron (Hutchinson et al. 2004, 
Baron et al. 2008, Dresow et al. 2008) which may act as a nutritional source 
and favour the proliferation of Plasmodium parasites (WHO 2007). Evidence 
in support of this hypothesised mechanism is, however, lacking. The absence 
of adequate protective immunity and the higher dose of iron per kilogram of 
bodyweight may have further contributed to the observed increase in rates 
in this subgroup. In children aged 35–60 months, the decrease in the rate 
of episodes with hyperparasitaemia due to multi-nutrients may indicate an 
immune-enhancing potential of supplementation, consistent with the idea 
that most micronutrients are essential for innate and acquired immunity 
and particularly for appropriate T cell responses to infections (Maggini et 
al. 2007, Duriancik et al. 2010). Such immunity is acquired with repeated or 
chronic exposure to infection, and plays a minor role in younger children. 
Subgroup analysis should generally be interpreted with caution (Sun et al. 
2010). On one hand, we did not specify interactions between multi-nutrient 
supplementation and iron status a priori, and the direction of the subgroup 
effect is in contrast with the findings previously obtained in the Pemba 
substudy with iron and folic acid (Sazawal et al. 2006). On the other hand, the 
difference in effects of multi-nutrients between children with and without 
iron deficiency was large (hazard ratios for episodes with parasitaemia > 
10,000/µL: 1.53 versus 0.89), the statistical evidence for effect modification 
was strong (p=0.007), and it is biologically plausible that the effect of multi-
nutrient supplementation on malaria rates depends on iron deficiency (and 
immune status) at baseline.
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In their report of the findings from the Pemba sub-study, Sazawal et al. (2006) 
were cautious in their interpretation of the subgroup effect, stating that their 
results suggested that supplementation with iron and folic acid is beneficial 
in children with iron deficiency, but unsafe in those who are iron-replete. 
Based on these findings, an expert group convened by WHO recommended 
that iron supplements should be administered routinely to iron-deficient 
infants in settings with adequate access to anti-malarial treatment (WHO 
2007). Unfortunately our findings challenge this recommendation. In the 
Pemba substudy, iron deficiency was defined by elevated molar ratios of 
zinc protoporphyrin and haem, while plasma ferritin concentration (that was 
used in our study) is probably a more specific indicator of iron deficiency.
In conclusion, subgroup analysis suggests that the effect of multi-nutrients 
on malaria varies strongly with age and iron status. In children aged 0.5 to 1.5 
years, and those with iron deficiency, supplementation with multi-nutrients 
may be unsafe; although these children were better able to maintain their 
haemoglobin concentration during malaria attacks when having received 
multi-nutrients, they also had an increased risk of malaria, particularly of 
episodes with hyperparasitemia (> 100,000/µL). Supplying multi-nutrients 
at levels normally provided through supplementation or home fortification, 
even when targeting deficient children in settings with adequate access to 
care, cannot be recommended in malaria-endemic areas until its safety has 
been demonstrated. 
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Summary
Background: The efficacy of preventive zinc supplementation against 
diarrhea and respiratory illness may depend on population-specific factors. 
Simultaneous supplementation with multiple micronutrients may be 
required to overcome the lack of response that can be found when zinc is 
given alone.
Objective: We aimed to assess the effect of supplementation with zinc 
and multiple micronutrients on diarrhea and other causes of non-malarial 
morbidity. 
Design: Rural Tanzanian children (n=612) aged 6–60 months and with 
height-for-age z-score < –1.5 SD were randomized to daily supplementation 
with zinc (10 mg) alone, multi-nutrients without zinc, multi-nutrients with 
zinc, or placebo. During follow-up, we recorded morbidity episodes. The 
study was registered with ClinicalTrials.gov (NCT00623857).
Results: We found no evidence that concurrent supplementation with 
multi-nutrients influenced the magnitude of the effect of zinc on rates of 
diarrhea, respiratory illness, fever without localizing signs, or other illness. 
Zinc supplementation reduced the hazard of diarrhea by 24% (4%–40%). 
By contrast, multi-nutrients seemed to increase this rate (HR; 95% CI: 1.19; 
0.94–1.50), particularly in children with asymptomatic Giardia infection 
at baseline (2.03; 1.24–3.32). Zinc also protected against episodes of fever 
without localizing signs (0.75; 0.57–0.96), but we found no evidence that it 
reduced the overall number of clinic visits.
Conclusion: We found no evidence that the efficacy of zinc supplements in 
reducing diarrhea rates is enhanced by concurrent supplementation with 
other micronutrients. By reducing rates of fever without localizing signs, 
supplementation with zinc may reduce inappropriate drug use with anti-
malarial medications and antibiotics.
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Introduction
There are no policy recommendations for preventive zinc interventions in 
developing countries, despite evidence from a recent meta-analysis of trials, 
mostly conducted in Asia and Latin America, that it can reduce the overall 
rates of diarrhea and respiratory illnesses by 20% and 14%, and rates of 
mortality by 6%. Results have varied between trials, however, probably due 
to heterogeneity in study populations with respect to factors that determine 
the response to zinc (Brown et al. 2009a).
Zinc deficiency often coexists with other nutritional deficiencies, and 
simultaneous supplementation of multiple micronutrients may be required 
to overcome the lack of response that can be found when zinc is given alone 
(Shrimpton et al. 2005). In a recent review of steps to be taken to translate 
research into zinc intervention programs, the International Zinc Nutrition 
Consultative Group urged the implementation of studies to assess the efficacy 
of zinc in combination with other micronutrients (Brown et al. 2009b).
Relatively few trials have been conducted in Africa, where the etiology of 
disease and environmental factors such as diet and micronutrient deficiencies 
may be different than in Asia and Latin America.
In this study, we aimed to assess the effect of supplementation with zinc 
and multiple micronutrients on diarrhea and other causes of non-malarial 
morbidity in young, rural Tanzanian children. In addition, we explored 
baseline factors that determined the magnitude of the morbidity response to 
such supplementation.
Subjects and methods
Study area: The study was part of a trial with the primary aim to assess the 
effects of supplementation with zinc and other micronutrients on malaria 
rates. Details of study design and effects on malaria rates will be reported 
elsewhere (Veenemans et al. submitted). The trial was performed in four 
villages (Ngojoro, Kwangwe, Bondo and Kwadoya) near Segera (S 05°23.050, 
E 038°34.745) in Handeni District, north-eastern Tanzania. This rural area 
is highly endemic for malaria, and access to health care is limited, with no 
primary care facilities in the study area except the research dispensary that 
was constructed specifically for this study. The vast majority of families live in 
self-constructed clay houses, few with adjacent pit-latrines. Most households 
are self-sustaining and the dietary intake of the children restricted to maize 
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and beans, with very low intake from animal products. This food contains 
a high concentration of phytates that limits the absorption of several trace 
elements, including zinc. 
Recruitment: Data were collected between February 2008 and March 2009. 
All resident children aged 6–60 months were invited for screening. Venous 
blood and fresh stool samples were collected, anthropometric measurements 
recorded in duplicate, and children were examined by a clinical officer. 
Children were eligible when having a height-for-age z-score ≤ –1.5, no signs 
severe chronic diseases, weight-for-height z-score > –3 SD, and hemoglobin 
concentration > 70 g/L. Children whose parents refused consent or intended 
to move outside the study area during the follow-up period were excluded.
Randomization and interventions: Children were randomized within 
6 strata defined by malaria infection (binary) and age class (6–17 months, 
18–35 months and 36–60 months) and randomly permuted blocks with size 
randomly selected of 4 or 8. Children received daily supplements with either 
zinc alone (10mg as gluconate), multi-nutrients without zinc, zinc combined 
with multi-nutrients or placebo. The levels of magnesium and vitamin C 
in the multi-nutrient supplement were below upper limits that were based 
on osmotic diarrhea and related gastrointestinal disturbances as critical 
endpoints (WHO/FAO 2004); further details about the composition of the 
multi-nutrient supplement are shown in Annex 3. Supplements were packed 
as transparent blister-strips, each containing 15 capsules with powder that 
was similar in taste and appearance for all 4 intervention groups. Capsules 
were color-coded to reduce the chance that children would receive the wrong 
supplement. The color code was not disclosed to the researchers until after 
the database had been finalized.
Follow-up and case detection: Supplementation was performed by 
community volunteers, each supervising approximately 20 children. 
Supplements were taken out of capsules, mixed with water and administered 
early in the morning separate from the meal. All volunteers reported daily to 
the research dispensary, and project staff followed up immediately in case a 
child had missed a daily supplementation dose. Parents or guardians were 
requested to bring study children to the dispensary when they noticed fever 
or when their child was otherwise unwell. A clinical officer was on permanent 
duty, and assessed sick children according to a standardized form. In case 
of reported cough or difficult breathing, the clinical officer looked for signs 
of respiratory distress and counted breathing frequency twice, each time 
for one full minute. All children received first-line treatment free of charge. 
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When indicated, they were referred and provided with transport to the 
nearest district hospital. Parents could withdraw consent at any time. 
Supplementation and follow-up continued until 12 March 2009, when the 
trial was stopped for all children simultaneously.
Outcome definitions: We used the following case definitions: 1) Diarrhea: 
guardian-reported loose or watery stools, with episodes separated by at 
least 48 h. To increase the specificity of the case definition we also defined 
cases as episodes as defined above with > 3 loose or watery stools during a 
24-h period; 2) Acute lower respiratory infections (ALRI): reported cough with 
respiratory rate exceeding age-specific cut-off values (> 50/min or > 40/min 
for children aged 6–12 mo and 12–60 mo, respectively (WHO 2000); 3) Severe 
pneumonia: ALRI as defined above with one or more danger signs (lower 
chest in drawing, nasal flaring, grunting or head nodding) (WHO 2000); 4) 
Any respiratory illness: guardian-reported cough or difficult breathing; 5) Fever 
without localizing signs: guardian reported fever that was not accompanied 
by cough, diarrhea or other localizing signs and with a negative result for 
a malaria dipstick test; 6) Any other illness: guardian-reported illness with 
symptoms involving skin, ears, eyes and abscesses, but excluding trauma 
or burns. Malaria was defined by a positive result for the malaria dipstick 
test in children with guardian-reported fever and any of the following: a) 
confirmed fever (axillary temperature ≥ 37.5°C), or b) unconfirmed fever 
with inflammation (whole blood C-reactive protein concentrations ≥ 8 
mg/L), separated by at least 14 days from a previous malaria episode. The 
definitions provided above are not always mutually exclusive. In those cases 
when illness episodes fulfilled the criteria for more than one definition, they 
contributed to the analyses of all of these case definitions. Children who 
attended the dispensary for invited follow-up visits were only counted as 
new episode if presenting with new symptoms. 
Laboratory procedures: Venous blood samples were collected in tubes with 
EDTA and centrifuged within 2 h after collection. An aliquot was analyzed 
the same day by hematology analyzer (Sysmex KX21, Kobe, Japan). As a 
measure of inflammation, we measured whole blood C-reactive protein 
concentration in the field by immunoturbidimetric assay (QuikRead, Orion 
Diagnostica, Espoo, Finland). Plasma concentrations of zinc were determined 
by inductively-coupled plasma-mass spectrometry. Plasma concentrations 
of C-reactive protein and ferritin were measured in The Netherlands on a 
Beckman Coulter Unicel DxC880i system. Stool samples collected during the 
surveys were preserved in sodium acetate acetic acid formalin, stored at 4 °C 
and tested for Giardia intestinalis parasites by enzyme-linked imunosorbent 
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assay (ProSpecT Giardia Microplate Assay, ProSpecT Giardia Microplate 
Assay, Oxoid, Basingstoke, UK). This test has a sensitivity and specificity of 
93% and 100%, respectively, as compared to detection by either microscopy 
or the EIA in at least one of two sequential stool samples from individual 
subjects (Mank et al. 1997).
Statistical analysis: All data were double-entered, cleaned and analyzed in 
SPSS (v15·0 for Windows, SPSS, Chicago, IL) and STATA (v11; College Station, 
Tx). Height-for-age z-scores were calculated using Epi Info (version 3.3.2; 
http://www.cdc.gov/epiinfo); differences in proportions were calculated 
using CIA.(Altman et al. 2000) Being stunted was defined as height-for-age 
z scores < –2 SD.
We report incidence rates, and used a Cox proportional hazard model to 
assess intervention effects as crude and adjusted hazard ratios. We explored 
effects on diarrhea and respiratory illness by analyzing cases with and 
without fever separately. We conducted subgroup analyses to explore 
potential effect-modification by age classes (as defined by the strata used for 
randomization), being stunted, and the presence of G. intestinalis infection 
at baseline. In this analysis, we pooled children aged 18–35 mo and 16–60 
mo because there were only 44 cases in the oldest age class. We explored to 
what extent adjustment for factors that were predictive for morbidity (age 
class, stunting, distance to the dispensary [≥ or < 4 km, which is close to 
the median], and mosquito net use) influenced estimates of the intervention 
effects.
Results
The trial profile is shown in Figure 1. Baseline characteristics were similar 
between intervention groups (Table 1). The prevalence of zinc deficiency 
was high (67%). Giardia infection was detected in 192 children (31%), and 426 
children (70%) were stunted.
There were 3,268 clinic visits during the study period, of which 2,462 (75%) 
were accompanied by guardian-reported fever and 1,572 (48%) classified 
as malaria. Among the non-malarial fever cases, 658 were accompanied by 
diarrhea, cough, or other localizing signs, either alone or in combination, 
while 232 fever cases were without localizing signs (Table 2). For 223 children 
(36%), parents or caretakers reported at least one episode of diarrhea. A 
total of 390 diarrhea episodes were recorded, with an incidence rate of 0.74/
child-year. There were 1,333 episodes of reported cough, but only few (181) 
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Invited for screening
n=1,265
Screened
n=1,029
No show
n=236
Excluded (n= 417)
Parents refused consent: 21
Height‐for‐age >–1.5 SD: 359
Medical reasons: 13
Date of birth unclear: 8
Unlikely to comply with intervention: 16
Eligible
n=612
Zinc
n=153
Multi‐nutrients
without zinc
n=155
Multi‐nutrients
with zinc
n=151
Placebo
n=153
Lost to 
follow‐up: 5
Refused: 1
Lost to 
follow‐up: 3
Died: 2
Lost to 
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Died: 1
Lost to 
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n=150 (97%)
Complied:
n=148 (95%)
Completed
n=146 (97%)
Complied:
n=146 (97%)
Completed
n=149 (97%)
Complied:
n=148 (97%)
Figure 1. Trial profile
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Table 2. Incidence rates for various illnesses, stratified by the presence of fever
All Fever reported No fever reported
Total observation time, child-years 526 526 526
All clinic visits 6.2 (3,268) 4.7 (2,462) 1.5 (806)
Diarrhea
Guardian-reported episodes 0.74 (390) 0.47 (248) 1 0.27 (142)
> 3 loose stools/24h 0.44 (233) 0.41 (216) 0.03 (17)
Respiratory illness
Cough 2.5 (1,333) 1.9 (998) 1 0.64 (334)
Cough with fast breathing 0.34 (181) 0.28 (147) 1 0.06 (34)
Severe pneumonia 0.05 (24) 0.04 (20) 0.01 (4)
Other illnesses 2 1.4 (744) 0.68 (3,566) 1 0.74 (388)
Fever without localizing signs 3 0.44 (232) NA NA
Malaria 3.0 (1,572) NA NA
Hospital referrals 0.13 (68) 0.13 (68) 0.00 (0)
Values indicate the total number of episodes per child-year observed. Numbers between brackets 
indicate the number of episodes.
NA: Not applicable (fever is part of the case definition)
1 Among these, the following number of cases was also classified as malaria: reported diarrhea: 
137 (35%); reported diarrhea with ≥ 3 loose stools/24h: 69 (30%); reported cough: 491 (36%); 
other: 166 (22%).
2 Includes symptoms of skin, ears, and eyes and abscesses; excluding trauma or burns.
3 Cases classified as fever without localizing signs are not included in any of the other categories.
98 Chapter 5
fulfilled criteria of ALRI as established by the World Health Organization 
(WHO 2000). The number of severe pneumonia cases (24) was insufficient 
for meaningful analysis. There were 744 visits for other reasons, mainly 
abscesses and symptoms involving skin, ears, and eyes.
Upon examination of interaction effects (Table 3), we found no evidence that 
concurrent supplementation with multi-nutrients influenced the magnitude 
of the effect of zinc on rates of diarrhea, respiratory illness, fever without 
localizing signs, or other illness. Thus in the remainder of this report, 
we will present marginal effects whereby the effect of multi-nutrients is 
assessed by comparing the pooled groups receiving placebo or zinc with the 
pooled groups receiving multi-nutrients, and the effect of zinc is assessed 
by comparing the pooled groups receiving no zinc (with or without multi-
nutrients) and the pooled groups receiving zinc (with or without multi-
nutrients).
Zinc supplementation reduced the rate of diarrhea by 24% (95% CI: 4% to 
40%) (Figure 2), while multi-nutrients seemed to increase rates by 19% (–6% 
to 50%). We found similar effects when restricting the analysis to cases of 
diarrhea with ≥ 3 loose stools/24h (Figure 2). The protective effect appeared 
more evident for cases of diarrhea that were accompanied by fever (HR 0.73 
[0.55-0.98]) than for those not accompanied by fever (HR 0.80 [0.55-1.16]), but 
the difference in effect was small.
There was no evident effect of either intervention on episodes of respiratory 
illness, whether defined as reported cough or as cough with fast breathing, 
or on episodes of other illnesses (Figure 2). By contrast, zinc reduced the 
rates of fever without localizing signs by 25% (4%—43%; adjusted for age 
class and distance between homestead and research clinic.
Age was strongly predictive for all morbidity outcomes, but there was 
no evidence that age class influenced the magnitude of the effect of the 
interventions for any of the outcomes considered (not shown). We found 
weak evidence that the zinc-induced reduction in diarrhea rates was more 
pronounced in stunted children (0.66; 0.49–0.90) than in those with a lesser 
degree of stunting (0.95; 0.62–1.45; interaction effect: 0.68 (0.41–1.15); Figure 
3; upper panel, left).
The effect of multi-nutrient supplementation on diarrhea depended on 
the presence of Giardia infection at baseline (Figure 3; upper panel): multi-
nutrient supplementation doubled the rate of diarrhea among those with 
Giardia at baseline (2.03; 1.24–3.32), whereas it had no obvious effect 
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Figure 3.  Subgroup analysis of effects of supplementation with zinc or multi-nutrients 
on diarrhea (top panels) and fever without localizing signs (bottom panels). 
Values between brackets indicate the number of children in each subgroup. Horizontal line 
bars indicate 95% CIs. Effects are adjusted for age class, being stunted and distance (< or ≥ 4 
km) unless these factors were used to define subgroups. Values on the right indicate p-values 
for interaction tests. Because the presence of Giardia infection could not be assessed in 54 
children due to missing stool samples, the analysis is based on fewer cases of diarrhea (361) 
and fever without localizing signs (216) than reported in the text.
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among those without Giardia infection (1.03; 0.78–1.36). This difference in 
intervention effect between Giardia-positive and Giardia-negative children 
was independent of age and stunting, and unlikely to have occurred by 
chance (interaction effect: 1.98; 1.13–3.47; p=0.02).
With regards to the effects of multi-nutrients on fever without localizing 
signs, patterns observed in the subgroup analysis largely resembled those 
observed for diarrhea (Figure 3; lower panel). Both Giardia infection and being 
stunted at baseline determined the magnitude of the effect of multi-nutrients 
on disease rates. Multi-nutrients resulted in increased rates (1.39; 0.82–2.36) 
in children with Giardia infection and decreased rates in those without (0.74; 
0.53–1.03) (interaction effect: 1.86; 1.00–3.47). In stunted children, however, 
multi-nutrients decreased rates (0.67; 0.46–0.97), whereas in children with 
a lesser degree of stunting, multi-nutrients seemed to increase rates (1.46; 
0.93–2.28; interaction effect: 0.47; 0.26–0.83).
Lastly, multi-nutrients also increased the rate of reported cough among 
stunted children, but not so in their less stunted counterparts (HR: 1.34; 1.06–
1.69 versus 0.98; 0.82–1.17; p-value for interaction: 0.05). When analyzing 
effects on ALRI, a similar pattern was seen (1.41; 0.79–2.52 versus 0.99; 0.65–
1.50 among stunted and less stunted children respectively), but the number 
of cases was lower and thus the statistical evidence for this interaction 
weaker (p=0.33).
Discussion
We found no evidence that the effect of zinc supplementation on any of the 
morbidity outcomes assessed was influenced by concurrent supplementation 
with other micronutrients. Daily supplementation with zinc reduced the 
rate of fever without localizing signs by approximately one-quarter. By 
contrast, supplementation with multi-nutrients seemed to increase the rate 
of diarrhea, mostly so in children with Giardia infection at baseline. 
The effect of zinc on diarrhea found in our study is consistent with the 20% 
reduction reported in a recent systematic review (Brown et al. 2009a). Contrary 
to the findings from this meta-analysis (Brown et al. 2009a), however, we 
found no evidence that this protection depended on age class, and we found 
only weak support that it depended on the initial degree of stunting. The 
incidence of diarrhea in our study was comparatively low, however, and the 
number of cases may have been too low to show such effect modification. 
For the same reason, we may have failed to show an effect of either zinc or 
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multi-nutrients on rates of respiratory illnesses. 
Multi-nutrient supplementation seemed to increase diarrhea rates by 25%, 
whereby the subgroup analysis suggested that it more than doubled this 
rate among children with Giardia infection at baseline. This adds to findings, 
based on data from the same trial, that multi-nutrients increase the rate of first 
malaria attacks by 30% (8%-55%; figure 2), and the rate of all malaria episodes 
among the children aged 6-17 months and those with iron deficiency by 26% 
(0%-57%) and 41% (9%-82%), respectively (Veenemans et al. submitted).
Two other trials that investigated the added benefit of multi-nutrients in 
addition to zinc in preventing episodes of diarrhea also failed to show an 
advantage of combined supplementation above supplementation with zinc 
alone. In Peruvian preschool children, zinc alone tended to reduce the risk 
of diarrhea and respiratory illness, whereas supplementation with multi-
nutrients including zinc tended to increase this risk (Penny et al. 2004). In 
South African children, there was no evidence that supplementation with 
multi-nutrients including zinc was more efficacious than zinc alone in 
reducing the burden of diarrhea or respiratory illnesses (Chhagan et al. 2009, 
Luabeya et al. 2007). Taken together, these findings do not support and even 
caution against multi-nutrient supplementation in areas that are endemic for 
malaria and other infectious diseases.
Giardia infection at baseline influenced the effect of multi-nutrients on rates 
of fever without localizing signs in a similar pattern as the effect on diarrhea, 
even when adjusting for age and distance between homestead and research 
clinic. Although our definition of fever cases without localizing signs 
excluded cases of diarrhea, this similarity in effect patterns (including the 
fact that zinc protected against both outcomes) suggests that many of these 
fever episodes may have been due to enteric infections. Further studies are 
needed to establish whether Giardia infection caused this effect modification 
or whether it was a marker of an unknown factor that may have played such 
a role, and to identify the mechanisms involved. 
Our study design did not allow us to identify single nutrients that may 
have caused the increase in diarrhea associated with the multi-nutrient 
supplement among children with Giardia. At the doses provided, it is unlikely 
that magnesium or vitamin C caused osmotic diarrhea; we also found no 
evidence, which otherwise might have been expected, that the increased 
diarrhea rates were larger in the youngest children who received a larger dose 
per body weight that older children (Figure 3). Whilst most micronutrients 
seem to protect against diarrhea (Long et al. 2007), supplementation with 
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iron may increase the diarrhea incidence (Gera and Sachev 2002), possibly 
by enhancing proliferation and virulence of enteric pathogens, or facilitating 
pathogen invasion by increasing permeability of the small intestine (Foster 
et al. 2001, Nchito et al. 2006). Iron may also influence or impair the immune 
responses to pathogens (Long et al. 2007). In vitro studies using Caco-2 cells 
suggest that copper may also impair intestinal barrier function by enhancing 
paracellular permeability (Ferruzza et al. 1999, Liu and Chen 2004).
We found no evidence that the addition of vitamins and other minerals to 
zinc supplements is helpful in preventing morbidity; in fact, it may increase 
the diarrhea rates in specific subgroups. This study adds support that zinc 
supplementation reduces the risk of diarrhea in African children and, 
although it did not reduce the overall number of clinic visits, it may reduce 
inappropriate use of anti-malarial drugs and antibiotics by reducing rates 
of fever without localizing signs. Our results should therefore encourage 
efforts to increase the intake of zinc in vulnerable populations.
Contributors: JV was responsible for data collection and analysis, 
administration and drafted the manuscript; LRAS assisted in data collection; 
TGM advised on design; DRAU, RMO and HFJS provided supervisory 
support; AYD and RJK provided laboratory support in The Netherlands; 
HV was responsible for concept, design and supervision of all aspects of 
the study; HV and HFJS obtained funding. All authors participated in data 
interpretation and critical revision of the report for intellectual content; and 
provided final approval of the submitted version.
References
Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics with confidence: 
confidence intervals and statistical guidelines. London, UK: BMJ Books, 2000.
Brown KH, Peerson JM, Baker SK, Hess SY. Preventive zinc supplementation among 
infants, preschoolers, and older prepubertal children. Food Nutr Bull 2009a;30(1 
Suppl):S12–40.
Brown K, Baker SK, and the IZiNCG Steering Committee. Galvanizing action: 
conclusions and next steps for mainstreaming zinc interventions in public health 
programs. Food Nutr Bull 2009b;30(1 Suppl):S179–84.
Chhagan MK, Van den Broeck J, Luabeya K-KA, Mpontshane N, Tucker KL, Bennish 
ML. Effect of micronutrient supplementation on diarrhoeal disease among 
stunted children in rural South Africa. Eur J Clin Nutr 2009;63:850–7.
Ferruzza S, Sambuy Y, Rotilio G, Ciriolo MR, Scarino ML. The effect of copper on 
tight junctional permeability in a human intestinal cell line (Caco-2). Adv Exp 
Med Biol 1999;448:215–22.
Micronutrients and non-malarial morbidity 105
FNB/IOM. Dietary Reference Intakes (DRIs). Food and Nutrition Board, Institute of 
Medicine, National Academies, 2004. (Accessed May 17, 2010, at http://www.
iom.edu/Global/News%20Announcements/~/media/Files/Activity%20Files/
Nutrition/DRIs/DRISummaryListing2.ashx)
Foster SL, Richardson SH, Failla ML. Elevated iron status increases bacterial invasion 
and survival and alters cytokine/chemokine mRNA expression in Caco-2 human 
intestinal cells. J Nutr 2001;131:1452–58.
Gera T, Sachdev HPS. Effect of iron supplementation on incidence of infectious 
illness in children: systematic review. BMJ 2002;325:1142.
Liu Z. Chen B. Copper treatment alters the barrier functions of human intestinal 
Caco-2 cells: involving tight junctions and P-glycoprotein. Human Exp Toxicol 
2004;23:369–77.
Long KZ, Rosado JL. Fawzi W. The comparative impact of iron, the B-complex 
vitamins, vitamins C and E, and selenium on diarrheal pathogen outcomes 
relative to the impact produced by vitamin A and zinc. Nutr Rev 2007;65:218–32.
Luabeya K-KA, Mpontshane N, Mackay M, et al. Zinc or multiple micronutrient 
supplementation to reduce diarrhea and respiratory disease in South African 
children: a randomized controlled trial. PLoS One 2007;2:e541.
Mank TG, Zaat JO, Deelder AM, van Eijk JT, Polderman AM. Sensitivity of microscopy 
versus enzyme immunoassay in the laboratory diagnosis of giardiasis. Eur J Clin 
Microbiol Infect Dis 1997;16:615–19.
Nchito M, Friis H, Michaelsen KF, Mubilaa L, Olsen A. Iron supplementation 
increases small intestine permeability in primary schoolchildren in Lusaka, 
Zambia. Trans R Soc Trop Med Hyg 2006;100:791–94.
Penny ME, Marin RM, Duran A, et al. Randomized controlled trial of the effect of 
daily supplementation with zinc or multiple micronutrients on the morbidity, 
growth, and micronutrient status of young Peruvian children. Am J Clin Nutr 
2004;79:457–65.
Shrimpton R, Gross R, Darnton-Hill I, Young M. Zinc deficiency: what are the most 
appropriate interventions? BMJ 2005;330:347–49.
WHO. Management of the child with a serious infection or severe malnutrition: 
guidelines for care at the first-referral level in developing countries. Reference 
no. WHO/FCH/CAH/00.1. Geneva, Switzerland: World Health Organization, 
Department of Child and Adolescent Health and Development, 2000.
WHO. Diarrhoea treatment guidelines for clinic based health workers. Geneva, 
Switzerland: World Health Organisation, 2005.
WHO/FAO. Vitamin and mineral requirements in human nutrition, 2nd ed. Geneva, 
Switzerland: World Health Organization, 2004.

Chapter 6 
Protection against diarrhea and fever 
without localizing signs associated with 
asymptomatic Giardia intestinalis infection is 
lost with multi-nutrient supplementation: 
a prospective study among rural Tanzanian 
children
Jacobien Veenemans, Theo G. Mank, Maarten Ottenhof, 
Erasto V.Mbugi, Ayse Y. Demir, Jos P.M. Wielders, 
Huub F.J. Savelkoul, Hans Verhoef
Submitted for publication
108 Chapter 6
Summary
Background: Asymptomatic infections with Giardia intestinalis are common 
among children in developing countries, and its role as pathogen in such 
settings has been questioned. We recently showed in an intervention trial 
among rural Tanzanian children that multi-nutrient supplementation 
increased diarrhea rates among children who tested positive, but not among 
those who tested negative at baseline. In the current paper we describe 
to what extent Giardia influenced the risk of diarrhea and fever without 
localizing signs, and how the infection influences the effect of the intervention 
on nutritional status.
Methods: Data were collected in the context of a randomized placebo-
controlled efficacy trial with 2x2 factorial design assessing the effects of zinc 
and/or multi-micronutrients on morbidity (n=612; height-for-age z-score < 
–1.5 SD). Outcomes measures were episodes of diarrhea (any reported, or 
with > 3 stools in the last 24 h) and fever without localizing signs. Giardia was 
detected in stool by enzyme-linked immunosorbent assay.
Findings: Among children who did not receive multi-nutrients, asymptomatic 
Giardia infection was associated with a substantial reduction in the rate of 
diarrhea (HR 0.32; 0.15–0.66) and fever without localizing signs (HR 0.56; 
0.36–0.87), whereas no such effect was observed among children who 
received multi-nutrients (p-values for interaction 0.03 for both outcomes). 
This interaction was independent of age, height-for-age z-scores and distance 
to the research dispensary. 
Conclusion: Although causality of the Giardia associated reduction 
in morbidity cannot be established, the data show that multi-nutrient 
supplements neutralise this protection and are thus likely to influence the 
proliferation or virulence of Giardia or associated intestinal pathogens. 
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Introduction
In developed countries, Giardia intestinalis (syn. G. duodenalis, G. lamblia) 
causes diarrhea while the prevalence of infections in the general population 
usually does not exceed 5% (Marshall et al. 1997). In developing countries, 
however, asymptomatic infections are much more common, with prevalence 
values in pediatric populations typically being around 30% (Mason and 
Patterson 1987, Fraser et al. 1997, Siwila et al. 2010), and reports on their 
association with diarrhea are inconsistent. Some reported an association with 
persistent (Bhandari et al. 1999, Newman et al. 2001) but not acute diarrhea 
(Bhandari et al. 1999, Gascon et al. 2000, Fraser et al. 2000, Newman et al. 
2001, Hollm-Delgado et al. 2009), whereas other studies found that Giardia 
infection was associated with protection against acute diarrhea (Fraser et al. 
1997, Bilenko et al. 2004, Albert et al. 1999, Haque et al. 2009).
Because the role of Giardia as diarrhea-causing agent is controversial and 
re-infection can occur rapidly, it has been recommended that children with 
asymptomatic infection should not be treated in highly endemic areas 
(Gilman et al. 1988, Sullivan et al. 1988). This notion is challenged, however, 
by findings from surveys (Loewenson et al. 1986, Muniz-Jungqueira and 
Oliveira Queiróz 2002, Sackey et al. 2003, Al-Mekhlafi et al. 2005, Ettehad et 
al. 2010) and a prospective cohort study (Prado et al. 2005) suggesting that 
such infections may impair linear growth, presumably by reducing intake 
and causing malabsorption of nutrients. In addition, in a prospective cohort 
study, it was found that episodes of Giardia with diarrhea but not diarrhea 
itself were associated with impaired cognition, perhaps because infection 
can lead to deficiencies of zinc and other micronutrients that have been 
associated with deficits in cognitive development (Berkman et al. 2002).
In a community-based trial in Tanzanian preschool children, we found that 
multi-nutrient supplementation resulted in increased rates of diarrhea and 
fever without localizing signs (Veenemans et al., submitted). In the current 
study, we aim to explore the influence of asymptomatic Giardia infection at 
baseline on the effect of multi-nutrient supplementation, to compare rates 
of diarrhea and fever without localizing signs in children with and without 
Giardia infection, and to assess the influence of micronutrient supplementation 
on these rates. In addition, we explore the influence of Giardia infection on 
the response of nutritional indicators to multi-nutrient supplementation.
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Methods
Study population: This study was part of a randomized placebo-controlled 
trial in children aged 6–60 months, with the primary aim to assess the effect 
of supplementation with zinc and other micronutrients on malaria rates. It 
was conducted in a rural area in Handeni District, Northern Tanzania that 
is highly endemic for malaria. In a pilot survey among children aged 6–72 
months in 2006 (n=304), we found a high prevalence of Giardia intestinalis 
(30%; assessed by microscopic examination of a single stool sample per child), 
and only few cases of Ascaris lumbricoides, Trichuris trichiura or Schistosoma 
intestinalis (3%, 5% and 0%, respectively) (unpublished results). Residents in 
the area virtually all comprise poor farmer families engaged in subsistence 
farming, with oranges being produced seasonally as cash crops. Families 
are living in self constructed clay houses, with very few having pit latrines. 
Water for drinking and household use is collected from central shallow wells. 
Few people boil drinking water. Access to health care was limited until we 
constructed a research clinic at a central location in the study area, which 
provided free primary care to study participants.
The study was approved by ethical review committees in The Netherlands 
and Tanzania; parents or guardians gave written consent.
Design: Details about study design will be published elsewhere. In brief, 
between February and August 2008, we recruited all resident children aged 
6–60 months, and excluded those with height-for-age z scores > –1.5 SD, 
weight-for-age z-score < –3 SD, haemoglobin concentration < 70 g/L and with 
signs of severe or chronic disease, until attaining the target number (n=600) 
(Webfigure).
The trial had a 2×2 factorial design with children receiving either multi-
nutrients with zinc (Webtable), multi-nutrients without zinc, zinc alone (10 
mg), or placebo. The levels of magnesium and vitamin C in the multi-nutrient 
supplement were below the upper limits that were based on osmotic diarrhea 
and related gastrointestinal disturbances as critical endpoints (WHO/FAO 
2004). Supplements were color-coded and administered daily by community 
volunteers.
At baseline, we collected venous blood in tubes suitable for trace element 
analyses (Becton-Dickinson, Franklin Lakes, NJ) and a fresh stool sample 
for each child in a vial that was pre-filled with sodium acetate-acetic acid-
formalin (SAF) and stored in a refrigerator immediately after collection. A 
second vial with unfixed feces was stored in liquid nitrogen (–196°C) for 
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subsequent genotyping. We computed anthropometric indices as the average 
of two recordings, taken on consecutive days.
At recruitment, we asked parents or guardians to bring their children to 
the research clinic if they noticed any signs of illness. A clinical officer was 
on 24h-duty and collected medical information on standardised forms that 
included a section on diarrhea. A second survey, at 251 days (median; 95% 
reference range: 191–296 days) after enrolment, followed similar procedures 
as the baseline survey. Follow-up continued for all children until March 
2009, when the study ended for all children simultaneously.
Laboratory analyses: Stool samples were analyzed for the presence of Giardia-
specific antigen by enzyme immunoassay (ProSpecT Giardia Microplate 
Assay, Oxoid, Basingstoke, UK). This test has a sensitivity and specificity of 
93% and 100%, respectively, as compared to detection by either microscopy 
or the EIA in at least one of two sequential stool samples from individual 
subjects (Mank et al. 1997). Methods for measuring plasma indicators have 
been described elsewhere (Veenemans et al. submitted).
Statistical analyses: Cases of diarrhea were defined as: a) all dispensary visits 
for parent- or guardian-reported loose or watery stools, with episodes being 
separated by at least 48 h of being without symptoms; or b) similar episodes 
with ≥ 3 loose or watery stools per 24-h period. Fever without localizing signs 
was defined as cases with reported fever that did not classify as malaria and 
were not accompanied by cough, diarrhea or other localizing signs. Thus 
cases of diarrhea and fever without localizing signs were mutually exclusive. 
Data were analyzed using SPSS (v15·0 for Windows, SPSS, Chicago, IL, USA) 
and STATA (v11; College Station, Tx, USA). We report incidence rates and 
assessed group differences by Kaplan-Meier analysis with Tarone-Ware 
test. Differences in the association between Giardia and morbidity outcomes 
between intervention groups were assessed by analysis within intervention 
strata, and directly by Cox regression analysis that included dummies for 
intervention groups and interaction terms. Cross-over between groups, 
whereby infected children became infection-free and vice versa, may dilute a 
potential effect of Giardia over time. For this reason, we restricted our primary 
analysis to first episodes, because an analysis of all events is probably more 
susceptible to such dilution of effect. However, because a substantial number 
of children experienced recurrent events and analysis of all events may better 
reflect total disease burden, we repeated these analyses based on all events, 
with robust estimates of the standard error to account for correlation between 
episodes within children. We explored potential confounding by adjusting 
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for factors that were previously found to be prognostic for diarrhea (age, 
distance and height-for-age z scores) (Veenemans et al, submitted).
We also used multivariate linear regression analysis with interaction terms 
to assess to what extent the effect of zinc and multi-nutrient supplementation 
(either alone or combined) on indicators of nutritional status depended on 
Giardia infection.
Results
The study profile is shown in Figure 1. G. intestinalis was detected in 192 
children (31%). We failed to obtain fresh stool samples for 54 children at 
baseline and for 50 children during the second survey, when 20 children were 
lost to follow-up. Baseline characteristics are presented in Table 1. Children 
with Giardia infection were on average 3.3 months older than their uninfected 
peers, resided somewhat closer to the dispensary, had a lower prevalence 
of inflammation, marginally higher hemoglobin concentrations, as well as 
marginally lower plasma concentrations of soluble transferrin receptor and 
folate. All other biochemical indicators of nutritional status were similar, 
and we found no evidence that Giardia was associated with symptoms as 
reported by the mother. The percentage of children who received antibiotic 
or anti-malarial treatment at baseline was similar in both groups.
At the time of the second survey, 43% of children with Giardia infection at 
baseline no longer carried the parasite, while 23% of children who tested 
negative at baseline had become infected (Figure 1).
The incidence of first episodes of diarrhoea was almost 50% lower among 
children with Giardia at baseline than among those without (Table 2).There 
was no evidence that the association between Giardia infection and diarrhea 
differed between children receiving placebo or zinc (in both groups the 
infection was associated with a protection), or between children receiving 
multi-nutrients with or without zinc (no association in either group; Figure 
2); we therefore combined children who received multi-nutrients with or 
without zinc (henceforth referred to as ‘with multi-nutrients’), as well as 
their peers who received zinc or placebo (‘without multi-nutrients’) as two 
separate groups.
Thus analyzed, Giardia infection was associated with a substantial reduction 
in time to first diarrhea episode with ≥ 3 watery stools/24h (p<0.001), but 
only so among children without multi-nutrients, whereas no association 
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Screened:
1,029
Excluded: 417
 Parents refused consent: 21
 Height‐for‐age >–1.5 SD: 359
 Medical reasons: 13
 Date of birth unclear: 8
 Unlikely to comply with intervention: 16
Eligible:
612
Second survey:
Without Giardia 
infection: 254
With Giardia
infection: 86
No stool sample 
obtained: 18
Second survey:
Without Giardia 
infection: 24
With Giardia
infection: 18
No stool sample 
obtained: 10
Second survey:
Without Giardia 
infection: 82
With Giardia
infection: 98
No stool sample 
obtained: 8
Without Giardia 
infection: 366
With Giardia 
infection: 192
No stool sample 
obtained: 54
Lost to follow‐up: 3
Died: 1
Lost to follow‐up: 1
Died: 1
Lost to follow‐up: 8
Completed the 
study: 354
Completed the 
study: 52
Completed the 
study:  186
Lost to follow‐up: 2Lost to follow‐up: 3
Died: 1
Figure 1.  Study profile
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Table 1. Baseline characteristics, by Giardia intestinalis infection status at baseline
Characteristic Giardia-positive Giardia-negative p
n 192 366
Age, [mean] 35.0 ±14.5 31.7 ±16.1 0.02
6–17 mo 16% (31) 27% (97)
18–35 mo 35% (68) 33% (122)
36–60 mo 48% (93) 40% (147)
Sex, boys:girls (n:n) 53%:47% (102:90) 46%:54% (168:198) 0.06
Distance between homestead and research 
dispensary, km
3.1 (1.8) 3.7 (2.3) 0.01
Mosquito net use 31% (117) 33% (59) 0.43
Anthropometric indices
Height-for-age z-score, SD –2.44 ± 0.75 –2.40 ± 0.67 0.49
Weight-for-height z-score, SD –0.17 ± 0.80 –0,07 ± 0.83 0.20
P. falciparum antigenemia (n) 1 44% (84) 43% (157) 0.46
Inflammation 2 24% (46) 37% (134) 0.001
Biochemical indicators of nutritional status
Hemoglobin concentration, g/L 104.8 ± 12.1 101.7 ± 12.6 0.005
Anemia 3 65% (125) 71% (260) 0.09
Plasma zinc concentration, mmol/L 4 9.0 ± 2.4 9.0 ± 2.3 0.86
Plasma ferritin concentration, µg/L 5,6 31.1 (26.8–36.1) 35.1 (32.0–40.4) 0.14
Iron deficiency 5 20% (38) 17% (60) 0.17
Plasma sTfR concentration, mg/L 5 2.4 (2.2–2.5) 2.6 (2.5–2.7) 0.02
Plasma cobalamin concentration, pmol/L 5 347 (326–369) 333 (318–350) 0.33
Plasma folate concentration, nmol/L 5 7.1 (6.5–7.7) 8.6 (7.9–9.2) 0.002
Symptoms reported at clinical assessment
Sick (according to mother) 20% (39) 23% (84) 0.27
Fever now or in the last 24 h 16% (30) 19% (68) 0.43
Sick according to clinical officer 5% (10) 6% (22) 0.44
Abdominal pain/discomfort 24% (46) 31% (112) 0.06
Diarrhea 10% (19) 12% (42) 0.34
Vomiting 3% (5) 4% (13) 0.37
Lack of appetite 12% (23) 11% (40) 0.49
Treatment provided at baseline 
Metronidazole 2% (3) 3% (10) 0.29
Mebendazole 10% (19) 8% (29) 0.26
Beta-lactam antibiotics 12% (22) 10% (36) 0.32
Artemether-lumefantrine 44% (84) 43% (157) 0.46
sTfR: soluble transferrin receptor. Values indicate mean ± SD unless indicated otherwise. For 54 children, infec-
tion status for Giardia intestinalis was unknown because fresh stool samples could not be obtained.
1 As determined by pLDH test; children with a positive test result were treated with artemether-lumefantrin, 
regardless of the presence or absence of malaria symptoms (see text); 2 Inflammation: whole blood C-reactive 
protein concentration > 8 mg/L; 3 Anemia: hemoglobin concentration < 110 g/L; 4 Iron deficiency: plasma ferritin 
concentration < 12 µg/L (6 missing values); 5 Geometric mean (95% confidence interval)
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Table 2. Incidence rates of diarrhoea or fever of unknown origin by baseline Giardia test 
result by Giardia intestinalis infection status at baseline and intervention group 1
Giardia-
positive
Giardia-negative Rate ratio p
Analysis of first episodes
Any reported diarrhea (223) 2
All 0.43 [58/135.6] 0.68 [147/217.6] 0.63 [0.46–0.86]
Without multi-nutrients 0.29 [21/72.5] 0.72 [79/109.7] 0.40 [0.24–0.66]
With multi-nutrients 0.43 [37/63.1] 0.68 [68/107.9] 0.93 [0.60–1.41] 0.01
Episodes with > 3/24 h (157) 2
All 0.24 [36/149.3] 0.45 [109/244.7] 0.54 [0.36–0.79]
Without multi-nutrients 0.11 [9/79.7] 0.46 [57/123.2] 0.24 [0.11–0.50]
With multi-nutrients 0.39 [27/69.6] 0.43 [52/121.4] 0.91 [0.55–1.47] 0.003
Fever without localizing signs 
(172) 2
All 0.43 [49/144.8] 0.68 [110/255.2] 0.78 [0.55–1.11]
Without multi-nutrients 0.31 [23/74.1] 0.48 [60/124.0] 0.64 [0.37–1.05]
With multi-nutrients 0.37 [26/76.6] 0.38 [50/131.2] 0.97 [0.58–1.58] 0.25
Analysis of all episodes
Any reported diarrhea (390)
All 0.55 [95/172.1] 0.85 [266/311.9] 0.66 [0.49–0.89]
Without multi-nutrients 0.35 [30/85.3] 0.88 [138/157.2] 0.41 [0.25–0.67]
With multi-nutrients 0.75 [65/83.8] 0.82 [128/154.7] 0.93 [0.63–1.36] 0.01
Episodes with > 3/24 h (223)
All 0.30 [51/172.1] 0.53 [164/311.9] 0.58 [0.39–0.84]
Without multi-nutrients 0.16 [14/85.3] 0.52 [82/157.2] 0.32 [0.15–0.66]
With multi-nutrients 0.43 [37/83.8] 0.53 [82/154.7] 0.83 [0.53–1.30] 0.03
Fever without localizing signs (232)
All 0.38 [66/172.1] 0.48 [150/311.9] 0.79 [0.57–1.10]
Without multi-nutrients 0.32 [27/85.3] 0.57 [89/157.2] 0.56 [0.36–0.87]
With multi-nutrients 0.45 [39/83.8] 0.39 [61/154.7] 1.13 [0.71–1.80] 0.03
Rate ratios indicate crude incidence ratios for first or only events, and crude hazard ratios for recurrent events. 
p-values based on tests for differences between rate ratios in children with and without multi-nutrients (based 
on Cox proportional hazards model that included interaction term between multi-nutrients and Giardia)
1 Numbers in intervention groups: without multi-nutrients: n =306 (96 Giardia-positive, 185 negative, 25 
missing); with multinutrients: n=306 (96 Giardia-positive, 181 negative, 29 missing); 2 19,12 and 13 cases of 
reported diarrhea, diarrhea with ≥ 3 loose stools/24h and fever without localizing signs occured in children for 
whom Giardia status was unknown 
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10.1 0.5 2 30.05
Zinc
Multi‐nutrients without zinc
Multi‐nutrients with zinc
Placebo
0.36 (0.14‐0.95)
0.85 (0.39‐1.56)
1.01 (0.50‐2.08)
0.15 (0.05‐0.50)
Hazard ratio← Favours infection Favours absence of infection→
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Figure 2.  Association between Giardia and rates of diarrheal episodes with ≥ 3 watery 
stools/24h, by intervention group
Estimates indicate crude incidence ratios of first or only episodes, with 95% confidence 
intervals. 
Figure 3.  Association between Giardia infection and time to first episode of diarrhea 
with ≥ 3 watery stools/24-h (upper panels; 157 cases) or fever without localizing signs 
(lower panels; 172 cases), by intervention group.
Panels on the left and right: children without and with multi-nutrients, respectively; 
solid and dashed lines: children without and with Giardia intestinalis infection at baseline, 
respectively. Values indicate p-values for group differences (Tarone-Ware test). Hazard ratios 
for interaction between Giardia and multi-nutrient supplementation were 3.55 (1.52–8.24) and 
1.50 (0.76–2.92) for diarrhea and fever without localizing signs, respectively (Cox proportional 
hazards model).
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0.84  (0.64‐1.09)
All 
children
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Figure 4.  Associations between Giardia infection and diarrhea, and between Giardia 
and fever without localizing signs, assessed in all children (upper panel) or by intervention 
group (lower two panels).
Black square: fever without localizing signs; blue diamond: reported diarrhea, ≥ 3 watery 
stools per day; red circle: reported diarrhea. Hazard ratios (95% CIs) were calculated using 
multivariate Cox regression, adjusted for age (continuous), height-for-age z-score (continuous) 
and distance between homestead and research clinic (< or ≥ 4 km. Further adjustment for sex, 
zinc deficiency, mosquito net use, weight-for-height z scores and inflammation at baseline led 
to virtually identical estimates; not shown).
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Figure 5.  Effect of multi-nutrient supplementation on indicators of nutritional status, 
by Giardia intestinalis infection status at baseline.
sTfR: soluble transferrin receptor; MN: multi-nutrients. Grey and blue: without and with 
Giardia infection, respectively. Dependent variables were log-transformed as appropriate, and 
expressed in natural units by exponentiation of estimates resulting from the analysis. For each 
nutritional status indicator investigated, effects are adjusted for the same indicator measured 
at baseline. Line bars indicate 95% CIs.
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was found between Giardia infection and diarrhea in those receiving multi-
nutrients (Figure 3; top panels). 
Adjustment for age and distance to the dispensary led to smaller but 
still substantial associations between Giardia infection and diarrhea (all 
events), whilst interaction effects between infection and the multi-nutrient 
intervention remained virtually unchanged (Figure 4). Further adjustment 
for baseline factors previously found to be prognostic for diarrhea (height-
for-age z-scores, sex, inflammation and use of mosquito nets) led to similar 
effect estimates (not shown). We also explored the association between 
Giardia infection and diarrhea within age classes in children without multi-
nutrients; although the numbers of cases within these strata was low, all 
estimates pointed towards a protective association (HR: 0.36 [0.13 to 1.01], 
0.81 [0.43 to 1.55], 0.19 [0.04 to 0.84] in children aged 6–17 months, 18–35 
months and 36–60 months, respectively).
 
Similar patterns were seen for episodes of fever without localizing signs: 
Giardia infection was associated with a reduction in the time to first episodes 
of such fevers among those receiving zinc or placebo, but not among those 
receiving multi-nutrients. Adjusted estimates of hazard ratios (including all 
events) are shown in figure 3.
The effect of the multi-nutrients on height-for-age z-scores, hemoglobin 
concentrations and plasma transferrin receptor concentrations measured at 
the second survey tended to be greater in children without Giardia infection 
at baseline, whereas supplements seemed to have little effect in those who 
tested positive at baseline (Figure 5). The overall effects were rather small, 
and statistical evidence for differences in effect between children with and 
without Giardia was weak (p-values for interaction between Giardia and multi-
nutrients: 0.13 [height-for-age z-scores], 0.24 [hemoglobin concentrations] 
and 0.32 [plasma soluble transferrin receptor concentrations]). Adjustment 
for age led to similar conclusions (not shown). For other indicators of 
nutritional status (plasma concentrations of zinc, magnesium, cobalamin, 
folate and ferritin), there was no evidence that Giardia infection influenced 
the effect of supplementation.
Discussion
Giardia intestinalis infection at baseline was associated with a marked 
reduction in the rates of subsequent diarrhea among children receiving 
zinc or placebo, but not in those receiving multi-nutrients. Multi-nutrient 
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supplementation among children with Giardia infection resulted in disease 
rates similar to those found in uninfected children. Similar patterns were 
observed for cases of fever without localizing signs.
Substantial cross-over occurred between groups in the course of the study, 
and this may lead to underestimates of differences between children with 
and without Giardia infection. Our Kaplan-Meier analysis indicates, however, 
that the protective association occurred almost from the start of the follow-
up period, when presumably few cross-over cases had occurred.
Our study is limited by the observational nature of our data, which does 
not allow a conclusion that the protection observed was caused by Giardia 
infection. Although this association was still present after adjustment for age 
and other potentially confounding factors, we cannot exclude the possibility 
that children with Giardia infection differed from their uninfected peers 
in other unmeasured characteristics that are prognostic for diarrhea (e.g. 
sanitation, or previous or current exposure to other gastro-enteric pathogens). 
We did not measure breastfeeding behavior, but it is unlikely that this could 
have explained the protective association found against diarrhea in children 
not receiving multi-nutrients: even in older children (aged 36–60 months), 
Giardia infection was associated with a reduction in hazard rates by 81% 
(16% to 96%).
Our findings support the view that the parasite is not an important cause 
of diarrhea in our study population. G. intestinalis comprises various 
genotypes, and its prevalence and its association with diarrheal symptoms 
seems to vary with geographic areas (Ward 2009). A recent study showed that 
Giardia infection was associated with protection against diarrhea, whereas G. 
intestinalis assemblage A was associated with acute diarrhea (Haque et al. 
2009). Thus, due to variation in genotypes and environmental factors, our 
findings may not apply to other populations, and further research is also 
needed to determine G. intestinalis genotype in this population. 
It is not inconceivable that Giardia infection protects against diarrhea, for 
example by competing with or suppressing other enteric pathogens, or 
by inducing changes in mucosal immunity (e.g. Ljungstrom et al. 1985, 
Bilenko et al. 2004). Chronic or repeated exposure to non-pathogenic Giardia 
genotypes may have induced immunity against more pathogenic genotypes. 
This cannot fully explain the protective effect observed, however, because 
the magnitude of the protective association found probably exceeds the 
Giardia-attributable fraction of diarrhea.
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Giardia infection may also be a marker of an unknown factor (e.g. previous 
exposure to other pathogens) that leads to protection against both diarrhea 
and fever without localizing signs. Whatever the cause, Giardia-associated 
protection was no longer present when giving multi-nutrients. This interaction 
is supported by the magnitude of the subgroup effect, the consistency in 
the protective effect being observed in groups receiving placebo and zinc 
and with respect to two mutually exclusive but probably related outcomes 
(diarrhoea and fever without localising signs), whilst the probability that the 
association is due to chance seems low. 
Further studies are needed to evaluate how supplemental micronutrients 
influence the composition, proliferation and pathogenicity of intestinal 
biota, and the interaction of these biota with their host. Iron deserves special 
attention in view of findings that it can enhance the virulence and invasion 
of Salmonella enteritidis (Foster et al. 2001), whilst a recent study suggest that 
supplementation with bovine lactoferrin, an iron binding-protein, reduced 
the prevalence of Giardia among in Peruvian preschool children (Ochoa et al. 
2008). 
Our study findings do not support treatment of Giardia infections in 
symptom-free children, and question the benefit of providing multi-nutrient 
supplements in populations frequently exposed to diarrheal diseases.
In conclusion, Giardia infection at baseline was associated with a marked 
reduction in the rates of subsequent diarrhea. Our data suggest that it is a 
marker for the response in diarrhea to multi-nutrient supplements.
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Summary
Background: Hospital-based studies have found that α+-thalassemia is 
associated with a marked protection against admission with severe, life-
threatening falciparum malaria. Evidence suggests that α+-thalassemia does 
not prevent infection or high parasite densities, but rather limits progression 
to severe disease, in particular severe malarial anemia. However, evidence 
of a protective effect against anemia due to mild or asymptomatic infections 
is inconclusive. 
Methods: In two community-based surveys in Kenya and Tanzania among 
afebrile children (0.5 to 8 years, n=801) we assessed to what extent α+-
thalassemia influences the effect of asymptomatic P. falciparum infections on 
hemoglobin concentrations. 
Results: The effect of infection on hemoglobin concentrations was most 
pronounced in children with inflammation. Among these children, P. 
falciparum was associated with a reduction of hemoglobin concentration 
by 21.8 g/L in those with a normal genotype, as compared to only 16.7 g/L 
(difference, 95% CI: 17.2 g/L, 8.3 to 26.2 g/L) and 4.6 g/L (5.1 g/L, 1.0 to 11.1g/L) 
in children with hetero- and homozygous α+-thalassemia, respectively. 
In children without inflammation, the effect of infection was smaller and 
similar between genotypes.
Conclusions: α+-thalassemia limits the decline in hemoglobin concentration 
that is associated with afebrile infections. This protective effect depends on 
the presence of inflammation. 
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Introduction
α+-thalassemia is highly prevalent in sub-Saharan Africa, Asia and Melanesia. 
Heterozygosis is characterized by the commonly deletional loss of one of the 
duplicated α+-globin genes (-α/αα) and slight hematologic changes, whereas 
homozygotes (-α/-α) generally have mild microcytic anemia (Williams et 
al. 1996, Mockenhaupt et al. 1999, Weatherall and Clegg 2001). Case-control 
studies have consistently shown that α+-thalassemia protects against severe, 
life-threatening malaria requiring hospital admission (Mockenhaupt et al. 
2004, Allen et al. 1997, Williams et al. 2005, May et al. 2007). This protective 
effect is most pronounced in homozygotes, and acts primarily against severe 
malarial anemia (Allen et al. 1997, Wambua et al. 2006, May et al. 2007). No 
study has found evidence of a reduced incidence of uncomplicated malaria 
episodes in α+-thalassemic children (Wambua et al. 2006, Williams et al. 1996, 
2005). Similarly, none of the above studies found an association between α+-
thalassemia and parasite prevalence or density. Although the mechanisms of 
protection are largely unknown, these findings suggest that α+-thalassemia 
prevents disease progression through mechanisms other than limiting 
parasite replication, and that the protection by α+-thalassemia is limited to 
severe manifestations of disease (Williams 2006, Pasvol 2006).
Severe malarial anemia can develop rapidly as a result of hemolysis during 
acute malaria episodes (Ekvall et al. 2001, Ekvall 2003), but may also be the 
cumulative result of smaller reductions in hemoglobin concentration during 
repeated episodes of uncomplicated malaria or impaired erythropoiesis 
during chronic asymptomatic infections (Casals-Pascual and Roberts 2006). 
The notion that severe malarial anemia can develop gradually is supported 
by observations from community-based surveys and hospital studies that 
many cases occur with only mild or no symptoms, no reported history of 
fever, and relatively low parasite densities (Marsh et al. 1995, Menendez et 
al. 1997, Biemba et al. 2000, Mockenhaupt 2004, Koram et al. 2005, Ong’chega 
et al. 2006), suggesting that adaptation to low hemoglobin concentrations 
has taken place over time.
Recently, it has been hypothesized that the protection by α+-thalassemia 
is restricted to severe malarial anemia resulting from acute hemolysis, 
while conferring no protection against gradual reductions in hemoglobin 
concentrations during chronic or repeated infections (May et al. 2007). 
This was supported by findings from a large cohort study among Kenyan 
children, which found no evidence that α+-thalassemia influences the degree 
of anemia associated with episodes of uncomplicated falciparum malaria 
(Wambua et al. 2006).
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By contrast, based on a birth cohort study in Melanesia, Oppenheimer et 
al. suggested that malarial anemia is relatively mild in children with α+-
thalassemia, although this effect was detected only at the age of 6 months 
and was no longer present at 12 months (Oppenheimer et al. 1987). In non-
hospitalized Nigerian children, malaria-associated anemia seemed less 
pronounced in heterozygous than in normal children and was virtually absent 
in homozygotes, although the difference in effect of infection on hemoglobin 
concentration was not statistically significant (Mockenhaupt et al. 1999). 
Similarly, a study in Ghana among predominantly asymptomatic pregnant 
women showed that the effect of P. falciparum infection on hemoglobin 
concentration was less pronounced in women with α+-thalassemia than in 
their counterparts with a normal genotype (Mockenhaupt et al. 2000).
We hypothesized that α+-thalassemia exerts its protective effect against 
severe malarial anemia by preventing the gradual decline in hemoglobin 
concentrations during milder or asymptomatic P. falciparum infections. The 
present study aimed to investigate to what extent α+-thalassemia influences 
the degree of anemia associated with P. falciparum infection among afebrile 
children recruited during community-based surveys. 
Materials and methods
Study area and population: We used data from two community-based 
surveys: The first survey was conducted in a lowland area in northern 
Tanzania, around Segera and Kwedizinga wards in Handeni District, in May–
July 2006. The second survey was conducted in Marafa, the hinterland of 
Malindi district, in the coastal lowlands of Kenya, in May 2004, as a baseline 
assessment for an intervention trial (details are reported elsewhere; Andang’o 
et al. 2007). Malaria transmission is intense and perennial in both areas, with 
virtually all infections due to P. falciparum. In both areas poor farmer families 
predominate, with limited access to health care. The study was approved by 
the responsible Ethics Review Committees in The Netherlands, Kenya and 
Tanzania; informed consent was obtained from community leaders and local 
government officials, and from parents or guardians.
Sampling methods and eligibility criteria: For the Tanzanian survey, 
children were randomly selected from a census list that included all resident 
children aged 6–72 months in the study area. Children were eligible to 
participate in the survey when they had no signs of severe febrile disease 
or severe malnutrition at the time of assessment. Not all selected children 
participated; non-participating children were on average younger than their 
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participating peers. To avoid bias on replacement, we re-sampled children 
from within the same age category as the non-participants (age categories: 
6–18 months, 18–36 months and 36–72 months) until 304 participating 
children were obtained.
From 325 children selected, 21 did not participate in the study: 2 children 
died between the time of the census and the start of the study; 3 children 
were temporarily absent; for 10 children, the parents refused consent; 4 
children did not show up for unknown reasons; and 2 children were not 
eligible because they were sick and referred to the hospital on the day of 
recruitment. The Kenyan survey (n=516) was conducted in four schools, 
among all children who were enrolled in nursery or the first year of primary 
school. Three weeks before the baseline assessment of the trial, 528 children 
were screened for eligibility. Seven children with hemoglobin concentrations 
below 70 g/L, and five who were expected to be non-compliant or absent 
during the subsequent intervention period were excluded from participation.
Field procedures: All children were examined by a clinical officer, who 
also measured axillary temperature. Anthropometric measurements were 
collected from all children. Venous blood was collected in containers with 
sodium heparin as anticoagulant (Becton-Dickinson, Franklin Lakes, NJ). 
Children were treated free of charge for common childhood infections and 
anemia according to guidelines of the Kenyan and Tanzanian Ministries of 
Health.
Laboratory procedures: In Tanzania, parasitemia was detected by rapid 
immunochromatographic assay (Optimal, Flow Inc., Portland, OR). Contrary 
to most other types of rapid dipstick tests, this test detects P. falciparum-
specific lactate dehydrogenase (pLDH) which is only produced by live 
parasites. The test result becomes negative rapidly after parasite clearance 
(Makler et al. 1998, Piper et al. 1999). In Kenya, parasitemia was detected by 
conventional microscopy. 
Whole blood hemoglobin concentrations were measured by hematology 
analyzers (Beckman Coulter, Fullerton, CA; and KX-21, Sysmex Corporation, 
Kobe, Japan; for samples collected from Tanzania and Kenya, respectively).
Plasma was separated by centrifugation, transferred to cryotubes and stored 
in liquid nitrogen. We preserved red cells, including the buffy coats (90 
µL), in microcentrifuge tubes containing a DNA-stabilizing buffer (AS1, 
Qiagen, Valencia, CA) at 4 °C, for subsequent α+-thalassemia genotyping. 
Plasma concentrations of ferritin and C-reactive protein were measured as 
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indicators of iron status and inflammation, on a Behring nephelometer (BN-
prospec, Dade-Behring, Marburg, Germany) in The Netherlands (Meander 
Medical Centre, Amersfoort). DNA was extracted using the QIAamp DNA 
blood Mini Kit (Qiagen, Hilden, Germany) according to instructions by the 
manufacturer. The –α3.7 deletion type of α+-thalassemia was determined by 
polymerase chain reaction assays, as described by Lui et al. (2000). Other 
types of α+-thalassemia, including the –α4.2 type, occur only sporadically in 
Africa (Weatherall and Clegg 2001, Ekvall 2003).
Statistical analyses: We used the following definitions: current infection: 
the presence of at least one asexual P. falciparum parasite upon microscopic 
examination of blood smears from Kenyan children, or a positive result for 
the pLDH test in blood collected from Tanzanian children; inflammation: 
plasma C-reactive protein concentrations > 10 mg/L (Gabay and Kushner 
1999); anemia: hemoglobin concentrations < 110 g/L and < 115 g/L for 
children aged < 5 years and ≥ 5 years, respectively; iron deficiency: plasma 
ferritin concentration < 12 µg/L and < 15 µg/L for children aged < 5 years 
and ≥ 5 years, respectively (WHO 2001). Because it is difficult to interpret 
estimates of iron deficiency in a population with high prevalence of malaria 
and inflammation (both affect plasma ferritin concentrations independently 
of iron status), we restricted this analysis to children without inflammation.
All data were entered in a dedicated Microsoft Access database, and cleaned 
and analyzed using SPSS (vs 13.0 for Windows; SPSS Inc., Chicago, IL). 
Anthropometric z-scores were calculated using Epi Info software (version 
3.3.2; www.cdc.gov/epiinfo). For normally distributed variables, we 
calculated means, SDs and 95% CIs. For variables that were not normally 
distributed, we calculated the geometric mean. We used the normal 
approximation of the binary distribution to obtain prevalence differences 
and their corresponding 95% CIs. For variables that could not be normalized 
by log-transformation, we assessed group differences by Mann-Whitney or 
Kruskal-Wallis tests.
We assessed the effect of P. falciparum infection on hemoglobin concentrations 
in a multivariate linear regression model that adjusted for age, weight-for-
height z-score, iron deficiency, and study site. In this model, we evaluated 
whether the effect of P. falciparum infection depended on genotype, by 
examining interaction terms (dummies for α+-thalassemia genotype × 
infection status). We did not adjust for the presence of inflammation because 
we considered that the effect of infection on hemoglobin concentration may 
at least in part be mediated through inflammation. Thus, we repeated the 
above analysis whereby we stratified children with P. falciparum infection 
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by inflammation status. The groups thus formed were mutually exclusive, 
and were compared to the reference group of children without malaria, and 
without inflammation. For each of the groups, we directly evaluated whether 
the effect of infection on hemoglobin concentration depended on genotype 
by multivariate analysis.
Results
In Kenya and Tanzania, ten and nine children, respectively, were febrile at 
the time of examination and excluded from the analysis. The characteristics 
of the remaining 801 children are shown in Table 1. Eight Tanzanian 
children were afebrile but reported sick by the clinical officer (five were weak 
without localized signs but with a history of fever, one had signs of an upper 
respiratory tract infection, two had signs of a gastro-intestinal infection and 
one was completing a quinine course for malaria). Mothers of the Tanzanian 
children reported the following symptoms at the time of examination: 
history of fever in the last 24 h (23%), cough (43%), vomiting or diarrhea 
(16%), ear problems (5 %), skin lesions (19%). For Kenyan children, none of 
the children included in the study was reported sick by the clinical officer but 
mothers were questioned about the history of illness in the previous 2 weeks. 
The following symptoms were reported: history of fever (8%), cough (18%), 
gastro-intestinal symptoms (11%), ear problem (1%) and skin problem (5%). 
The Tanzanian children were younger and their hemoglobin concentrations 
were lower as compared to the children in Kenya. There were no children 
with a hemoglobin concentration below 50 g/L. In Kenya and Tanzania, 
the prevalence of P. falciparum infection was similar, but the prevalence of 
inflammation was higher in Tanzania (78/295; 26%) than in Kenya (35/506; 
7%). Children with P. falciparum infection had a higher prevalence of 
inflammation than those without infection (21% vs 8%; difference, 95% CI: 
13 %, 9% to 18%), and higher plasma concentrations of C-reactive protein 
(p<0.001; Mann-Whitney test). We found no evidence that parasite density 
was different between the study sites (p=0.11, Mann-Whitney test), but the 
frequency of inflammation among children with P. falciparum infection was 
lower in the children from Kenya (9%; 25/265) than in those from Tanzania 
(43%; 58/134). In the following paragraphs, data are presented from the 2 
study sites combined unless specified otherwise.
For 47 children, α-globin genotyping results were not available because 
samples were unclearly labeled or because of technical problems. Among 
the remaining children, 12% were homozygous, 46% were heterozygous 
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α+3.7-genotype
Normal Heterozygote Homozygote Undetermined
Tanzanian and Kenya combined, % (n) 42.0 (317) 45.8 (345) 12.2 (92) 47 
Tanzania, % (n) 62.1 (169) 33.5 (91) 4.4 (12) (23) 
Age, years 2.7 (1.6) 2.9 (1.5) 2.3 (2.0) 2.6 (1.6)
Hemoglobin concentration, g/L 105.3 (17.2) 107.6 (17.1) 94.2 (14.3) 104.3 (19.2)
Anemia, % (n) a 55.6 (94) 48.4 (44) 100 (12) 52.2 (12)
Plasma ferritin concentration, µg/L b,c 19.7 22.0 21.5 13.8
Iron deficiency, % (n) a,b,d 13.2 (16) 16.7 (12) 16.7 (1) 22.2 (4)
Inflammation, % (n) a 28.4 (48) 20.9 (19) 50.0 (6) 21.7 (5)
P. falciparum infection, % (n) a 49.1 (83) 39.6 (36) 50.0 (6) 39.1 (9)
Height-for-age z-score –1.76 (1.27) –1.64 (1.23) –1.57 (0.89) –1.41 (0.87)
Kenya, % (n) 30.7 (148) 52.7 (254) 16.6 (80) (24) 
Age, years 5.9 (1.5) 5.9 (1.5) 5.8 (1.5) 5.9 (1.3)
Hemoglobin concentration, g/L 113.6 (11.8) 111.9 (10.3) 104.8 (11.47) 114.2 (8.12)
Anemia, % (n) a 39.9 (59) 59.4 (151) 80.0(64) 45.8 (11)
Plasma ferritin concentration, µg/L c 23.8 22.6 27.3 21.3
Iron deficiency, % (n) a,d 16.8 (23) 17.8 (43) 5.6 (4) 23.5 (5)
Inflammation, % (n) a 7.4 (11) 5.1 (13) 10 (8) 12.5 (3)
P. falciparum infection, % (n) 48.6 (72) 53.5 (136) 56.3 (45) 50 (12)
Height-for-age z-score –0.77 (0.72) –0.76 (0.72) –0.85 (0.72) –0.58 (0.59)
Mean (SD) unless otherwise indicated. 
a Definitions as specified in the text; b n=90 for heterozygotes due 1 missing value for plasma ferritin concentra-
tion; c Geometric mean; d Restricted to children without inflammation
Table 1. Characteristics of study population, by genotype and study site
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Figure 1.  Associations between 
hemoglobin concentration and malarial 
infection, by α+-globin genotype.
Footnote: Hemoglobin concentrations 
indicated are group means (upper panel) 
or differences in means (lower panel) 
as obtained by multivariate regression 
analysis that adjusted for standardized 
age and height-for-age z-score, iron 
deficiency and study site. White bars: 
without P. falciparum infection; black 
bars: with P. falciparum infection. Line 
bars indicate 95% CIs
Figure 2.  Hemoglobin concentration 
in groups defined by malarial infection, 
inflammation and α+-globin genotype.
Footnote: Hemoglobin concentrations 
indicated are group means (upper panel) 
or differences in means (lower panel) 
as obtained by multivariate regression 
analysis, adjusted for standardized 
age and height-for-age z-score, iron 
deficiency and study site. White bars: 
without P. falciparum infection and 
without inflammation (plasma C-reactive 
protein concentrations > 10 mg/L); black 
bars: with P. falciparum infection but 
without inflammation; grey bars: without 
P. falciparum infection and without 
inflammation. There were insufficient 
children with inflammation but without 
P. falciparum infection for meaningful 
analysis; these data were therefore left 
out. Line bars indicate 95% CIs.
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and 42% had a normal genotype. Compared to their Tanzanian peers, the 
children in Kenya had a higher prevalence of both hetero- and homozygous 
α+-thalassemia. There was no evidence that parasite density was associated 
with genotype (p=0.67; Kruskal-Wallis test). 
In children with normal, heterozygous and homozygous genotypes, 
P. falciparum infection was associated with reductions in hemoglobin 
concentration of 9.3 g/L, 6.7 g/L and 3.2 g/L, respectively (Figure 1). Compared 
to the effect observed in children with a normal genotype, this reduction 
appeared smaller in heterozygotes (difference, 95 % CI: 2.6 g/L, –1.0 g/L to 
6.3 g/L) and was clearly smaller homozygotes (6.1 g/L, 0.5 g/L to 11.7 g/L). 
This pattern of protection by α+-thalassemia was seen consistently within the 
populations from both study sites, although it seemed less pronounced in 
the Kenyan children (data not shown). 
Compared to uninfected children without inflammation, children in whom 
P. falciparum infection was accompanied by inflammation generally had 
larger reductions in hemoglobin than those with infection but without 
inflammation (Figure 2). In children without inflammation, P. falciparum 
infection was associated with only small reductions in hemoglobin 
concentration, whereby the effects were similar across α-globin genotypes. 
By contrast, in infected children with inflammation, the P. falciparum-
associated reduction in hemoglobin concentration strongly depended on 
genotype; in children with a normal genotype this reduction was 21.8 g/L 
(18.0 to 25.6 g/L), as compared to 16.7 g/L (11.9 to 21.9 g/L) in heterozygotes, 
and only 4.6 g/L (–3.5 to 12.7 g/L) in homozygotes. The difference in effect 
was 5.1 g/L (–1.0 to 11.1 g/L) and 17.2 g/L (8.3 to 26.2 g/L), for heterozygotes 
and homozygotes respectively. These estimates were adjusted for study site, 
age, height-for-age z-scores and iron deficiency. There were only 27 children 
with inflammation but without malaria. Among these children, we found no 
evidence of a protection by thalassemia, but the estimates in this group were 
imprecise (data not shown).
Among children without infection and without inflammation, homozygotes 
had lower hemoglobin concentrations than those with a normal genotype 
(difference in means: –11.1 g/L, –7.0 g/L to –15.2 g/L) (figure 2). The opposite 
was observed among children with P. falciparum infection and with 
inflammation: among these children, homozygotes tended to have higher 
hemoglobin concentrations than those with a normal genotype (6.2 g/L, 95% 
CI: –1.8 g/L to 14.2 g/L).
Reanalysis of these data by study site led to similar results and conclusions, 
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although the estimates obtained were less precise due to smaller numbers 
Both in Tanzania and Kenya, the P. falciparum-associated hemoglobin 
reduction in the presence of inflammation, was significantly smaller in 
homozygous children than in those with a normal genotype (difference in 
effects, 95% CI: 24.2 g/L, 2.8 g/L to 45.7 g/L and 13.6 g/L, 2.6 g/L to 24.5 g/L, 
for children from Tanzania and Kenya, respectively). 
As a last step, we evaluated plasma concentrations of C-reactive protein 
among children with P. falciparum infection by genotype. In the presence of P. 
falciparum infection, inflammation occurred less frequently in heterozygous 
children than in their counterparts with a normal genotype (14% versus 29%; 
difference, 95% CI: 15%, 10% to 20%). Likewise, plasma C-reactive protein 
concentrations were lower in these children than in those with a normal 
genotype (p=0.005; Mann-Whitney test). Among homozygotes, inflammation 
occurred less frequently than in children with a normal genotype (18% 
versus 29%; difference, 95% CI: 11%, 2% to 20%), but the group was small and 
we found no evidence of a difference in C-reactive protein concentrations 
(p=0.63; Mann-Whitney test). 
Discussion
The data from our survey among afebrile children from communities with 
intense malaria transmission support our hypothesis that α+-thalassemia 
protects against the decline in hemoglobin concentration associated with 
mild or asymptomatic P. falciparum infections. The protective effect was 
more pronounced in homozygotes than in heterozygotes, and was observed 
when infection was accompanied by inflammation. In children without 
inflammation, P. falciparum was associated with only small reductions of 
hemoglobin concentrations that were similar across genotypes.
Children in Kenya were older and may have had higher degrees of protective 
immunity against malaria than their peers in Tanzania. They also may have 
differed in other, unmeasured characteristics. However, reanalysis of the data 
presented in Figures 1–2 by study site yielded similar results. In addition, 
the estimates were obtained from a multivariate analysis that adjusted for 
study site, and several other factors that may have been associated with 
anemia. Thus it is unlikely that our results can be explained by differences 
in population characteristics between the study sites. Because data were 
collected cross-sectionally we have no insight in the dynamics of the decline 
in hemoglobin concentrations, or the preceding duration of infection at the 
point of measurement. We have no reason to assume, however, that the 
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duration of infection was different between the genotype groups, and we 
do not think that the cross-sectional design has affected the validity of our 
results.
Our data show that protection by α+-thalassemia is not confined to the 
severe forms of malarial anemia, as suggested by others (Wambua et al. 
2006, May et al. 2007). A recent large study at the Kenyan coast reported that 
both in children recruited from community-based surveys (‘steady state’) 
and in those with uncomplicated malaria, the reductions in hemoglobin 
concentrations due α+-thalassemia were similar, suggesting no interaction 
between P. falciparum infection and α+-thalassemia during uncomplicated 
disease episodes. Among children admitted to the hospital with severe 
malaria, however, heterozygotes and homozygotes had higher mean 
hemoglobin concentrations than children with normal genotype (Wambua 
et al. 2006). This suggested that protection by α+-thalassemia mainly 
prevents the decline in hemoglobin concentration during the progression 
from episodes of uncomplicated malaria to severe malarial anemia, and 
does not play a role during milder infections. It should be noted, however, 
that the group of children in ‘steady state’ probably included both children 
with and without (asymptomatic) malaria infection, and that their infection 
status was not considered in the analysis. Moreover, children in this group 
were on average five years older than patients with uncomplicated malaria. 
By contrast, our findings show that α+-thalassemia already protects against 
malaria-associated anemia in children with P. falciparum infections that are 
accompanied by inflammation but without febrile illness. This is compatible 
with our hypothesis that α+-thalassemia protects against severe malarial 
anemia by preventing the gradual decline in hemoglobin concentration 
during repeated or chronic infections.
Because the protective effect was observed particularly when the infection 
was accompanied by inflammation, our findings suggest that even in a 
spectrum of relatively mild infections, there may be differences in severity 
between children with and without thalassemia. This was supported by 
the finding that plasma concentrations of C-reactive protein were lower 
among heterozygotes and also seemed lower among homozygotes. In 
addition to having smaller declines in hemoglobin concentration when 
infection is accompanied by inflammation, children with α+-thalassemia 
may also be less likely to develop inflammation when infected. Similarly, 
among predominantly asymptomatic pregnant Ghanaian women with P. 
falciparum infection, α+-thalassemia was associated with reduced frequency 
of inflammation (Mockenhaupt et al. 2001). In the same women, the effect 
of P. falciparum infection on hemoglobin concentration was less pronounced 
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among those with α+-thalassemia than among their counterparts with a 
normal genotype (Mockenhaupt et al. 2000).
In endemic areas, many children have P.falciparum infection with 
inflammation but without symptoms (Hurt et al. 1994, Verhoef et al. 2002). 
However, increased concentrations of C-reactive protein among infected 
children can not always be attributed to parasitemia (Hurt et al. 1994). Thus 
the protection by α+-thalassemia among children with P. falciparum infection 
and inflammation, as observed in this study, may not be specific for malaria. 
In inflammatory processes, cytokines such as TNF-α, IL-1, IL-6 and IFN-γ 
limit the supply of iron to the erythron through the action of hepcidin 
(Nemeth et al. 2006), and limit the proliferation of erythroid progenitor 
cells by suppressing the production of and responsiveness to erythropoietin 
(Weiss et al. 2005). Thus, even when inflammation is not due to P. falciparum 
infection, it may exacerbate anemia by interfering with the host’s ability to 
effectively compensate for the loss of red blood cells due to malaria. Several 
studies have suggested that α+-thalassemia may restrict the consequences 
of inflammatory processes in general. In a study in Papua New Guinea, 
α+-thalassemia not only reduced hospitalizations due to severe malaria, 
but also and to a similar extent reduced the risk of hospitalization due to 
other infectious diseases (Allen et al. 1997). Similarly, other observations 
suggest that α+-thalassemia also protects against severe non-malarial anemia 
(Mockenhaupt et al. 2004, Pasvol 2006). Our sample size was insufficient to 
evaluate the protective effect among children with inflammation but without 
parasitemia. Moreover, such analysis would have been difficult to interpret 
because inflammation may be milder in those children, and also because 
bone marrow suppression and anemia may persist after the infection has 
been cleared (Camacho et al. 1998, Kurtzhals et al. 2003, Helleberg et al. 
2005). The question whether α+-thalassemia protects against anemia during 
inflammatory processes other than malaria therefore remains unanswered. 
Similarly, the exact mechanism whereby α+-thalassemia might modify the 
inflammatory response remains unresolved.
In conclusion, our data show that the protective effect of α+-thalassemia 
against malaria-associated anemia is not confined to severe malaria cases, 
but is already present in mild, predominantly asymptomatic P. falciparum 
infections. The protective effect is evident only when the infection is 
accompanied by inflammation. This observation, in combination with the 
finding that the protection by α+-thalassemia seems to be restricted to the 
anemic forms of disease, may give further direction in the search for the 
protective mechanisms in α+-thalassemia.
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Summary
Background: It is controversial to what degree α+-thalassemia protects 
against episodes of uncomplicated malaria and febrile disease due to 
infections other than Plasmodium. 
Methods: In a community-based cohort study among pre-school Tanzanian 
children aged 6-60 months (n= 612), we compared rates of fevers due to 
malaria and other causes between children with homo-or heterozygous α+-
thalassemia and those with a normal genotype, using a Cox proportional 
hazards model that included multiple events per child.
Results: The overall incidence of uncomplicated malaria was 2.93 (1572/526 
child-years), and we found no evidence of group differences between the 
genotypes (hazard ratios 0.93; 95% CI: 0.82-1.06 and 0.91; 0.73-1.14 for 
hetero- and homozygotes respectively, adjusted for baseline factors that 
were predictive for outcome). However, the effect of α+-thalassemia strongly 
depended on age; α+-thalassemic children below 18 months experienced 
episodes more frequently than those with a normal genotype (1.30; 1.02-
1.65 and 1.15; 0.80-1.65 for hetero- and homozygotes respectively), whereas 
among older children we observed protective effects (0.80; 0.68-0.95 and 0.78; 
0.60-1.03; p-value for interaction 0.001 and 0.10 for hetero- and homozygotes 
respectively). No effect was observed on non-malarial febrile episodes.
Conclusions: α+-thalassemia influences the risk of uncomplicated malaria 
in an age-dependent manner, whereby an initial increase of febrile episodes 
among the youngest children is followed by a protection at older age. 
This suggests that the acquisition of protective immunity is more efficient 
among α+-thalassemic children, and contributes important information to 
the existing epidemiological evidence that directs the search of protective 
mechanisms involved.
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Introduction
α+-thalassemia is a common genetic trait in malaria-endemic areas in sub-
Saharan Africa, Asia and Melanesia. Normal individuals have 4 genes coding 
for α-globulin (duplicate genes located on each chromosome 16) while hetero- 
and homozygous individuals have only 3 (-α/αα) or 2 (-α/-α) functional 
genes. Consequently, children with α+-thalassemia produce fewer α-globin 
chains, resulting in some reduction in hemoglobin concentrations but no 
other manifestations. In fact, in areas that are highly endemic for malaria, 
they may be protected against the decline in hemoglobin concentration that 
is associated with asymptomatic Plasmodium infection (Veenemans et al. 
2008). 
While case-control studies (Allen et al. 1997, Mockenhaupt et al. 2004, May et 
al. 2007) and two cohort studies (Williams et al. 2005a, Wambua et al. 2006) 
have consistently shown that α+-thalassemia is associated with reduced 
risks of severe malaria, reports on its effect on uncomplicated malaria are 
inconsistent. A study in Vanuatu showed that, among children aged below 5 
years, homozygous (but not heterozygous) α+-thalassemia was paradoxically 
associated with an increased incidence of uncomplicated malaria due to both 
Plasmodium vivax and P. falciparum (incidence ratio [95% CI]: 2.2[1.3–2.7] and 
1.6[1.0–2.6], respectively); among children aged 5–9 years, however, there 
was no evidence of such an association (Williams et al. 1996). The authors 
suggested that early exposure to the more benign P. vivax induced cross-
species protection against P. falciparum. Subsequent studies in Africa found 
no effect (Allen et al. 1993, Williams et al. 2005b, Wambua et al. 2006) or 
protection (Enevold et al. 2008) by α+-thalassemia against uncomplicated 
malaria due to P. falciparum.
In a prospective case-control study in Papua New Guinean children, α+-
thalassemia was also strongly protective against hospitalization for disease 
episodes caused by infections other than malaria (Allen et al. 1997). 
We conducted a community-based cohort study among preschool children 
to assess effects of α+-thalassemia on the rate of fevers due to malaria and 
fever due to other causes, and evaluated to what extent this effect depended 
on age.
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Methods
Study area and population: The study was conducted in February 2008–
March 2009 in 4 rural villages in Handeni District, northeastern Tanzania. 
People originally belonged to the Wazigua and Wabondei tribes, but 
settlement of migrant plantation workers in the past has resulted in a 
mixture of many tribes with different origins. Plantations have long since 
closed, and the population, residing in scattered hamlets in the area, is 
mainly comprised of poor farmer families engaged in subsistence farming. 
Transmission of malaria (more than 95% due to Plasmodium falciparum) is 
intense and perennial, with peaks during the rainy seasons and annual 
inoculation rates of 35–400 per year (Ellman et al. 1998). Access to primary 
health care is limited: apart from several local traditional healers the research 
dispensary was the only health facility in the area. Artemether-lumefantrine 
was the first-line treatment for uncomplicated malaria, and available for 
free only in public health care facilities but not in local shops; accordingly, 
home treatment with efficacious anti-malarial drugs probably occurred only 
sporadically.
Study design: This prospective cohort study was part of a double-blind 
randomized trial aimed at measuring the effects of preventive supplementation 
with zinc and other multi-nutrients on the incidence of malaria (Veenemans 
et al. submitted). During the follow-up period, children daily visited a 
centre close to their homestead where micronutrient supplements were 
administered by community volunteers. Malaria morbidity was assessed by 
passive case detection; parents were encouraged to bring their children to 
the research dispensary in case of fever or other signs of illness.
Ethical approval was provided by the review committees in The Netherlands 
and Tanzania. Individual written consent was obtained from parents or 
guardians.
Recruitment: Before recruitment, which took place between February and 
August 2008, we conducted a census and registered all resident children 
aged below 60 months. Parents and guardians were invited to an information 
seminar and subsequent 2-day screening procedure to determine eligibility. 
A medical examination was performed by a clinical officer, anthropometric 
indices were calculated as the average of two recordings taken at consecutive 
days, and venous blood samples were collected. An aliquot of blood was 
centrifuged immediately after collection, and a 90 µL red cell pellet with the 
buffy coat was mixed with 90 µL phosphate-buffered saline and 180 µL a 
DNA stabilizing buffer (AS1; Qiagen, Hilden, Germany) and stored at 4 °C 
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for subsequent genotyping. Plasma was stored in liquid nitrogen. A second 
aliquot of whole blood was examined by hematology analyzer (Sysmex 
KX21, Kobe, Japan) the same day.
Children were eligible to be randomized when aged 6-59 months, and 
with height-for-age z-score <-1.5SD. We excluded children with weight-
for-age z-score <–3SD, hemoglobin concentration <70 g/L, or signs of 
severe or chronic disease, those unlikely to comply with interventions, or 
whose parents/guardians refused consent. Eligible children were randomly 
allocated to receive daily supplements with zinc alone, zinc in combination 
with other micronutrients, micronutrients alone, or placebo. We used block 
randomisation within 6 strata defined by Plasmodium infection and age 
class (6-17 months, 18-35 months and 36-60 months). Further details about 
allocation procedure, composition of the supplements and intervention 
effects will be reported elsewhere. All children with Plasmodium infection 
were treated with artemether-lumefantrine (Novartis Pharma, Basel, 
Switzerland) upon enrollment. 
Follow-up: During the follow-up period, a clinical officer was on permanent 
(24 h) duty at the research clinic. For any child reporting with fever (axillary 
temperature ≥ 37.5 °C) or a history of fever according to the guardian, a 
finger-prick blood sample was collected to detect the presence of malaria 
parasites. For all children with a positive dipstick we prepared two blood 
slides and measured whole blood concentrations of haemoglobin and 
C-reactive protein. Children were treated free of charge, and referred to the 
district hospital when indicated.
Laboratory procedures: 
In samples collected during the baseline survey and from sick children, 
we used a dipstick test (pLDH rapid dipstick test, CareStart™, Access 
Bio, Monmouth Jct, USA) to detect the presence of parasite-specific lactate 
dehydrogenase (P. falciparum and other Plasmodium species). This test has 
a sensitivity of 96% for blood samples with > 50 parasites/µL (Piper et al. 
1999). Blood films were prepared using standard methods. For slides of sick 
children, parasites were counted against at least 200 leukocytes, and parasite 
density was calculated assuming a leukocyte count of 8000/µL. At least 500 
leukocytes were counted before a slide was considered negative. When 
densities were very high, parasites were counted per 2,000 erythrocytes, in 
which case we used the estimated erythrocyte count at the time of the episode 
to determine the number of parasites per µL blood. The erythrocyte density 
was estimated based on the haemoglobin concentration measured at the time 
of the episode, using a linear model based on survey data that described the 
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relation between haemoglobin concentration and erythrocyte count.
Within 6 months after collection, DNA was isolated from whole blood 
samples and the –α3,7 deletion type of α+-thalassemia was determined by 
polymerase chain reaction (Liu et al. 2000). This type of deletion is the most 
common form of α+-thalassemia in Africa (Williams 2006), with prevalence 
values often exceeding 50% in eastern Africa (Williams 2006, Enevold et al. 
2008, Veenemans et al. 2008); other types of thalassaemia are rare.
Whole-blood concentrations of hemoglobin and C-reactive protein were 
measured in the field using a photometer (HemoCue, Ängelholm, Sweden) 
and a immunoturbidimetric test (QuikRead, Orion Diagnostica, Espoo, 
Finland), respectively. Plasma concentrations of C-reactive protein and 
ferritin for survey samples were measured in The Netherlands (Meander 
Medical Centre, Amersfoort) on a Beckman Coulter Unicel DxC880i system 
according to the manufacturer’s instructions. Plasma concentrations of 
P. falciparum specific histidine-rich protein-2 (HRP2) in samples collected 
during the first malaria episode were measured using a commercial enzyme-
linked immunosorbent assay kit (Malaria Ag Celisa; Cellabs, Brookvale NSW, 
Australia). This protein is released into the plasma at schizont rupture, and 
its plasma concentration may more accurately represent total body parasite 
biomass, because it also reflects the presence of sequestered parasites that 
remain largely undetected with conventional microscopy (Dondorp et al. 
2005).
Statistical analysis: All data were double-entered and analyses were 
performed using SPSS (v15·0 for Windows, SPSS, Chicago, IL), CIA (v2.1.2) 
(Altman et al. 2000) and STATA (v11; College Station, Tx) Anthropometric 
indices were calculated using Epi Info software (version 3.3.2; http://www.
cdc.gov/epiinfo). 
The primary outcome, an episode of malaria, was pre-defined as a guardian-
reported history of fever accompanied by either an axillary temperature ≥ 
37,5 °C or inflammation (whole blood C-reactive protein concentration ≥ 8 
g/L), plus a positive result for the pLDH rapid dipstick test. We assumed 
that children were protected against new malaria infections for 14 days after 
treatment with artemether-lumefantrine, so any recurrent symptoms during 
this period were assumed to be part of the initial episode and were not 
counted as separate episodes. Additional outcomes were hospital admissions 
or death due to infection-related causes (combined end-point), non-malarial 
febrile episodes (defined as any episode of reported fever that did not classify 
as malaria, separated by at least 2 days), and the severity of malaria episodes 
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as indicated by parasite density, hemoglobin concentrations, concentration 
of whole blood C-reactive protein and plasma HRP2. 
In the primary analysis we compared disease rates between genotypes using 
Cox regression with robust estimates of the standard error to account for 
multiple episodes within children). We explored to what extent adjustment 
for baseline factors presumed or shown to be prognostic for malaria (age 
class, mosquito net use, Plasmodium infection, distance between homestead 
and clinic, and height-for-age z-score and intervention) influenced the 
estimates. Because we anticipated that the effect of α+-thalassemia would 
depend on age, we conducted a stratified analysis within each of the three 
age classes used for randomization, and assessed interaction using a Cox 
regression model. We calculated incidence rates and rate ratios for first or 
only episodes, but used Cox regression model to obtain adjusted hazard 
ratios. Continuous variables were log-transformed as appropriate to obtain 
normal distributions, and associations were assessed by ANOVA and 
multiple linear regression analysis.
Results
Of 1,029 children screened, 417 were not eligible, mostly because their height-
for-age score exceeded –1.5 SD, and 612 children were enrolled (Figure 1). 
During follow-up, 20 of 612 (3%) children were lost (3 died; 2 withdrawn by 
parents; 15 moved away).
Of 612 children included for follow-up, 304 (50%) had a normal genotype, 41% 
(251) were heterozygote, 9% (55) were homozygous, whilst DNA could not 
be amplified for 2 children. Plasmodium infection was detected in 265 children 
(43%), virtually all due to P. falciparum (261), with similar prevalence values 
among the genotypes. Homozygotes had lower hemoglobin concentrations 
and height-for-age z-scores, seemed slightly younger, appeared to have a 
higher prevalence of iron deficiency, and used mosquito nets less frequently 
than those with a normal genotype. They also less frequently received zinc 
supplements, with or without multi-nutrients (Table 1). No major differences 
were found between children with heterozygous and normal genotype in 
factors that were prognostic for malaria. Hemoglobin concentrations were 
lower among children with α+-thalassemia.
Of 2,462 episodes of reported fever, 1,618 had a positive dipstick test result, and 
1,572 episodes were classified as malaria cases that occurred in a total follow-
up time 526 child-years. The incidence of malaria was 2.93 per child-year at 
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Invited for screening
n=1,265
Screened
n=1,029
No show
n=236
Excluded (n= 417)
 Parents refused consent: 21
 Height‐for‐age >–1.5 SD: 359
 Medical reasons: 13
 Date of birth unclear: 8
 Unlikely to comply with intervention: 16
Normal
n=304
Heterozygote
n=251
Homozygote
n=55
Lost to follow‐
up: 8
Died: 2
Refused: 2
Lost to follow‐
up: 6
Completed
n=292 (96%)
Completed
n=245 (98%)
Completed
n=55 (100%)
Failure to obtain sample for genotyping: 
2 (1 died, 1 moved away)
Eligible
n=612
Figure 1.  Study profile. 
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Heterozygotes Homozygotes
Hazard ratio
associated with increased riskα+‐ thalassemia associated with protection
0.91 (0.75‐1.11)
1.04 (0.75‐1.45)
1.30 (1.02‐1.65)
1.15 (0.80‐1.65)
0.77 (0.62‐0.96)
0.82 (0.59‐1.12)
0.83 (0.66‐1.05)
0.69 (0.47‐1.02)
Overall
By age group
Age 6‐17
Age 18‐35
Age 36‐59
0.80.4 1.00.2 0.6 1.4 1.8 2.4
Episodes as predefined
 
Heterozygotes Homozygotes
0.80.4 1.0
Hazard ratio
associated with increased riskα+‐ thalassemia associated with protection
0.93 (0.79‐1.10)
0.92 (0.68‐1.24)
1.41 (1.06‐1.87)
1.28 (0.84‐1.96)
0.75 (0.58‐0.97)
0.75 (0.46‐1.22)
0.78 (0.57‐1.06)
0.58 (0.30‐1.11)
0.2 0.6 1.4 1.8 2.4
Overall
By age group
Age 6‐17
Age 18‐35
Age 36‐59
Episodes with density 
>10,000/ µL
 
Figure 2.  Association between α+-thalassemia and malaria rates, overall and by age 
class. Top panel: episodes as predefined; bottom panel: episodes as predefined, but with 
densities of asexual parasites >10,000/µL.Line bars and values between brackets indicate 95% 
CIs. Estimates adjusted for baseline Plasmodium infection status, distance between homestead 
and clinic (continuous variable), height-for-age z-score (continuous variable), mosquito net use 
and experimental intervention produced similar estimates; adjusted p-values for difference in 
hazard ratios between children < 18 months or ≥ 18 months: 0.006 and 0.18 for hetero-and 
homozygotes, respectively. Bottom panel: adjusted p-values for difference in hazard ratios 
between children < 18 months or ≥ 18 months: 0.002 and 0.07 for hetero-and homozygotes, 
respectively.
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risk; 507 children (83%) experienced at least one malaria episode, recurrent 
episodes occurred in 395 (63%) of children. The remaining 890 episodes were 
classified as non-febrile malaria episodes; the incidence of such cases was 
1.69/child-year. Hospital-referral for infection-related causes occurred in 68 
cases, of which 30 were malaria (19 cases with hemoglobin concentration < 
60 g/L, all except one without signs of heart failure or respiratory distress). 
Malaria incidence decreased with age class (3.73, 3.48 and 2.19 episodes/year 
for age classes 6–17, 18–35 and 36–59 months respectively; p<0.001). 
Rates of uncomplicated malaria were similar among the three genotypes 
(Table 2, Figure 2), whether analyzed with or without adjustment for 
mosquito net use, Plasmodium infection at baseline, distance to the research 
clinic, stunting and experimental intervention. Stratification by age-class, 
however, showed that heterozygotes had increased malaria attack rates 
when aged below 18 months (hazard ratio: 1.30 [1.02–1.65]), whereas they 
were protected against malaria when aged older than 18 months (Figure 2; 
hazard ratio for all children ≥18 months combined: 0.80 [95% CI: 0.68-0.95]; 
p-value for effect difference between age classes: 0.001). A similar pattern 
occurred in homozygotes, even though estimates were less precise due to the 
smaller number of cases (hazard ratio for all children ≥18 months combined: 
0.78; 0.60-1.03; p-value for the effect difference between age classes: 0.10). 
Restriction of the analysis to malaria cases with densities above 5,000 or 
10,000 parasites/µL resulted in similar overall estimates (Table 2), and also 
revealed similar age-dependent patterns with and without adjustment for 
baseline factors prognostic for malaria (data shown for cut-off 10,000 in 
Figure 2, bottom; p-values for interaction tests between genotype and age: 
0.001 and 0.05, for hetero-and homozygotes respectively). There was no 
evidence that the magnitude of the effects of thalassemia on malaria rates 
were influenced by the intervention (p=0.94 and 0.95 for interaction with 
hetero- and homozygotes respectively).
We found no evidence that α+-thalassemia was associated with a change in 
time to first event, or with the rate of relatively severe malaria episodes (with 
densities above 100,000 parasites/µL or hemoglobin concentrations < 80 g/L; 
Table 2). In fact, the rate of episodes with hemoglobin concentrations < 80 g/L 
was highest among homozygotes and lowest among children with a normal 
genotype (regardless of age), whereby the overall incidence of these episodes 
strongly decreased with age (0.82, 0.33 and 0.09 episodes/child-year, for age 
classes 6–17, 18–35 and 36–59 months, respectively).
When genotype was not taken into account, parasite densities during the 
first malaria episode declined with age (p<0.001; Figure 3). In children 
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P=0.18 P=0.33
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Figure 3.  Association between α+-thalassemia and parasite density during first episode 
of malaria, by age class. Markers and line bars indicate geometric means and 95% CIs, 
respectively; p-values for differences between genotypes within age classes obtained by 
ANOVA)
aged below 18 months, α+-thalassaemia seemed associated with increased 
parasite densities (Figure 3), although the statistical evidence for such an 
association was weak (p-value for the difference between genotypes: 0.18). 
For homozygotes, the association between genotype and density seemed to 
depend on age (p=0.04), while for heterozygotes there was no such evidence 
(p=0.78). α+-thalassaemia was not found to be associated with parasite density 
in older age groups. Other indicators of severity (plasma concentrations of 
C-reactive protein or HRP2) were comparable between genotypes, whether 
analyzed for all age classes combined or separately (data not shown).
The declines in average hemoglobin concentrations between baseline and 
the first malaria episode were only minor and not substantially different 
in hetero- or homozygotes (-4.5 g/L and -2.1 g/L) from values observed in 
children with a normal genotype (-3.0 g/L).
Lastly, the rate of non-malaria febrile episodes was similar for all genotypes 
(Table 2); stratification by age did not indicate differences in age-specific 
effects (not shown).
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Discussion
In this cohort of Tanzanian children, α+-thalassemia was associated with in-
creased rates of malaria in children aged < 18 months, but with protection 
against malaria in older children. This effect appeared specific for malaria; 
we found no evidence that it applied to febrile episodes due to other causes. 
We did not find α+-thalassemia to be associated with the severity of malaria 
episodes as measured by hemoglobin concentrations and other indicators.
Although we treated all Plasmodium-infected children at baseline, the 
specificity of our case definition may have gradually decreased with time, 
as more children became asymptomatically infected. Similar results were 
obtained, however, when restricting the analysis to cases with parasite 
densities > 10,000/µL. Because this case definition is more specific for 
detecting true malaria cases, it is unlikely that a low specificity affected the 
validity of our conclusions.
Our results contribute to evidence that predisposition to malaria due to P. 
falciparum in both heterozygotes and homozygotes for α+-thalassemia early in 
life results in protection against malaria due to the same species at older age. 
In an area adjacent to ours, α+-thalassemia was found to be associated with 
protection against malaria in children aged 6 months to 20 years (Enevold et 
al. 2008). This protection seemed more pronounced among children aged > 5 
years, but the analysis was based on 50 episodes (41 among children aged < 5 
years) and had insufficient precision to adequately assess age-specific effects 
in early life.
In Vanuatu (Williams et al. 1996), the incidence of malaria due to P. falciparum 
and P. vivax was increased in children aged < 5 years with homozygous α+-
thalassemia relative to children with normal genotype, but the study found 
no evidence of protection among either hetero- or homozygotes in children 
aged 5-9 years. Contrary to our findings, the incidence rates in heterozygotes 
and children with normal genotype were similar, regardless of whether 
the analysis was stratified by age or not. Our estimates are more precise, 
however, due to the larger number of malaria cases in our study (622 and 812 
in children with heterozygote and normal genotypes, respectively, versus 
159 and 304 in Vanuatu).
The mechanism underlying the protection is thus probably based on the 
earlier acquisition of protective immunity in children with thalassemia. The 
age that forms a turning point between increased risk and protection will 
hence depend on transmission intensity, which may at least in part explain 
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differences between studies; under conditions of intense transmission, such 
as in our study, this turning point would be attained earlier in life than in 
conditions of less intense transmission, such as encountered elsewhere in 
Tanzania (Enevold et al. 2008) and in Vanuatu (Williams et al. 1996). 
It has been put forward that Plasmodium parasites preferentially invade 
reticulocytes. Thus reticulocysis, induced by thalassemia-associated 
ineffective erythropoiesis, would favor proliferation of Plasmodium parasites 
(Weatherall et al. 2001). However, we did not find strong support that 
thalassemia was associated with increased parasite densities in young 
children, and neither did any previous study. In addition, a recent study 
found no evidence that reticulocyte counts were increased in individuals 
with α+-thalassemia (Krugner et al. 2006). 
Others hypothesized that increased parasite-induced surface expression of 
neo-antigens on thalassemic erythrocytes results in enhanced binding of 
IgG antibody and more rapid clearance of parasitized erythrocytes in the 
spleen (Luzzi et al. 1991). Clearance in the spleen may be further enhanced 
by a reduced red cell deformability of thalassemic cells (Dondorp, 1999). In 
children aged 6-18 months, in whom protection by maternal antibodies has 
waned but acquired immunity is still low and parasite replication only partly 
restrained by an effective circulating antibody repertoire, such increased 
antigen presentation in the spleen may result in a more rapid development 
of symptoms.
 
Our finding that α+-thalassemia is associated with an increased frequency 
of malaria episodes in children aged 6-18 months may seem contradicting 
with reports from hospital-based studies that α+-thalassemia protects against 
severe malarial anemia (Wambua et al. 2006, May et al. 2007), which has 
the highest incidence in the same age range (Snow et al. 1997). An increase 
in fever rate may, however, not necessarily translate to an increased risk of 
severe malaria anemia if the decline in haemoglobin during these attacks 
is halted or sufficiently slowed down to before reaching a critical level 
that leads to admission. A potential mechanism for such phenomenon has 
recently been proposed (Fowkes et al. 2008). In thalassemia, the total amount 
of hemoglobin is divided over erythrocytes that are disproportionately 
increased in numbers but reduced in size and hemoglobin content. Thus, 
an equal proportion of erythrocytes being destroyed by malaria parasites 
results in a smaller hemoglobin reduction in individuals with α+-thalassamia 
than in their peers with normal genotype.
When analyzing the decline in hemoglobin concentration between baseline 
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and the first malaria episode, we did not find evidence of such protection. 
It should be noted, however, that the average decline in hemoglobin 
concentration during malaria episodes was relatively small, and that very 
few episodes (19) occurred whereby hemoglobin concentrations dropped 
below 60 g/L. This is probably due to good access to primary care and 
prompt effective treatment, and hematological gains due to the nutrient 
interventions. By contrast, in a pilot survey in the same area in 2006, we 
found that children with α+-thalassemia were protected against the decline 
in hemoglobin concentration associated with mild and asymptomatic 
infections (Veenemans et al. 2007). At that time, there were no first-line 
health facilities in the area, and artemether-lumefantrine was not available 
through public facilities. Thus this setting was probably better comparable to 
the circumstances under which α+-thalassemia has been providing a survival 
advantage in the past.
In pre-school Tanzanian children living in an area of intense transmission, 
effects of α+-thalassemia on malaria rates were age-dependent: it was 
associated with increased rates in children aged <18 months as opposed 
to decreased rates in older children. We did not find evidence that α+-
thalassemia was associated with the severity of malaria episodes.
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This chapter aims to assist in the interpretation of key findings for policy 
makers and fellow researchers. This discussion will be presented in the light 
of three of the specific objectives presented in the introductory chapter of 
this thesis:
1. To assess the effect of supplementation with zinc, alone or in 
combination with other nutrients, on the rates of malaria (primary 
objective);
2. To assess intervention effects on rates of other common diseases 
(diarrhoea, respiratory infections, non-malarial febrile illness);
3. To identify factors that determine the magnitude of the effect of the 
interventions.
The last specific objective dealing with α+-thalassaemia will not be further 
discussed beyond the relevant chapters of this thesis. I will focus here on 
lessons about study design and analysis that are critical in addressing the 
objectives formulated above and which are pertinent to the study described 
in this thesis.
1. Design of malaria intervention trials
1.1.  Malaria case definition
In our trial, we administered a therapeutic course of artemether-lumefantrine 
to all Plasmodium-infected children at baseline, with the aim to clear asexual 
parasitaemia and thus to increase the specificity of our case definition for 
malaria episodes. There is limited experience with this approach. In several 
efficacy malaria vaccine trials, all participants were pre-treated with either 
sulfadoxine-pyrimethamine (Alonso et al. 1994, D’Alessandro et al. 1995) 
or quinine-doxycycline (Sherwood et al. 1996). In another malaria vaccine 
trial in Thailand, participants at baseline received treatment with artesunate/
mefloquine or with chloroquine when infected with P. falciparum or P. vivax, 
respectively (Nosten et al. 1996).
One reported disadvantage of pre-treating trial participants at baseline is that 
it can suppress new infections for some time (Coulibaly et al. 2002, Moorthy 
2009, see also Annex 2). Thus in a malaria vaccine trial, pre-treatment 
with sulfadoxine-pyrimethamine resulted in a reduction of the number of 
infections and a corresponding loss of power to detect effects on the study 
end point, geometric mean parasite density (Genton et al. 2002). Because 
the drugs used for pre-treatment in our study have relatively short terminal 
elimination half-lives (artemether: 1 h, lumefantrine: 3 days; WHO 2010), 
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this drug combination produces a shorter post-treatment prophylactic effect, 
and may be more suitable than the relatively long-acting drugs that have 
been used in previous studies (terminal elimination half-lives: 4–9 days for 
sulfadoxine, 4 days for pyrimethamine, 15-23 hour for doxycycline, 21 days 
for mefloquine and 1-2 months for chloroquine; WHO 2010, FK/CvZ 2010). 
We also selectively pre-treated children with Plasmodium infection at baseline 
(as opposed to treating all children), and we assessed the influence on 
effect estimates of censoring for a pre-specified period of 14 days following 
treatment. Such censoring resulted in similar effect estimates. 
Another, more critical problem identified by our study is that the validity of 
the efficacy estimate is undermined by children becoming asymptomatically 
infected in the course of the intervention period. When finalising our 
statistical analysis plan, we were aware that this might constitute a problem 
but, in retrospect, we probably insufficiently appreciated that even small 
reductions in specificity of the case definition can lead to substantial bias. 
It would have been more appropriate to base the primary analysis on the 
effect on all episodes in a relatively short period (e.g. the first 100 days) after 
randomisation. Even though pre-treatment of infected children at baseline 
was only partially effective in increasing the specificity of our case definition, 
the alternative approach of defining cases based on fever thresholds of 
parasitaemia also suffers from severe shortcomings (Chapter 2). Further 
research is needed to resolve this issue. For the time being, it would seem 
prudent to combine these approaches, similarly to the analyses that I present 
in this thesis.
Additional research is also needed to replace conventional microscopy as 
the technique of choice to detect and quantify parasitaemia. Several new 
methods are available that may be more suitable for incorporation in malaria 
case definitions. First, fluorescence cytometry using DNA-selective stains 
allows examination of a larger volume of a blood specimen than microscopy, 
and offers the possibility to both precisely count malaria parasites and to 
accurately differentiate P. falciparum from other human malaria species 
(Shapiro and Mandy 2007, Shapiro and Perlmutter 2008). Second, because 
parasite counts by microscopic examination of peripheral blood poorly 
reflect the total body parasite biomass, it would be helpful to use markers 
that are specific for malaria-induced pathology. One such candidate marker 
is plasma concentration of histidine-rich protein-2 (HRP-2) (Dondorp 
et al. 2005). A key issue to be evaluated is to what extent plasma HRP2 
concentrations can be used to distinguish between asymptomatic infections 
and febrile malaria episodes. There are virtually no data available from large 
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scale community-based studies, however, which describe plasma HRP2 
concentrations in children with asymptomatic infection. One complicating 
factor is that plasma HRP-2 concentrations may persist and accumulate 
over time during infection, so that they do not necessarily reflect current but 
also recent parasite load. Hence, an alternative or perhaps complementary 
marker may be plasma concentration of Plasmodium-specific or Plasmodium 
species-specific lactate dehydrogenase (pLDH), a soluble enzyme that is 
expressed at high levels in blood-stage parasites. pLDH is released during 
lysis of parasitized erythrocytes and is rapidly eliminated following parasite 
clearance; its plasma concentrations therefore reflect current parasitaemia 
(Oduola et al. 1997, Piper et al. 1999, Moody et al. 2000, Singh et al. 2003, 
Hopkins et al. 2007).
1.2.  Analysis of recurrent events vs first or only event
As discussed above, a gradual loss of specificity of the case definition 
probably explains the discrepancy between effect estimates obtained in the 
time to first event analysis and those obtained in the analysis of all events 
over the total follow-up period. On the other hand, multi-nutrients may 
have resulted in a transient increase in malaria rates, which was not detected 
when assessing effects on all events over the total follow-up time. A transient 
increase in rates may theoretically occur if episodes of malaria induced 
by multi-nutrients result in acquired immunity that prevents subsequent 
episodes. When planning our statistical analysis (Annex 2), we anticipated 
that our interventions would protect against malaria, and considered 
changes in the degree of protective efficacy less relevant for public health 
than an overall reduction in total burden of disease. For this reason, our 
primary analysis was based on all events over the total intervention period. 
In retrospect, however, if an intervention would lead to transiently increased 
rates of severe disease or death, then a time to first event analysis may be of 
greater public health importance than an analysis of all events.
2. Zinc interventions in Africa
2.1 What does this study add?
The trial reported in this thesis is the first to examine the potential benefit of 
combining zinc with vitamins and other minerals. With an analysis based 
on 1,572 cases, we believe it is by far the largest to date to assess the effect of 
nutrient interventions on malaria.
We found no evidence that concurrent supplementation with multi-nutrients 
influenced the magnitude of the effect of zinc on rates of malaria (Chapter 
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3) or diarrhoea (Chapter 5). The absence of an evident protection against 
malaria (Chapters 3 and 4) is consistent with the report from Burkina Faso 
(Muller et al. 2001).
2.2 Implications for public health policies and research
There has been frustratingly little programmatic progress for preventive zinc 
interventions. It is usually a body of evidence consisting of many studies, 
rather than a single trial, that changes medical or public health practice. 
The findings described in this thesis strengthen the case for scaling up zinc 
interventions in deficient populations by confirming its protective role against 
diarrhoea in African population of children (Chapter 5), by providing new 
evidence that it protects against episodes of fever without localizing signs 
(Chapter 3) and episodes of non-malarial fever accompanied by diarrhoea 
(Chapter 5). Such interventions can be implemented in Africa without 
concerns that it will cause adverse effects due to malaria (this thesis) or HIV 
infection (Bobat et al. 2005). The finding that zinc alone can achieve these 
benefits without addition of other micronutrients is of particular relevance for 
efforts to develop biofortified crops, because this approach must necessarily 
focus on single nutrients or at most a few nutrients (Chapter 1).
Our results do not preclude that zinc can protect against disease associated 
with severe malaria. There is increasing evidence that severe malaria may 
predispose to increased small bowel permeability (Wilairatana et al. 2007) 
and invasive bacterial disease (Mabey et al. 1987, Graham et al. 2000a, Calis 
et al. 2008, Berkley et al. 2009, Najm et al. 2010, Mackenzie et al. 2010), mainly 
due to enteric pathogens such as non-typhoidal Salmonellae, but also due 
to species normally found in the respiratory system such as Haemophilus 
influenzae b and Streptococcus pneumonia (Berkley et al. 1999, 2009, Graham 
et al. 2000b,c, Walsh et al. 2000, Bronzan et al. 2007, Nadjm et al. 2010, 
Chimalizeni et al. 2010). The reason for this predisposition is not known but 
may be due to increased availability of iron following haemolysis, or because 
intestinal permeability is increased in inflammatory conditions (Graham 
et al. 2000b, Bronzan et al. 2007, Graham 2008). Invasive bacteraemia 
contributes to the pathophysiology of severe malaria, and is associated with 
increased mortality (Berkley et al. 1999, Morpeth et al. 2009). Increased small 
bowel permeability may also be due to persistent mucosal enteropathy 
that is common in African children and characterized by villous atrophy, 
crypt hyperplasia and increased numbers of intra-epithelial lymphocytes 
(Campbell et al. 2003), and probably a consequence of repeated mucosal 
injury and inflammation (Lunn et al. 1991, Campbell et al. 2003). 
By improving intestinal integrity and hence barrier function, zinc may 
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reduce susceptibility to invasive infection. Thus, one might expect it to have 
at least some effect in protecting against malaria-associated severe disease 
and death, consistent with the small reduction in mortality found in the 
zinc supplementation study in Pemba (Sazawal 2007). Therapeutic zinc 
supplementation can reduce the duration of acute and persistent diarrhoea 
(Haider and Bhutta 2009), suggesting that it may act fast. Thus a trial is 
warranted to assess possible benefits of zinc supplementation as adjunct 
therapy in children admitted to hospital with severe malaria.
3. Interventions with multi-nutrients in malaria-endemic settings
3.1  What does this study add?
Determinants of anaemia: In the study population described in this thesis, 
there was strong evidence of deficiencies in zinc, iron, folate and vitamin 
B12, as shown by the effect of supplementation on biochemical indicators 
of nutritional status (Chapter 6, Figure 5). Iron deficiency occurred in one-
quarter of children at baseline (Chapter 3, Table 1). At the second survey, iron 
deficiency was virtually absent in the two groups receiving multi-nutrients 
(Chapter 4, Webtable). Children aged 6-17 months had the highest prevalence 
of iron deficiency at baseline, and had the highest response in haemoglobin 
concentration to multi-nutrient supplementation (Chapter 4, text and Figure 
1). Despite multi-nutrient supplementation, 50% of children remained 
anaemic at the second survey, which probably shows the importance of 
infections and infection-induced inflammation as determinants of anaemia.
Although malaria and iron deficiency are well-described causes of anaemia in 
rural African children, there have been few investigations of the contributions 
by other nutritional deficiencies. In our pilot study, we found that vitamin 
B12 deficiency is relatively rare (prevalence: 4%) but it is associated with 
marked reductions in haemoglobin concentration (Chapter 1). Vitamin A 
deficiency was more widespread (13%) but there was no evidence that it was 
independently associated with haemoglobin concentration in a multivariate 
model that also included other possible causes of anaemia. Although plasma 
folate concentration responded to supplementation with folic acid and other 
micronutrients (Chapter 6), baseline data of our trial showed no evidence 
that it was associated with haemoglobin concentrations. This corroborates a 
report from a case-control study in Malawi, in which deficiency of vitamin 
B12 but not of folate was associated with severe anaemia (Calis et al. 2008).
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Based on the same study in Malawi, the authors report that iron deficiency 
was not a prominent cause of severe anaemia, because children with severe 
anaemia (haemoglobin concentration < 50 g/L) had higher odds of being 
iron deficient (as indicated by plasma markers as a measure for stainable 
iron stores in bone marrow slides) than apparently healthy control children. 
We believe that their suggestion that iron deficiency protects against severe 
anemia is inappropriate, because infection-induced inflammation results 
in increased amounts of stainable haemosiderin iron in macrophages of 
the monocyte phagocyte system (Cavill 2002). It is more plausible that 
infections and bacteraemia, which were more common in children with 
severe anaemia than their controls, caused the presence of iron stores, 
instead of the reverse. Significantly, the authors found that hookworm was 
associated with increased odds of severe anaemia, a relationship that is 
mediated mostly by iron deficiency. Moreover, the fact that supplementation 
with iron and multi-nutrients tended to decrease the rate of episodes with 
hemoglobin concentration below 80 g/L in both the Pemba study and in our 
trial, contradicts this notion.
Effects on malaria: We found strong evidence that, even in a setting with 
good access to care, multi-nutrient supplementation increases malaria rates, 
perhaps transiently, as shown by the increased rates of all episodes in the 
first 50 or 100 days of intervention, the reduced time to first episode, and the 
increased incidence of first episodes (Chapter 2). We suspect that this effect 
can be largely attributed to iron.
Subgroup analysis suggested that the effect on malaria rates varied with 
age class and iron status, and was most pronounced in children within the 
youngest age class (6-17 months) and those with iron deficiency at baseline. 
In older children, multi-nutrients seemed to decrease the rate of malaria 
episodes with hyperparasitaemia. We found an opposite trend of the effect 
of multi-nutrients with age when malaria was defined as episodes with 
haemoglobin concentrations < 80 g/L, presumably because children who 
were initially iron deficient were better able to maintain their haemoglobin 
concentration during malaria attacks when having received multi-nutrients 
(Chapter 4). A synthesis of selected findings reported in Chapters 3 and 4 of 
this thesis is provided in Box 1.
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Box 1. Effects of haematinics on rates of malaria: synthesis of effects observed
Figure 1. Simulation model with hypothetical data illustrating possible interactions 
between iron deficiency and iron supplementation on rates of malaria and rates of 
malaria associated with haemoglobin concentrations < 80 g/L
Line bars indicate haemoglobin concentrations just before or at the onset of febrile 
malaria episodes (upper end) and at the time of detection of episodes and/or initiation 
of chemotherapy (lower end). Red and grey bars represent events in children receiving 
iron supplements or placebo, respectively. Dashed blue lines indicate a threshold used 
to define malaria episodes with haemoglobin concentration < 80 g/L; such episodes are 
marked with a circle at the lower end of the bar. For further explanation: see text.
The model in Figure 1 presents a synthesis of selected findings reported in 
Chapters 3 and 4 of this thesis, using simulated data from a fictive population 
of preschool children taking part in a trial comparing placebo versus 
supplementation with iron and other multi-nutrients. This model incorporates 
several phenomena that may explain our findings:
1. At randomisation, there is a subpopulation of children, mostly infants, with 
iron deficiency and low haemoglobin concentrations (upper panel) and a 
subpopulation of iron-replete children, mostly older, with haemoglobin 
concentrations that are higher (due to other causes of anaemia, these are still 
below reference values) (lower panel);
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2. Over time, supplementation with micronutrients results in increased 
haemoglobin concentrations in children with iron deficiency but not in those 
who are iron-replete;
3. When presenting with febrile malaria, children with iron deficiency 
at baseline who received multi-nutrients have elevated haemoglobin 
concentrations group as compared to their peers with iron deficiency at 
baseline who received placebo;
4. Multi-nutrient supplementation results in increased rates of malaria episodes 
in children with iron deficiency at baseline but not in those who were iron-
replete;
5. In children with iron deficiency, iron supplementation tends to result in 
decreased rates of malaria episodes with haemoglobin concentrations < 80 
g/L but not in those who are iron-replete. 
The direction of the subgroup effects measured in our trial (Chapter 4) is in 
contrast with the findings of the Pemba sub-study (Chapter 1). As correctly 
pointed out by others (Roth and Black 2010), the Pemba trial was unique in 
assessing effects on severe morbidity and death, which may be of greater 
public health relevance than trials such as ours that are based mostly on cases 
of uncomplicated malaria. In their report of the Pemba sub-study, however, 
Sazawal et al. (2006) were cautious in their interpretation of the subgroup 
effect, stating that their results suggested that supplementation with iron and 
folic acid is beneficial in children with iron deficiency, but unsafe in those 
who are iron-replete. The question arises whether this evidence is sufficient 
to support the WHO recommendation (WHO 2007) that iron supplements 
be administered routinely to iron-deficient infants under conditions with 
adequate access to anti-malarial treatment.
Examination shows that the evidence available meets only few criteria 
to make the claim of a subgroup effect credible (Table 2). The biological 
rationale for the interaction (Table 2, point 11) provided by the WHO Expert 
Consultation (WHO 2007) is that supplemental iron leads to the transient 
formation in plasma of non-transferrin bound iron (NTBI), but iron-deficient 
children may be protected from this effect because iron is removed more 
rapidly from the plasma due to their higher tissue requirements for iron. 
Indeed, a large bolus of supplemental ferrous salts taken in a single dose 
can lead to the transient formation in plasma of non-transferrin bound iron 
(NTBI) (Hutchinson et al. 2004, Baron et al. 2008, Dresow et al. 2008), which 
does not normally occur in healthy individuals (Esposito et al. 2002) and 
which may act as a nutritional source and favour the proliferation of blood 
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pathogens such as Plasmodium parasites (WHO 2007). There are also plausible 
mechanisms, however, to suggest that supplemental iron is more harmful in 
iron-deficient children than their iron-replete peers: because iron absorption 
is negatively associated with iron stores and is elevated in those with iron 
deficiency (Hunt 2003), one would expect NTBI production due to iron 
supplementation to be more pronounced in children with iron deficiency.
Table 2. Application of criteria 1 to evaluate the credibility of interaction of iron status 
at baseline on supplementation effect, as suggested by the Pemba sub-study 
(Sazawal et al. 2006)
Criterion Answer Credibility
Design
1 Is the subgroup variable a characteristic measured at 
baseline or after randomisation?
At baseline +
2 Is the effect suggested by comparisons within rather 
than between studies?
Yes +
3 Was the hypothesis specified a priori? Apparently not –
4 Was the direction of the subgroup effect specified a 
priori?
Apparently not –
5 Was the subgroup effect one of a small number of 
hypothesised effects tested?
Unknown 0
Analysis
6 Does the interaction test suggest a low likelihood that 
chance explains the apparent subgroup effect?
Interaction test 
result not reported
–
7 Is the significant subgroup effect independent? Not assessed 2 0
Context
8 Is the size of the subgroup effect large? Yes +
9 Is the interaction consistent across studies? No – 3
10 Is the interaction consistent across closely related 
outcomes within the study?
Not assessed –
11 Is there indirect evidence that supports the 
hypothesised interaction (biological rationale)?
Limited evidence 4 0
+: high; –: low; 0: neutral
1 Oxman and Guyatt 1992, Sun et al. 2010; 2 The supplementation effect also seemed to depend on the 
presence of anaemia at baseline. 3 Ac compared to evidence provided in Chapter 4 of this thesis. 4 See 
text.
 
Another issue is that the methods to detect iron deficiency differed between 
the Pemba study and our trial. We defined iron deficiency on the basis of 
plasma ferritin concentration while accounting for inflammation, which we 
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believe to provide a more valid indication than zinc protoporphyrin:haem 
(ZPP:H) ratio in whole blood, the marker used in the Pemba trial. To its 
credit, the ZPP:H ratio in whole blood may be less dependent on acute 
malaria than plasma ferritin concentration (Sazawal et al. 2006), and may 
react more slowly in response to inflammation, probably because of the 
time required for new erythrocytes with increased ZPP contents to enter 
the circulation and replace a substantial proportion of erythrocytes with 
normal ZPP contents. Nevertheless, Plasmodium infection may be associated 
with elevated ZPP:H ratios (Schneider et al. 1993, Stoltzfus et al. 2000), even 
in asymptomatic children (Veenemans and Verhoef, unpublished results). 
Plasma concentrations of bilirubin, a breakdown product of normal haem 
catabolism that is known to fluoresce in the same wavelength as ZPP 
(Buhrmann et al. 1978, Bartels et al. 1989) are increased under influence by 
haemolysis in febrile and asymptomatic malaria infections (Mishra et al. 
2004, Iwalokun et al. 2006, Brasseur et al. 2007, Tagbor et al. 2008). In our 
trial, baseline Plasmodium infection, inflammation, young age, homozygous 
α+-thalassemia and iron deficiency were all independently and significantly 
associated with increased ZPP:H ratios (Veenemans and Verhoef, unpublished 
results). Because it was logistically not feasible to measure ZPP:H ratios in 
fresh blood, these were measured in whole blood samples that had been 
stored in liquid nitrogen. 
Thus, it seems likely that elevated ZPP:H ratios at baseline in the Pemba sub-
study were co-determined to a large extent by current or recent Plasmodium 
infection, and hence had low specificity for detecting iron deficiency. Indeed, 
the prevalence of iron deficiency (75%) as reported by Sazawal et al. (2006) 
seems unrealistically high in view of lower prevalence estimates in similarly 
aged populations as reported in this thesis (28%–45%; Chapter 4) and 
elsewhere in eastern Africa (e.g. 45%–53%, Verhoef et al. 2001; 24%–38%, Desai 
et al. 2003). Consequently, ZPP:H ratios may have been a marker of frequent 
or chronic exposure to malaria and hence acquired immunity, rather than 
iron status. Such immunity may be further enhanced by iron supplements, 
in agreement with the protection against episodes with hyperparasitaemia 
that multi-nutrients seem to provide in older children (Chapter 4, Figure 2), 
explaining the beneficial effect of iron supplements in children with elevated 
ZPP:H ratios.
In our trial, examination of intervention effects within subgroups stratified 
by ZPP:H ratios shows that multi-nutrients appeared to increase malaria 
rates among children with ZPP:H ratios ≥ 80, similar to the effect observed 
among iron deficient children (RR 1.27 [95%CI: 1.01 to 1.61], 1.29 [0.94-1.71] 
and 1.53 [0.94-2.49]; for episodes as predefined and with densities > 10,000 
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and 100,000 parasites/µL respectively, with p-values for interaction 0.12, 0.10 
and 0.12). Thus, our results do not support a strategy of using ZPP:H ratios 
as marker to target children expected to benefit from iron supplementation. 
It may be argued that explanations can be found to reconcile the paradoxical 
findings of the subgroup analysis from our study and those from the Pemba 
study. One may reason that, in settings with good access to care, the eventual 
effect on mortality of multi-nutrient (or iron) supplementation in iron 
deficient children may be favorable despite an increase in parasite virulence 
and rates of uncomplicated malaria. For example, whilst early treatment 
of febrile episodes timely halts progression of uncomplicated episodes to 
cerebral malaria, supplementation may prevent deaths resulting from 
the (gradual) development of severe anaemia. We believe, however, that 
because such explanations are not directly substantiated by the available 
evidence, because they may not apply to all settings, and because alternative 
explanations for the discrepancy between the subgroup effects are possible, 
the current assumption that iron supplementation is safe when targeting iron 
deficient children in settings with adequate access to care is insufficiently 
justified. 
3.2 Implications for public health policies and research
The recommendation by the World Health Organization that iron supplements 
should be administered routinely to iron-deficient infants in settings with 
adequate access to anti-malarial treatment should be reconsidered because 
the evidence that such intervention is safe in this subgroup is limited. In 
settings different from the Pemba study, and/or when using more specific 
markers of iron deficiency, the current WHO recommendation may actually 
be harmful.
In general, our study results underscore the need to thoroughly assess the 
safety of micronutrients interventions before they can be recommended 
for public health in malaria-endemic areas, even when targeting deficient 
subgroups. This is the case for supplementation and home fortification using 
different combinations or levels of micronutrients than studied so far, but 
also applies to food-based interventions. 
Further research is needed to assess the safety of specific nutrients in such areas, 
and to identify and further characterise factors that determine the response 
to supplementation. Such studies will help to identify subpopulations that 
can benefit from these nutrients and other subpopulations in which they 
cause harm. Special consideration should be given to the influence of age, 
iron status and malaria exposure.
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4. Interaction by Giardia intestinalis on the effect of multi-nutrients 
on diarrhoea
4.1 What does this study add?
Because Giardia intestinalis infection had been described as a possible cause of 
nutrient malabsorption, we originally decided to include its assessment with 
a view to assess its possible association with micronutrient status, and as a 
possible modifier of the effect of micronutrient supplementation. Contrary 
to our expectation, we found that it was associated with marked protection 
against diarrhoea in the groups receiving placebo and zinc but not in the 
two groups receiving multi-nutrients (Chapters 5 and 6). The protection 
was particularly strong in the placebo group: children with Giardia infection 
had 85% fewer diarrhoea episodes (95% CI: 50%-95%) than those without 
infection (Chapter 6, Figure 2). To our knowledge, a protective effect of this 
magnitude has not been described so far in other studies. It is important 
because diarrhoea is one of the main causes of child mortality in developing 
countries.
How much credibility can be given to this interaction? Our claim is strongly 
supported by the magnitude of the subgroup effect, the consistency in the 
protective effect being observed in groups receiving placebo and zinc and 
with respect to two mutually exclusive but probably related outcomes 
(diarrhoea and fever without localising signs), whilst the probability that the 
association is due to chance seems low. On the other hand, the interaction was 
identified a posteriori, and a plausible mechanism to explain the interaction 
is missing (Table 3). There is little support from other studies; this may be 
due, however, to variation in Giardia genotypes that may occur in between 
geographical areas. In aggregate, the evidence is weak. 
4.2 Implications for public health policies and research
Our results do not support policies to control Giardia infection through 
community-based interventions. Further studies are needed to assess the 
association between Giardia infection and the burden of diarrhoea. Data may 
exist from past studies that can be helpful in this respect. Confirmation of 
a protective association would indicate that Giardia infection can possibly 
be used as a marker to predict the response to supplementation with multi-
nutrients. On the other hand, Giardia infection may also be a marker of 
underlying factors that cause the protection observed; if so, identification of 
these factors could possibly lead to new interventions to control diarrhoea. 
Additional research recommendations are discussed in Chapter 6.
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Table 3. Application of criteria 1 to evaluate the credibility of interaction of Giardia 
intestinalis infection at baseline on the effect of supplementation with multi-
nutrients on rates of diarrhoea
Criterion Answer Credibility
Design
1 Is the subgroup variable a characteristic measured at 
baseline or after randomisation?
At baseline +
2 Is the effect suggested by comparisons within rather than 
between studies?
Yes +
3 Was the hypothesis specified a priori? No –
4 Was the direction of the subgroup effect specified a priori? No –
5 Was the subgroup effect one of a small number of 
hypothesised effects tested?
Yes +
Analysis
6 Does the interaction test suggest a low likelihood that 
chance explains the apparent subgroup effect?
Yes +
7 Is the significant subgroup effect independent? Not applicable 2 0
Context
8 Is the size of the subgroup effect large? Yes +
9 Is the interaction consistent across studies? Not applicable –
10 Is the interaction consistent across closely related 
outcomes within the study?
Yes +
11 Is there indirect evidence that supports the hypothesised 
interaction (biological rationale)?
No –
+: high; –: low; 0: neutral
1 Oxman and Guyatt 1992, Sun et al. 2010; 2 We did not identify other baseline factors that modified the 
effect supplementation with multi-nutrients on diarrhoea.
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Sir,
Based on the finding that supplementation with iron and folic acid in 
malaria-endemic areas may cause an increased risk of hospitalization and 
death (Sazawal et al. 2006), an expert group convened by the World Health 
Organization (WHO) recommended that iron supplementation should 
be restricted in areas where malaria transmission is intense and infectious 
disease highly prevalent (WHO 2007). The group exempted industrial 
fortification with from these restrictions, under the assumption that the iron 
would be consumed in smaller amounts throughout the day and therefore 
absorbed more slowly. It also recommended that iron preparations added 
to food after cooking (‘home fortification’) should not be used in malaria-
endemic areas because, when administered in a single meal, the dose of iron 
is still relatively high (WHO 2007).
To circumvent this problem, Barbara Troesch and colleagues (2009) studied 
the effects of consuming food that was home-fortified with micronutrient 
powders containing low amounts of highly bioavailable iron. We disagree 
with their conclusion that this approach may allow for effective, untargeted 
in-home fortification of complementary foods: it can be valid only if 
the adverse effects of iron observed by Sazawal et al. (2006) were due to 
an increased proliferation and invasion of enteric pathogens. It is indeed 
conceivable that iron leads to invasive non-typhoid Salmonella bacteremia, 
a complicating factor associated with death in African children with severe 
malarial anemia (Graham et al. 2000).
The WHO expert group considered an alternative explanation, however, that 
a large bolus of iron taken in a single dose leads to the transient formation 
in plasma of non-transferrin bound iron (WHO 2007), which may act as a 
nutritional source and favor the proliferation of pathogens such as malaria. 
If this were indeed the underlying mechanism, then the increased risk of 
adverse events can be avoided only by reducing the amount of iron absorbed.
The micronutrient powder containing 3 mg iron as NaFeEDTA investigated 
by Troesch et al. (2009) would in fact supply more absorbed iron than the 
original formulation of Sprinkles™, which contain 12.5 g iron as ferrous 
fumarate (0.28 mg as compared with < 0.21 mg; Table 1). Moreover, in African 
populations, this difference would probably be more than indicated than in 
Table 1, because iron absorption is exponentionally increased in individuals 
with iron deficiency (Hallberg 2001), as opposed to the volunteers investigated 
by Troesch et al. (2009), who were mostly healthy and iron replete.
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Table. Amounts of iron absorbed through various iron interventions
Native iron 
in food
Dose of iron 
ingested
Fractional iron 
absorption
Amount of iron 
absorbed, mg
Complementary food (60 g whole 
maize flour) fortified with 3 mg 
iron as NaFeEDTA 1
0.75 mg 3 mg 7.39% 0.28
Complementary food (60 g whole 
maize flour) fortified with 3 mg 
iron as ferrous sulfate 1
0.75 mg 3 mg 1.55% 0.06
Complementary food (60 g whole 
maize flour) fortified with 12.5 
mg iron as ferrous fumarate 2
0.75 mg 12.5 mg < 1.55% 3 < 0.21
Dose and formulation of iron 1 as investigated by Troesch et al. (2009) or 2 as in Sprinkles™ (http://
www.sghi.org/);
3 The fractional iron absorption is below 1.55% because it is known to be negatively associated with 
the dose of iron ingested (Hallberg 2001).
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This plan is based on the original proposal, and has been finalised before 
analyses of the intervention effects were performed.
To assess intervention effects on the primary outcome (episodes of malaria), 
and related endpoints, we will take the following steps (in sequential order):
1.  Flow of trial participants and compliance to treatment, by treatment 
group
When describing the flow of participants, we will account for all individuals 
who were invited for screening. Compliance will be measured as the 
proportion of children who have consumed > 95% of scheduled supplements. 
In addition, intervention efficacy in improving plasma zinc concentration 
or height-for-age z-score will also be considered as indicative of good 
compliance. For individuals who were randomised to treatment but who 
stopped their participation before the scheduled end of intervention, we will 
provide reasons for their drop-out, if possible.
2.  Description of baseline characteristics, by treatment group
Groups will be described regarding baseline characteristics. We will refrain 
from formal testing for group differences, because differences that do exist 
are necessarily caused by chance alone. In addition, minor imbalances at 
baseline are unlikely to be detected by statistical testing, but may still lead to 
confounding if the variable is strongly associated with outcome.
Baseline characteristics of each group will be described in the baseline table 
(prevalence, means ± SD, or median ± IQR, as appropriate).
3. Group descriptions for (primary) outcomes
The primary endpoint is an episode of uncomplicated malaria, defined as: 
a) reported febrile illness with axillary temperature ≥ 37.5 °C and a positive 
result for a pLDH dipstick test, OR b) reported febrile illness, with whole 
blood C-reactive protein concentration ≥ 8 mg/L and a positive result for a 
pLDH dipstick test.
For each intervention group, we will report the median survival time to 
1st episode of uncomplicated malaria, and the cumulative incidence over 
the minimum follow-up period (224 days; i.e. the time period between 01 
August 2008, the last recruitment, and 12 March 2009, the end date of the 
trial) as estimated by Kaplan Meier method, the total number of episodes 
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of uncomplicated malaria, the time at risk and the incidence rate (total 
number of episodes divided by time at risk). In addition, we will report the 
number of episodes of severe malaria and death (composite indicator) in 
each intervention group.
3.1 Comments on case definition:
Sensitivity: Our case definition is based on the detection of Plasmodium 
lactate dehydrogenase (pLDH) by immuno-chromatographic dipstick test 
(Makler et al. 1998, Piper et al. 1999). This test has high sensitivity (> 95%) 
for P. falciparum, but also for other Plasmodium spp., when used under field 
conditions (Cooke et al. 1999, Piper et al. 1999, Moody 2002, WHO 2009).
Specificity: To clear infection, and improve the specificity of our primary 
endpoint, all children with a positive result for a malaria dipstick test 
at baseline were given a 3-day course of anti-malarial drugs (artemether-
lumefantrine). This drug combination is very efficacious in the treatment of 
uncomplicated malaria due to Plasmodium falciparum (Ogbonna and Uneke 
2008) and also against infections caused by P. vivax, P. malariae, and P. ovale 
(White 2008). We therefore assume that a case as defined above is specific for 
an episode of malaria due to a newly acquired infection. 
Nonetheless, the specificity of the case definition probably decreased with 
time since the last treatment: at the second survey (median follow-up time: 
271 days or 8.5 months), we found that 32% of children were infected as 
assessed by pLDH test even if the overwhelming majority were symptom-
free. In children who have become asymptomatically infected in the course 
of the intervention period, febrile illness and other symptoms may be due 
to another condition and the malaria parasites in their blood are merely 
coincidental, so that these cases would erroneously be considered as being 
malaria. On the other hand, we found that most malaria cases occurred 
in the first few months after randomization (e.g. at 61 days and 271 days, 
50% and 83% of children, respectively, had experienced their first malarial 
episode). Thus we expect that our case definition has a high specificity and 
high positive predictive value to detect malaria, particularly in the first few 
months of the intervention; the gradual loss in specificity that may have 
developed over time probably will not cause substantial underestimation of 
intervention effects. 
The use of threshold parasite density to define malaria cases: The use of a pre-
specified threshold parasite density in peripheral blood has been advocated 
and is widely used to increase the specificity of case definitions for malaria in 
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endemic populations (Schellenberg et al. 1994, Smith et al. 2004). Although 
we may use this approach to explore to what extent it influences intervention 
effect, we decided not to do this in our primary analysis, for the following 
reasons:
1. The simple case definition used above (i.e. without threshold density) is 
probably quite specific;
2. Many assumptions must necessarily be made in establishing this 
threshold density: it is likely to depend on immunity, and therefore on 
age, nutritional status (e.g. intervention arm and duration) and numerous 
behavioural and environmental factors that influence exposure (Koram 
and Molyneux 2007);
3. Parasite density is only a weak predictor of mortality in falciparum 
malaria, because the circulating stages do not necessarily reflect the total 
body load of parasites: the latter also comprises the more pathogenic 
mature stages in parasitized erythrocytes that are usually sequestered 
by cytoadherence to endothelial cells in the microvasculature of organs 
(Dondorp et al. 2005). Cytoadherence may also explain the great 
variations in parasite density that have been observed within short 
periods of time (Koram and Molyneux 2007).
4. The parasite count by examination of blood films is subject to large 
variation, even with well-trained microscopists, and may not represent 
actual circulating parasite concentrations. This is particularly the case 
when the true parasite density is low.
a. Counting 200 WBC is equivalent to counting a volume of 
approximately 0.025 µL (assuming an average WBC count of 
8×106/mL). This is only 0.004 part of the total volume in the 
thick film. Counting such small volumes make the result of the 
count subject to great variation.
b. Many parasites are washed off during the staining.
c. In our trial, it was for practical reasons not possible to count 
WBCs in blood samples collected from sick children. Thus 
we would be restricted to using an assumed, fixed WBC 
count. Because malaria is known to suppress immunity and 
reduce WBC counts (McKenzie et al. 2005), this could lead to 
substantially biased (overestimated) parasite counts. On the 
other hand, many children may have had concurrent bacterial 
infections, with an accompanying increase in WBC count, 
which would lead to substantial underestimates of parasite 
density.
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We will explore to what extent the estimates of intervention effects are 
modified by using various cut-off values for parasite density (1,000, 3,000 
and 5,000 parasites per µL). 
Plasma concentration of histidine-rich protein-2 may be a better ‘signature’ 
indicator for incorporation in malaria case definitions. This protein is found 
in the parasite cytoplasm or parasite food vacuole, but it is also found in 
the host erythrocyte cytoplasm and red cell membrane. At schizont rupture, 
sequestered falciparum parasites secrete histidine-rich protein-2 into the 
plasma. Plasma concentrations of histidine-rich protein-2 accurate indicate 
the total body parasite biomass in acute falciparum malaria, and can be 
measured with a commercially available enzyme-linked immunosorbent 
assay that is based on monoclonal-antibodies specific for P. falciparum 
(Cellabs, Sydney, NSW, Australia). 
Severe malaria will be defined as haemoglobin concentration < 60 g/L with 
confirmed P. falciparum infection or P. falciparum antigenaemia, or fever 
with a positive pLDH dipstick test result and manifestations of neurological 
involvement (e.g. seizures).
4. Analysis of intervention effects
4.1 Primary analysis
The primary measure of intervention efficacy is calculated as the percentage 
reduction in the total number of malaria episodes, estimated as (100 x 
(1-hazard ratio)) relative to placebo, by using a Cox regression model that 
includes multiple episodes. A robust estimate of the standard error will be 
used to allow for dependence among multiple events within each person. 
The primary analysis is by intention-to-treat; in addition, we will conduct 
an exploratory per protocol analysis. In the primary analysis we will adjust 
for covariates that are prognostic for outcome. These covariates are divided 
into 2 groups: a) variables known from previous studies to be associated 
with outcome, and that will be used as covariates whether or not they are 
significantly associated with outcome in this study, and b) variables that 
we suspect to be associated with malaria risk. The latter (group b) will only 
be included if they are significantly associated with outcome, or if they 
substantially change the effect estimate.
Group a) includes: 
a. Age class (6-17 months; 18-35 months; 35-60 months);
b. Exposure to malaria, indicated by malaria antigenaemia at baseline. 
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Group b) includes:
a.  Distance to the dispensary (continuous)
b.  Nutritional status (plasma concentrations of zinc and other nutrients; 
anthropometric indices, haemoglobin concentration) (continuous and 
dichotomized into deficient/replete, stunted/non-stunted, wasted/non-
wasted, and anaemic/non-anaemic);
Effects will be reported as point estimates with corresponding 95% CIs. 
Secondary analyses will include pairwise comparisons of the intervention 
groups with placebo, using the Kaplan Meier method (with p-values derived 
from Tarone-Ware test, based on 1st episodes), and measurement of the ratio 
of incidences (the total number of episodes divided by the time at risk in 
each group).
Summary 
4.1 Primary analysis Technique(s)
a. Measure hazard ratios based on time-
to-event analysis (including all events), 
adjusting for prognostic factors at baseline 
(see 4.1)
Cox PH regression model
4.2 Secondary analysis
b. Pairwise comparison of groups regarding 
time to event
Kaplan-Meier plots with p-value derived from 
Tarone-Ware test
c. Measure incidence ratios and incidence 
differences, attributable fractions, and 
child-years of supplementation required 
to prevent an incident case of malaria
As described by Altman et al. 2000; Sahai and 
Khurshid 1996
5. Assessment of effect modification
5.1 Interaction between interventions
We anticipated that zinc and multi-nutrients can synergistically reduce 
malaria; on the other hand, our sample size is probably insufficient to 
show such effect modification even if it exists. Stratified analyses and Cox 
regression models will be used to evaluate possible interaction between 
interventions, i.e. the effect on the time to the recurrent malaria episodes of 
supplementation with zinc and other micronutrients is greater than the sum 
of the effects by either zinc alone or micronutrients other than zinc alone 
(including an interaction term in the Cox model). If there is evidence of such 
interaction, then the effect of zinc will be reported separately for children 
who received supplements with and without multi-nutrients. On the other 
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hand, if there is no evidence of such interaction, then marginal effects of zinc 
will reported with adjustment for the effect of supplementation with multi-
nutrients. 
5.2 Interactions between baseline factors and interventions: subgroup analyses
We will consider a priori the following baseline factors as potential modifiers 
of the effects of supplementation with zinc and/or multi-nutrients:
Potential effect modifier Indicator of: Putative mechanism:
Age class Indicator of acquired 
immunity against malaria
The capacity of nutrients to boost 
immunity is likely to depend on the 
level of acquired immunity
P. falciparum parasitaemia Indicator of exposure to 
malarial infection and 
acquired immunity
See above
Plasma zinc concentration Considered the best 
available indicator of zinc 
status
The absorption and utilisation of 
supplemental zinc are increased 
in deficiencies of zinc and other 
micronutrients
Stunting Indicator of zinc status See above
Interactions will be assessed by stratified Kaplan-Meier analyses, and by 
multivariate Cox regression models with baseline factors either as categorical 
variables (age class, malaria antigenaemia) or continuous factors (plasma zinc 
concentration, height-for-age z-score) with non-linear terms, or analysed as 
categories, as appropriate. In these analyses, we will adjust for study design 
and baseline factors that are prognostic for outcome.
5.3 Interactions between interventions and time, or the number of episodes 
experienced
We hypothesize that children who received zinc and/or other micronutrients 
are better able to ‘utilise’ a malaria episode to develop protective immunity 
against subsequent symptomatic attacks. We will conduct an exploratory 
analysis to assess whether the intervention effect depends on (increases 
with) the number of episodes a child has experienced.
6. Analysis of recurrent events
6.1 Recrudescence versus reinfection
In the calculation of incidence of recurrent events, the total number of 
malaria episodes is counted, including multiple episodes in the same child. 
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Recurrent events can be caused by new infections or recrudescences. In our 
trial, we were not able distinguish between the two. 
Because new infections are very rare in the first 14 days after treatment 1 
(Mutabingwa 2005, WHO 2006), we considered all cases in which fever and 
parasitemia recurred or failed to resolve within 2 weeks as continuations of 
the same episode and not as new episodes. These cases were treated with 
the second-line drug, unless we had strong suspicion that children did not 
adhere to the initial treatment schedule of artemether-lumefantrine, in which 
case that treatment was repeated. 
In the period of 2 weeks after treatment and beyond, we considered it 
important to capture all episodes, regardless whether they were due to a 
new infection or recrudescence.
We have tried to optimise compliance to treatment by giving the 1st dose 
at the dispensary under supervision by project staff, and by subsequent 
supervision by community-volunteers. 
6.1 Censoring of observation time after chemotherapy 
Assuming successful treatment with artemether-lumefantrine, children 
subsequently enter a period that they are not at risk of developing malaria. 
Thus, a number of days should be subtracted from the total observation time 
to account for this gap in time at risk, because failure to do so would result 
in an underestimate of the intervention effect. 
The duration of this post-treatment prophylactic effect (PTP) varies between 
individuals. It is likely to depend on the pharmacokinetics of lumefantrine 
(which is eliminated much more slowly than its partner artemether; 3 days 
versus 1 h, respectively), the sensitivity of the parasites to the drugs, and the 
level of immunity of the individual concerned. 
Based on data from our trial, we estimate that the PTP ranges between 20-
30 days for the majority of children (figure 1). Data from most other trials 
suggest an almost absolute protection against reinfection during the 1st 
14 days post-treatment, but a decrease in protection between 14-28 days 
(Mutabingwa 2005, WHO 2006). 
1 In an effectiveness trial conducted in 2002 in an area adjacent to ours, parasitological failure 
after treatment with artemether-lumefantrine was found in 1% and 21 % of children at day 14 and 28 
respectively (Mutabingwa 2005). The majority among these represented new infections (0.3% and 18%, 
respectively), and recrudescences were very rare.
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To avoid excluding cases from the analysis as would occur when censoring 
a period during which some children are no longer protected, using a 
conservative estimate of the PTP is probably most appropriate. Censoring 
observation time after treatment should therefore not exceed 14 days. 
Some children presented within 14 days after the last treatment (see table 
below), with fever and a positive dipstick test result. There were, however, 
very few of such cases and we do not expect that excluding these cases will 
lead to bias.
Figure 1.  Kaplan-Meier curves showing time to first malaria episode (days), by infection 
status at baseline
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Recurrent events within 2 weeks 
1. After treatment for parasitaemia at baseline
	 6 children presented with fever and a positive dipstick within 14 days after baseline 
treatment. For 2 children, the attending clinician judged that these cases were probably 
malaria (based on additional features such as a considerable decline in haemoglobin 
concentration and the absence of another focus of fever). 
	 In the remaining 4 children, the symptoms were a-specific for malaria, the dipstick 
vaguely positive and the blood slide negative
2. After treatment for uncomplicated malaria
	 Number of recurrent episodes of uncomplicated malaria in our trial (all episodes, 
excluding the 1st): 1134.
	 14 (1.2 %) followed within 14 days since previous treatment;
	 For 10 of these children, we had serious doubts whether they actually adhered to the 
treatment schedule;
	 The remaining 4 children came back on day 14, 14, 13 and 13 respectively. They seemed 
to have taken the appropriate doses, and treatment failure may have been caused by 
unusual pharmacokinetic properties of the individual child or by drug resistance.
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For practical reasons, children participating in the study daily received one 
standard dose of supplements, i.e. one capsule, regardless of age class. Target 
levels of individual nutrients in the supplement were set to supply at least 1 
Recommended Daily Allowance (RDA) as determined for all children aged 
1-3 years (FNB/IOM 1998, 2000, 2001), with exceptions for zinc, iron and 
vitamin C. One RDA represents the average daily dietary intake level that 
is considered sufficient to meet the nutrient requirement of 97.5% of healthy 
children in Canada or the USA. Because children also receive nutrients 
from food, this will result in a higher total intake of micronutrients than 
recommended for US children. The micronutrients needs of children from 
poor, rural African families are likely to be higher than those of their US 
peers, however, because of infection-induced increases in metabolic rate or 
infection-induced losses of micronutrients.
For vitamins, an overage was used to compensate for possible losses or 
degradation during storage due to environmental factors, and to ensure 
that the target level will be minimally achieved. Because we could not 
find guidance on the overage levels to be used, we assessed these levels 
rather arbitrarily on the basis of guesstimated losses due to environmental 
degradation.
The calculation of RDAs is based on estimates of fractional absorption for zinc 
and iron that are inappropriately low for African children from poor rural, 
families, who typically have diets with high contents of phytates that inhibit 
the absorption of these trace elements. In our trial, zinc was supplemented at 
10 mg/day, with consideration that daily doses of 10-20 mg have been used 
repeatedly and successfully in many randomized controlled trials in children 
in the same age group without adverse effects (e.g. Bhandari et al 2002, 
Penny et al. 2004, Brooks et al. 2004, Castillo-Duran et al. 2001, Kikafunda 
et al. 1998, Muller et al. 2003, Sazawal et al. 1995, Roy 1991, Bhutta et al. 
1999, Umeta et al. 2000). It is unlikely that daily supplementation with zinc at 
such a dose will adversely affect copper and iron absorption and metabolism 
(Fischer Walker et al. 2005).
The supplements also contained 18 mg iron/day, close to the recommended 
nutrient intake (RNI) for infants aged 6-12 months and set to supply on 
average 2 mg/kg body weight, daily supplementation levels recommended 
to prevent iron deficiency anaemia (2 mg/kg, WHO 2001). (The intakes 
of supplemental iron actually achieved were 1.7 mg/kg for children of all 
ages; for children aged 6-17 months, 18-35 months and 36-60 months, these 
intakes were 2.3 mg/kg, 1.7 mg/kg and 1.3 mg/kg, respectively.) There 
is no evidence of adverse effects at this level of iron supplementation on 
198 Annex 3
biochemical zinc status, either whether given alone or in combination with 
zinc (Fischer Walker et al. 2005). For vitamin C, the RDA has been estimated 
as the amount required to provide antioxidant protection. Vitamin C was 
supplemented at levels above the RDA to optimise the absorption of iron. 
Even when absorption is doubled due to the high levels of vitamin C in the 
supplement (see below), the levels of supplemental iron would not exceed 
the Acceptable Intake (AI) or tolerable upper intake level (UL) for the age 
range included in this study (IOM 2001). For none of the nutrients included 
in the supplements would the levels of supplementation exceed the AI or 
UL for children within the age range in our study, even when assuming no 
losses due to environmental degradation.
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Summary
Background: Zinc is important for innate and adaptive immune responses 
to infection. Preventive zinc supplementation has been shown to reduce 
the incidence of acute diarrhoea by 20%. Few trials have evaluated its effect 
against malaria. Because trial results for both outcomes are inconsistent, 
research priorities must shift from studies to measure efficacy to identifying 
factors that determine the magnitude of the effect of zinc supplementation. 
We hypothesized that protection by zinc supplementation depends on 
concomitant supplementation with other nutrients. 
Objectives: Specific objectives were: a) to assess the effect of supplementation 
with zinc, alone or in combination with other nutrients, on the rates of malaria 
(primary objective); b) to assess intervention effects on rates of diarrhoea and 
other common diseases; c) to identify factors that determine the magnitude 
of the effect of the interventions. Our studies also provided an opportunity to 
assess effects of α+-thalassaemia on malaria and malaria-associated anaemia. 
This haemoglobin disorder is highly prevalent in eastern Africa and that has 
recently been reported to protect against severe malaria.
Methods: In a highly malaria-endemic area in rural Tanzania, we randomised 
children (n=612) aged 6-60 months with height-for-age z-score ≤ –1.5 SD to 
daily supplementation with: a) zinc, vitamins and other mineral elements 
(‘multi-nutrients’); b) zinc; c) multi-nutrients without zinc; or d) placebo. 
Those with Plasmodium infection at baseline were treated. Field staff 
and participants were blinded to treatment. Sick children were detected 
and evaluated in a research clinic. The primary outcome, an episode of 
malaria, was pre-defined as current Plasmodium antigenaemia in children 
with guardian-reported fever and any of the following: a) confirmed fever 
(axillary temperature ≥ 37.5 °C), or b) unconfirmed fever with inflammation 
(whole blood C-reactive protein concentrations ≥ 8 mg/L), separated by at 
least 14 days from a previous malaria episode.
Results: The primary analysis included 1,572 episodes of malaria and 526 
child-years of observation. The prevalence of zinc deficiency (plasma zinc 
concentration < 9.9 µmol/mL) was 67% overall, and 60% in those without 
inflammation (plasma C-reactive protein concentration < 8 mg/L). This 
prevalence was dramatically reduced by zinc supplementation.
We found no evidence that concurrent supplementation with multi-nutrients 
influenced the magnitude of the effect of zinc on rates of malaria or diarrhoea, 
so that marginal effects will be presented in the remainder of this summary.
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Although we found no evidence that zinc alone protected against malaria, it 
reduced rates of diarrhoea by 24% (95% CI: 4%–40%) and of episodes of fever 
without localising signs by 25% (4%–43%), two disorders with mutually 
exclusive case definitions.
We found no effect of multi-nutrients on the overall rate of malaria episodes, 
regardless the case definition used, but the effect estimate was likely 
underestimated by children becoming asymptomatically infected in the 
course of the intervention period. In the first 100 days of intervention, and 
in the analysis of first events, supplementation with multi-nutrients, with 
or without zinc, increased the hazard of malaria by one-third. In addition, 
subgroup analysis indicated that this effect depended strongly on age and 
iron status at baseline, with rates of episodes with parasite densities > 10,000 
parasites/ µL increasing by 27 % (1%-61%) and 53% (11%–111%) in the 
youngest children (6-17 months) and in children with iron deficiency, whilst 
there was no evident effect in older children or those without iron deficiency 
(p-values for interaction: 0.02 and 0.007).
Despite the increase in malaria rates, the children who had the lowest 
haemoglobin concentrations during malaria (those aged 6-17 months) 
were better able to maintain their haemoglobin concentrations when 
having received multi-nutrients. Direct epidemiological evidence is 
lacking, however, if and under what conditions the higher haemoglobin 
concentrations during malaria (and expected reduced risk of death due to 
severe malarial anemia) outweigh the possible increase in other potentially 
lethal disease manifestations. 
Multi-nutrient supplementation seemed to increase the rate of diarrhoea by 
19% (–6% to 50%). Subgroup analysis indicated that this effect depended 
on Giardia intestinalis infection at baseline (p-values for interaction: 0.03): in 
those without multi-nutrients, infection was associated with a reduction in 
rates of diarrhoea by 68% (34%-85%), whilst there was no evidence for such 
protection in those receiving multi-nutrients. Similar effect modification was 
found for fever without localizing signs.
Of 612 children in the trial, 50% had normal genotype, whilst 41% and 9% 
were heterozygote and homozygous, respectively, for α+-thalassaemia. We 
found no evidence of group differences in malaria rates between genotypes. 
Subgroup analysis suggested, however, that the effect of α+-thalassemia 
depended on age. Thus in children below 18 months, malaria rates were 
increased by 30% (2%–65%) in heterozygotes, whereas they were decreased 
by 20% (5%–32%) in older children (p-value for interaction: 0.001). Similar 
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patterns were found for homozygotes, even though estimates were less 
precise due the smaller numbers of children in this age class. Based on data 
from a pilot survey and a study in Kenya, we found that children with α+-
thalassaemia (particularly homozygotes) were protected against the decline in 
haemoglobin concentration associated with mild to asymptomatic infections, 
particularly when these infections were accompanied by inflammation.
Interpretation and conclusions for policies: We found no evidence that addition 
of vitamins and other mineral elements increased the health benefits of zinc 
supplements. The beneficial effects of zinc described in this thesis strengthen 
the case for scaling up zinc interventions in deficient populations of African 
children, without concerns that it will cause adverse effects due to malaria. 
Multi-nutrient supplementation may be unsafe in malaria-endemic areas, 
particularly in young children with iron deficiency. Thus the recommendation 
by the World Health Organization that iron supplements should be 
administered routinely to iron-deficient infants in settings with adequate 
access to anti-malarial treatment is insufficiently supported by evidence and 
should be reconsidered. Our results underscore that supplementation or 
home fortification, even when targeting deficient subgroups in settings with 
access to adequate primary care, should not be recommended in malaria-
endemic areas until their safety has been demonstrated.
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Samenvatting
Kinderen in ontwikkelingslanden hebben, vooral door een eenzijdig dieet, 
vaak een tekort aan vele voedingsstoffen. Van verscheidene van deze 
voedingsstoffen, o.a. van zink, wordt aangenomen dat zij een belangrijke rol 
spelen in de afweer tegen infecties. Inderdaad is in meerdere onderzoeken 
aangetoond dat het geven van zink het risico op diarree in jonge kinderen met 
20% kan verlagen, en bovendien de frequentie en duur van luchtweginfecties 
beperkt. Ondanks deze voordelen komen beleidsrichtlijnen of programma’s 
met het doel zinktekort op grote schaal te bestrijden nauwelijks van de grond.
Malaria is de belangrijkste kinderziekte op het platteland van Afrika; er wordt 
geschat dat er jaarlijk bijna 1 miljoen kinderen aan overlijden. In gebieden 
waar malaria veel voorkomt (hoog endemische gebieden) worden kinderen 
vanaf hun geboorte zo vaak blootgesteld dat hun afweersysteem de infectie 
op den duur onder controle kan houden. In de eerste 5 levensjaren is deze 
immuniteit echter nog niet compleet en gaan infecties vaak gepaard met 
koorts, of met ernstige ziekteverschijnselen, waaronder cerebrale malaria en 
ernstige bloedarmoede.
Het is onduidelijk of het geven van zink ook de frequentie en ernst van 
malaria aanvallen kan verminderen; hier zijn nog maar weinig onderzoeken 
naar gedaan, en met tegenstrijdige resultaten. Ook is er weinig bekend over 
de factoren die het effect van zink kunnen beinvloeden. Omdat kinderen met 
zinktekort vaak ook gebrek hebben aan andere voedingstoffen die essentieel 
zijn voor het immuunsysteem, veronderstelden wij dat de werkzaamheid 
van zink wordt verhoogd door gelijktijdig geven van andere mineralen en 
vitamines. Het in dit proefschrift beschreven onderzoek was primair opgezet 
om het effect van zink, al dan niet in combinatie met een ‘cocktail’ van andere 
voedingsstoffen (zie Annex 3) op het risico op malaria te evalueren. Het 
onderzoek vond plaats in een arm gebied op het Tanzaniaanse platteland, 
onder 612 jonge kinderen (0.5 tot 5 jaar), met een matige tot ernstige 
achterstand in lengtegroei. Deze kinderen kregen, gedurende minstens 7 
maanden, dagelijks een van de volgende voedingssupplementen : 1) alleen 
zink; 2) zink in combinatie met een ‘cocktail’ van andere voedingsstoffen 
(hierna‘multi-nutrienten’ genoemd); 3) multi-nutrienten maar geen zink; 
4) placebo. Kinderen werden willekeurig aan een van deze 4 groepen 
toegewezen (gerandomiseerd), en het was zowel voor de deelenemers als het 
studieteam onbekend welke combinatie de kinderen kregen (het onderzoek 
was geblindeerd). Aan de ouders van alle kinderen die aan de studie 
meededen werd gevraagd hun kind naar de kliniek te brengen wanneer zij 
merkten dat het koorts had, of zich anderszins onwel voelde. Bij ieder bezoek 
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aan de kliniek vanwege koorts werd middels een snelle diagnostische test 
(uitgevoerd met kleine druppel bloed ) vastgesteld of het kind malaria had. 
Indien het resultaat van deze test positief was werd ook het aantal parasieten 
per microliter bloed bepaald.
In totaal traden er tijdens de studie 1,572 malaria-aanvallen op (veel kinderen 
hadden meerdere episodes). Uit metingen in bloedmonsters die aan het 
begin van de studie waren verzameld, bleek dat zinktekort voorkwam bij 
67% van de kinderen, terwijl dit bij kinderen die zink hadden ontvangen aan 
het eind van de studie was teruggebracht tot 15%. Ondanks deze verbetering 
in zinkstatus vonden wij geen aanwijzingen dat er in de groep van kinderen 
die zink ontvingen minder malaria optrad (hoofdstuk 3). Ook bleek het effect 
van zink niet af te hangen van het gelijktijdig geven van multi-nutrienten. 
Wel hadden  kinderen die zink ontvingen minder vaak koortsaanvallen die 
niet door malaria veroorzaakt werden (hoofdstuk 3), en minder vaak diarree 
(hoofdstuk 5), dan degenen die geen zink kregen.
Veel jonge Afrikaanse kinderen hebben ook bloedarmoede, een tekort aan 
hemoglobine (een eiwit -met daarin ijzer-bevattende heemmolekulen- dat 
verantwoordelijk is voor zuurstoftransport naar weefsels). De belangrijkste 
oorzaken zijn ijzergebrek, malaria, andere veelvoorkomende infecties, 
en bepaalde erfelijke aandoeningen zoals alpha-thalassemie. Bij al deze 
aandoeningen treedt een onvoldoende aanmaak van hemoglobine op; bij 
malaria is er daarnaast ook sprake van een afbraak van rode bloedcellen en 
hemoglobine, dat  het voedingssubstraat van malariaparasieten vormt.
IJzer-bevattende voedingssupplementen verlagen het risico op bloedarmoede, 
en veelal werd aangenomen dat zij daarmee ook het risico op sterfte (tgv 
ernstige bloedarmoede) zouden kunnen verminderen. Ook in onze trial was 
ijzergebrek vrijwel afwezig nadat kinderen enkele maanden ijzer-bevattende 
supplementen hadden ontvangen (hoofdstuk 4). Omdat ziekteverwekkers 
echter ook baat hebben bij het ijzer in dergelijke supplementen, is het geven 
daarvan mogelijk niet altijd veilig. Dit geldt zeker wanneer het gaat om 
kinderen op van het platteland van Afrika, waar basisgezondheidszorg 
veelal afwezig is, en infecties (met name malaria) niet tijdig behandeld 
kunnen worden. 
Uit ons onderzoek bleek dat het toedienen van multi-nutrienten, al dan niet 
met zink, leidde tot een 30% toename in de incidentie van malaria, berekend 
op basis van eerste episodes. Omdat de meeste kinderen meerdere malaria 
episodes doormaakten hebben wij ook gekeken naar het effect van de 
interventie op het totaal aantal malaria-episodes; in deze analyse vonden wij 
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eveneens een toename in malaria ten gevolge van multi-nutrienten van 30% 
in eerste 100 dagen van de interventie (hoofdstuk 4). Wij nemen aan dat deze 
toename toe te schrijven is aan het ijzer in de supplementen, maar een rol 
van andere micronutrienten kan niet worden uitgesloten.
Ook liet ons onderzoek zien dat het effect van multi-nutrienten sterk afhangt 
van leeftijd en ijzerstatus; de kans op het optreden van relatief ernstige 
malaria (een episode met meer dan 10,000 parasieten per microliter bloed) 
nam met ruim 50% toe, juist kinderen met ijzergebrek, terwijl de interventie 
geen effect had onder kinderen zonder ijzergebrek (hoofdstuk 4). De kans 
dat dit verschil in effect tussen kinderen met en zonder ijzergebrek aan 
toeval te wijten was, was slechts 0.007%. Ondanks de geobserveerde toename 
in de frequentie van malaria episodes, hadden kinderen wel een kleinere 
kans op (ernstige) bloedarmoede tijdens een malaria aanval wanneer zij de 
supplementen hadden gekregen. 
De bevinding dat multi-nutrienten resulteerden in frequentere en/of 
ernstiger malaria episodes juist in kinderen met ijzergebrek is in contrast 
met de resultaten van een eerdere studie in Pemba, waar ijzer juist veilig 
leek te zijn in deze kinderen (in deze studie werd gekeken naar mortaliteit 
en ziekenhuisopname). Onze resultaten suggereren dat het geven van multi-
nutrienten (incl. ijzer) niet altijd veilig is, zelfs aan kinderen met aangetoond 
ijzergebrek. Deze infomatie heeft mogelijk consequenties voor de huidige 
WHO richtlijnen, waarin wordt aanbevolen ijzersupplementen alleen te 
geven aan kinderen met aangetoond ijzergebrek (hoofdstuk 9). 
Tenslotte vonden wij nog een andere aanwijzing dat het geven van multi-
nutrienten aan kinderen in dit soort settings niet altijd gunstig hoeft te zijn: 
onder kinderen die bij het begin van de interventie waren geïnfecteerd met de 
darmparasiet Giardia intestinalis, resulteerde het geven van multi-nutrienten 
in verdubbeling in de frequentie van diarree (hoofdstuk 5). De aanwezigheid 
van de parasite bij baseline was overigens ge-associeerd met een substantiele 
bescherming tegen diarree (hoofdstuk 6).
Samenvattend, vonden wij geen aanwijzingen dat zinksupplementen het 
risico op malaria verminderen. De bevinding dat zink leidt tot een reductie 
in de frequentie van diarree en koortsepisodes die niet door malaria worden 
veroorzaakt, ondersteunen de noodzaak om succesvolle zinkinterventies te 
ontwikkelen voor populaties waar zinktekort vaak voorkomt. 
Onze bevindingen benadrukken dat het geven van multi-nutrienten door 
middel van supplementen of  ‘home- fortification’ aan kinderen in malaria-
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endemische gebieden mogelijk onveilig is; het kan daarom niet worden 
aanbevolen totdat het tegendeel bewezen is. Op basis van onze gegevens lijkt 
zelfs het gericht geven van ijzersupplementen aan kinderen met ijzergebrek 
onveilig.
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